<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">Rev Lat Am Enfermagem</journal-id>
			<journal-id journal-id-type="publisher-id">rlae</journal-id>
			<journal-title-group>
				<journal-title>Revista Latino-Americana de Enfermagem</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Rev. Latino-Am. Enfermagem</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="epub">1518-8345</issn>
			<issn pub-type="ppub">0104-1169</issn>
			<publisher>
				<publisher-name>Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="other">00603</article-id>
			<article-id pub-id-type="doi">10.1590/1518-8345.5897.3597</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Artigo de Revisão</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Terapias complementares no controle de sintomas do trato urinário inferior masculino: revisão sistemática</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-5080-4643</contrib-id>
					<name>
						<surname>Mata</surname>
						<given-names>Luciana Regina Ferreira da</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-7881-0519</contrib-id>
					<name>
						<surname>Motter</surname>
						<given-names>Paula Giuliana Rodrigues</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5881-5710</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Cissa</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-5051-4910</contrib-id>
					<name>
						<surname>Bernardes</surname>
						<given-names>Mariana Ferreira Vaz Gontijo</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-8313-2791</contrib-id>
					<name>
						<surname>Chianca</surname>
						<given-names>Tânia Couto Machado</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-9586-9486</contrib-id>
					<name>
						<surname>Vasques</surname>
						<given-names>Christiane Inocêncio</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>1</label>
				<institution content-type="original"> Universidade Federal de Minas Gerais, Escola de Enfermagem, Belo Horizonte, MG, Brasil.</institution>
				<institution content-type="normalized">Universidade Federal de Minas Gerais</institution>
				<institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
				<institution content-type="orgdiv1">Escola de Enfermagem</institution>
				<addr-line>
					<city>Belo Horizonte</city>
					<state>MG</state>
				</addr-line>
				<country country="BR">Brazil</country>
			</aff>
			<aff id="aff2">
				<label>2</label>
				<institution content-type="original"> Universidade Federal de Viçosa, Departamento de Medicina e Enfermagem, Viçosa, MG, Brasil.</institution>
				<institution content-type="normalized">Universidade Federal de Viçosa</institution>
				<institution content-type="orgname">Universidade Federal de Viçosa</institution>
				<institution content-type="orgdiv1">Departamento de Medicina e Enfermagem</institution>
				<addr-line>
					<city>Viçosa</city>
					<state>MG</state>
				</addr-line>
				<country country="BR">Brazil</country>
			</aff>
			<aff id="aff3">
				<label>3</label>
				<institution content-type="original"> Universidade de Brasília, Faculdade de Ciências da Saúde, Brasília, DF, Brasil.</institution>
				<institution content-type="normalized">Universidade de Brasília</institution>
				<institution content-type="orgname">Universidade de Brasília</institution>
				<institution content-type="orgdiv1">Faculdade de Ciências da Saúde</institution>
				<addr-line>
					<city>Brasília</city>
					<state>DF</state>
				</addr-line>
				<country country="BR">Brazil</country>
			</aff>
			<author-notes>
				<corresp id="c1">
					<label>Autor correspondente</label> Christiane Inocêncio Vasques E-mail: <email>chvasques@unb.br</email>
				</corresp>
				<fn fn-type="edited-by" id="fn1">
					<label>Editora Associada</label>
					<p> Maria Lúcia Zanetti</p>
				</fn>
				<fn fn-type="con" id="fn2">
					<label>Contribuição dos autores</label>
					<p><bold>Concepção e desenho da pesquisa:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Christiane Inocêncio Vasques. <bold>Obtenção de dados:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. <bold>Análise e interpretação dos dados:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. <bold>Obtenção de financiamento:</bold> Luciana Regina Ferreira da Mata, Tânia Couto Machado Chianca. <bold>Redação do manuscrito:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes. <bold>Revisão crítica do manuscrito quanto ao conteúdo intelectual importante:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. Todos os autores aprovaram a versão final do texto.</p>
				</fn>
				<fn fn-type="conflict" id="fn3">
					<label>Conflito de interesse</label>
					<p> Os autores declararam que não há conflito de interesse.</p>
				</fn>
			</author-notes>
			<pub-date date-type="collection" publication-format="electronic">
				<year>2022</year>
			</pub-date>
			<pub-date date-type="pub" publication-format="electronic">
				<day>15</day>
				<month>07</month>
				<year>2022</year>
			</pub-date>
			<volume>30</volume>
			<elocation-id>e3597</elocation-id>
			<history>
				<date date-type="received">
					<day>10</day>
					<month>12</month>
					<year>2021</year>
				</date>
				<date date-type="accepted">
					<day>26</day>
					<month>02</month>
					<year>2022</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="pt">
					<license-p>Este é um artigo publicado em acesso aberto sob uma licença Creative Commons</license-p>
				</license>
			</permissions>
			<abstract>
				<title>Resumo</title>
				<sec>
					<title>Objetivo:</title>
					<p> avaliar as evidências científicas sobre a efetividade das terapias complementares no controle de sintomas do trato urinário inferior na população masculina adulta e idosa. </p>
				</sec>
				<sec>
					<title>Método:</title>
					<p> revisão sistemática desenvolvida de acordo com o <italic>checklist</italic> PRISMA. A busca foi realizada nas bases de dados CINAHL, <italic>Embase</italic>, LILACS, PEDro, PubMed, <italic>Web of Science</italic> e <italic>Google Scholar</italic>. </p>
				</sec>
				<sec>
					<title>Resultados:</title>
					<p> foram identificados 585 registros e selecionados 12 ensaios clínicos que atenderam aos critérios de inclusão. Os desfechos considerados pelos estudos para analisar a efetividade das terapias complementares foram questionários validados de avaliação da gravidade dos sintomas do trato urinário inferior (sensação de esvaziamento incompleto da bexiga, micções frequentes, fluxo intermitente, fluxo fraco, dor ou dificuldade na micção, noctúria e urgência) e parâmetros da urodinâmica. Os estudos analisaram as terapias complementares fitoterapia (n=8) e eletroacupuntura (n=4). Seis estudos relacionados à fitoterapia mostraram significância estatística. A eletroacupuntura mostrou melhora significativa dos sintomas em dois estudos.</p>
				</sec>
				<sec>
					<title>Conclusão:</title>
					<p> a fitoterapia foi efetiva para controle dos sintomas frequência, urgência, noctúria, esvaziamento incompleto, intermitência, fluxo fraco e esforço para iniciar a micção. Para confirmação da efetividade da eletroacupuntura ainda serão necessárias pesquisas com metodologias bem delineadas para sanar as divergências entre os estudos desta revisão. </p>
				</sec>
			</abstract>
			<kwd-group xml:lang="pt">
				<title>Descritores:</title>
				<kwd>Terapias Complementares</kwd>
				<kwd>Sintomas do Trato Urinário Inferior</kwd>
				<kwd>Revisão Sistemática</kwd>
				<kwd>Saúde do Homem</kwd>
				<kwd>Fitoterapia</kwd>
				<kwd>Eletroacupuntura</kwd>
			</kwd-group>
			<funding-group>
				<award-group award-type="contract">
					<funding-source>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</funding-source>
					<award-id>429958/2018-8</award-id>
				</award-group>
				<award-group award-type="contract">
					<funding-source>Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)</funding-source>
					<award-id>APQ 01034-21</award-id>
				</award-group>
				<funding-statement>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), processo nº 429958/2018-8 e da Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), processo APQ 01034-21, Brasil</funding-statement>
			</funding-group>
			<counts>
				<fig-count count="3"/>
				<table-count count="9"/>
				<equation-count count="0"/>
				<ref-count count="54"/>
				<page-count count="0"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<boxed-text id="bx1">
			<sec>
				<title>Destaques: </title>
				<p>(1) Terapias complementares podem ser efetivas em sintomas urinários masculinos. </p>
				<p>(2) A fitoterapia foi efetiva em seis dos oito estudos incluídos. </p>
				<p>(3) Estudos com eletroacupuntura e metodologias mais robustas são necessários.</p>
			</sec>
		</boxed-text>
		<sec sec-type="intro">
			<title>Introdução</title>
			<p>De acordo com a <italic>International Continence Society</italic> (ICS), os sintomas do trato urinário inferior (STUI) podem ser categorizados de acordo com a fase da micção: armazenamento, esvaziamento e pós-micção<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Os STUI de armazenamento, como noctúria e incontinência urinária, são os mais relatados pela população geral, seguidos pelo gotejamento pós-micção, redução no fluxo urinário e sensação de esvaziamento incompleto da bexiga, que também são queixas comuns<xref ref-type="bibr" rid="B2"><sup>2</sup></xref>.</p>
			<p>Os STUI são mais frequentes com o avanço da idade<xref ref-type="bibr" rid="B3"><sup>3</sup></xref>. Nos homens, existem diferentes apresentações clínicas de STUI, as quais estão relacionadas à bexiga, próstata, uretra, assoalho pélvico e/ou órgãos pélvicos adjacentes<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Estudos epidemiológicos realizados com a população masculina adulta e idosa apontam que a prevalência pode variar de 60 a 84%<xref ref-type="bibr" rid="B4"><sup>4</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. A etiologia mais frequentemente associada à ocorrência dos STUI em homens é a hiperplasia prostática benigna (HPB)<xref ref-type="bibr" rid="B3"><sup>3</sup></xref>. Embora não seja uma morbidade que determine gravidade associada à mortalidade, estes sintomas repercutem negativamente no cotidiano de pessoas com STUI, uma vez que afetam a qualidade de vida, acarretam insatisfação sexual e aumentam o risco de transtornos depressivos<xref ref-type="bibr" rid="B6"><sup>6</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
			<p>Existe uma variedade de estratégias de tratamento para o controle dos STUI<xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. O tratamento convencional geralmente envolve mudanças de comportamento, como a redução no consumo de cafeína e álcool, aumento de atividade física e redução do peso corporal. Tal tratamento, em alguns casos, pode ser relacionado a medidas farmacológicas, com destaque para alfa-bloqueadores e inibidores da 5-alfa-redutase<xref ref-type="bibr" rid="B9"><sup>9</sup></xref>. No entanto, há uma parcela de homens cuja resposta ao tratamento convencional é insatisfatória e requerem medidas cirúrgicas<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>. Ambas as opções implicam em custos médicos e possíveis danos relacionados aos efeitos adversos dos medicamentos ou sequelas pós-intervenções invasivas<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>.</p>
			<p>Neste contexto, intervenções pautadas nas terapias complementares (TCs) podem constituir estratégia efetiva de controle de STUI em homens, especialmente pelo menor custo e com mínimos efeitos adversos. As TCs, também denominadas Medicina Tradicional e Complementar, são um conjunto de conhecimentos, habilidades e práticas que originam das experiências e crenças de diferentes culturas que complementam as práticas da medicina convencional<xref ref-type="bibr" rid="B11"><sup>11</sup></xref>. </p>
			<p>A fitoterapia e a acupuntura têm sido avaliadas individualmente por meio de revisões sistemáticas quanto a sua efetividade<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref> e comparadas aos tratamentos convencionais para controle dos STUI<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Apesar disso, observa-se que a indicação das TCs muitas vezes ocorre de forma empírica<xref ref-type="bibr" rid="B16"><sup>16</sup></xref>. Portanto, espera-se que uma revisão sistemática consiga sumarizar as evidências disponíveis sobre a efetividade de diferentes TCs para controle dos STUI na população masculina e assim favorecer sua implementação na prática clínica.</p>
			<p>Ao considerar a popularização das TCs, percebe-se a necessidade de desenvolver uma revisão sistemática que tenha como objetivo avaliar as evidências científicas sobre a efetividade das terapias complementares no controle de sintomas do trato urinário inferior na população masculina adulta e idosa.</p>
		</sec>
		<sec sec-type="methods">
			<title>Método</title>
			<sec>
				<title>Delineamento do estudo</title>
				<p>Trata-se de uma revisão sistemática da literatura, sob registro na plataforma <italic>International Prospective Register of Systematic Reviews</italic> (PROSPERO) (Número de registro: CRD42021226480), desenvolvida de acordo com as recomendações do <italic>Preferred Reporting Items for Systematic Reviews and Meta-Analyses</italic> PRISMA <italic>Checklist</italic><xref ref-type="bibr" rid="B17"><sup>17</sup></xref> para relatar revisões sistemáticas. </p>
			</sec>
			<sec>
				<title>Critérios de seleção</title>
				<p>A estratégia PICO foi empregada para estabelecer a pergunta norteadora, na qual o P se refere à população ou grupo de pacientes (homens com STUI), I à Intervenção (TCs), C à comparação (não foi utilizada a comparação com outras intervenções) e O ao desfecho/<italic>outcomes</italic> (controle dos STUI). Portanto, esta revisão sistemática buscou responder a seguinte pergunta: Qual a efetividade das TCs no controle de STUI na população masculina?</p>
				<p>Foram elegíveis para a revisão sistemática apenas ensaios clínicos que avaliassem o uso de TCs para o controle dos STUI em homens adultos (18 anos ou mais). Não houve restrições para a elegibilidade quanto ao idioma ou ano de publicação.</p>
			</sec>
			<sec>
				<title>Definição da amostra e período </title>
				<p>Pela leitura do título e resumo foram excluídos estudos com amostras compostas por populações mistas, crianças e animais; pesquisas originais cujo delineamento não era de ensaio clínico; publicações do tipo revisões, cartas, editoriais, protocolos e relatos de caso; registros que não apresentavam resumo <italic>online</italic> disponível. A partir da leitura na íntegra foram excluídos ensaios clínicos que associaram o tratamento convencional às TCs no grupo intervenção e publicações do tipo protocolos de ensaios clínicos. Ressalta-se que também foram excluídos os estudos que embora tenham sido elegíveis pelo título e resumo, não foram localizados na íntegra <italic>online</italic> e nem disponibilizados pelos autores correspondentes, mediante contato via <italic>e-mail</italic>.</p>
				<p>A busca foi realizada nas seguintes bases de dados: <italic>Index to Nursing &amp; Allied Health Literature</italic> (CINAHL) via Portal de Periódicos CAPES, <italic>Embase, Latin American and Caribbean Health Sciences Literature</italic> (LILACS)<italic>, Physiotherapy Evidence Database</italic> (PEDro), PubMed, e <italic>Web of Science</italic>. Os estudos foram identificados a partir de estratégias de busca adaptadas especificamente para cada uma das bases utilizando terminologias definidas pelo <italic>Medical Subject Headings</italic> (MeSH/PubMed) e Descritores em Ciência da Saúde (DeCS), conforme apresentado na <xref ref-type="table" rid="t1">Figura 1</xref>. As buscas nas bases de dados foram realizadas em maio de 2021. Os pesquisadores fizeram uma busca manual nas listas de referências dos estudos selecionados para a identificação de possíveis referências que não foram identificadas na busca eletrônica. Por fim, o <italic>Google Scholar</italic> também foi considerado como estratégia de busca complementar. </p>
				<p>
					<table-wrap id="t1">
						<label>Figura 1</label>
						<caption>
							<title>Estratégia de busca e resultados em cada base de dados. Belo Horizonte, MG, Brasil, 2021</title>
						</caption>
						<table>
							<colgroup>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Base de dados </th>
									<th align="left">Estratégia de busca</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left">CINAHL</td>
									<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
								</tr>
								<tr>
									<td align="left"><italic>Embase</italic></td>
									<td align="left"><italic>(‘lower urinary tract symptom’/exp OR ‘lower urinary tract symptom’) AND (‘chinese medicine’/exp OR ‘chinese medicine’)</italic></td>
								</tr>
								<tr>
									<td align="left">LILACS</td>
									<td align="left"><italic>(tw:(((“Terapias Complementares” OR “Medicina Alternativa” OR “Medicina Complementar” OR “Terapias Alternativas” OR “Práticas Integrativas e Complementares” OR auriculoterapia OR “Acupuntura Auricular” OR “Terapia por Acupuntura” OR eletroacupuntura OR “Pontos de Acupuntura” OR moxibustão OR Medicina Tradicional Chinesa OR Meridianos OR Acupressão OR Orelha Externa OR “Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR electroacupuncture OR “Acupuncture Points” OR moxibustion OR “Medicine, chinese traditional” OR Meridians OR Acupressure OR “Ear, external”)))) AND (tw:(((“Incontinência Urinária” OR “Transtornos Urinários” OR “Incontinência Urinária por Estresse” OR “Urinary Incontinence” OR “Urination Disorders” OR “Urinary incontinence, stress”))))</italic></td>
								</tr>
								<tr>
									<td align="left">PEDro</td>
									<td align="left"><italic>Therapy: acupuncture; Problem: incontinence</italic></td>
								</tr>
								<tr>
									<td align="left">PubMed</td>
									<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
								</tr>
								<tr>
									<td align="left"><italic>Web of Science</italic></td>
									<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
								</tr>
								<tr>
									<td align="left"><italic>Google Scholar</italic></td>
									<td align="left"><italic>Advanced search With all the words: Complementary Alternative Medicine With the exact phrase: Lower urinary tract symptoms Without the words: Female; Children</italic></td>
								</tr>
							</tbody>
						</table>
					</table-wrap>
				</p>
			</sec>
			<sec>
				<title>Coleta de dados</title>
				<p>Para o agrupamento das buscas e exclusão de duplicatas utilizou-se o <italic>EndNoteBasic</italic> <sup>®</sup>, versão <italic>web</italic>. Posteriormente, todas as referências passaram por uma triagem manual para extração das informações-chave dos estudos (autores; ano; país; TCs; objetivo; tamanho amostral; características da amostra; características da intervenção e do controle; tempo de tratamento e seguimento; instrumentos de avaliação e outros desfechos; conclusões), as quais foram transcritas e organizadas em uma planilha do Microsoft Excel que facilitou o desenvolvimento da etapa de seleção.</p>
				<p>A seleção dos estudos foi realizada por duas pesquisadoras, doutorandas em enfermagem (P1 e P2), de forma independente em duas fases. Na primeira fase, a partir da leitura do título e do resumo, foram identificados aqueles estudos potencialmente elegíveis para a revisão sistemática, considerando os critérios de inclusão e exclusão definidos. Na segunda fase, os estudos selecionados foram lidos na íntegra e aqueles que não atenderam aos critérios de inclusão foram excluídos. As divergências de seleção entre as duas pesquisadoras (P1 e P2) foram discutidas e quando não havia um consenso, essas eram avaliadas por um terceiro pesquisador, doutor em enfermagem (P3), quem decidiu sobre a inclusão ou exclusão dos estudos.</p>
				<p>Duas pesquisadoras (P1 e P2) realizaram, de forma independente, a extração dos dados relevantes dos artigos selecionados para uma planilha elaborada no Microsoft Excel. Os dados extraídos foram: características gerais do estudo (autor, ano e país de publicação), objetivos, características da amostra (número de participantes e idade média), características da intervenção [fitoterapia (dose e duração)], acupuntura/eletroacupuntura (pontos de acupuntura, procedimentos de manipulação, frequência e intensidade de eletroestimulação, duração e número de sessões), outros braços do estudo], resultados (principais desfechos analisados e instrumentos utilizados) e a conclusão. Uma terceira revisora (P3) avaliou a acurácia dos dados coletados.</p>
			</sec>
			<sec>
				<title>Análise dos dados</title>
				<p>A avaliação da qualidade dos estudos selecionados foi realizada com base no <italic>Joanna Briggs Institute</italic> (JBI) <italic>Critical Appraisal Tool</italic> - <italic>checklist</italic> para ensaios clínicos randomizados. Trata-se de um formulário que avalia a qualidade metodológica e a abordagem de possíveis vieses no delineamento, conduta e análise de dados dos ensaios clínicos randomizados. Esse <italic>checklist</italic> é composto por 13 questões com quatro opções de resposta (sim, não, incerto ou não se aplica)<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>.</p>
				<p>Em relação à categorização da qualidade metodológica dos ensaios clínicos a partir do instrumento aplicado, estudos que tiveram 70% ou mais respostas “sim” foram classificados como baixo risco de viés, com 50 a 69% de respostas “sim” classificados como moderado risco e com 49% ou menos respostas “sim” classificados como alto risco. </p>
				<p>A avaliação do risco de viés foi realizada de forma independente por duas pesquisadoras (P1 e P2). Uma terceira pesquisadora (P3) foi considerada para a avaliação de possíveis divergências.</p>
			</sec>
		</sec>
		<sec sec-type="results">
			<title>Resultados</title>
			<p>Foram identificados 585 registros nas buscas realizadas nas bases de dados, dentre os quais 96 duplicatas foram removidas. Após a leitura de títulos e resumos, 478 registros foram excluídos na primeira fase e 11 artigos foram selecionados para a leitura na íntegra. Além desses, a busca por outros métodos resultou na seleção de três artigos e outros quatro artigos foram selecionados a partir das listas de referência. </p>
			<p>Ao considerar os critérios de inclusão e exclusão estabelecidos, dentre os 18 artigos selecionados e lidos na íntegra durante a segunda fase, seis foram excluídos. A amostra final foi composta por 12 estudos que atenderam aos critérios de seleção. O processo de identificação, inclusão e exclusão dos estudos está descrito na <xref ref-type="fig" rid="f1">Figura 2</xref>.</p>
			<p>
				<fig id="f1">
					<label>Figura 2</label>
					<caption>
						<title>Fluxograma das buscas nas bases de dados e critérios de seleção</title>
					</caption>
					<graphic xlink:href="1518-8345-rlae-30-e3597-gf1.png"/>
				</fig>
			</p>
			<p>Todos os estudos foram publicados em inglês entre os anos de 2001 e 2019. Quanto ao país de origem, quatro pesquisas foram desenvolvidas nos Estados Unidos<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref>, duas no Japão<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, duas na China<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, duas na República Tcheca<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, uma na Itália<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> e uma em Taiwan<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. </p>
			<p>A maioria dos ensaios clínicos avaliou a fitoterapia (n=8) para controle dos STUI na população masculina<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. Os demais ensaios clínicos desta revisão abordaram a eletroacupuntura (n=4)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. A descrição de cada artigo está detalhada na <xref ref-type="table" rid="t2">Figura 3</xref>.</p>
			<p>
				<table-wrap id="t2">
					<label>Figura 3</label>
					<caption>
						<title>Descrição das características dos estudos incluídos na revisão sistemática (n=12)</title>
					</caption>
					<table>
						<colgroup>
							<col span="3"/>
							<col span="2"/>
							<col span="3"/>
							<col span="2"/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left" colspan="3">Características do estudo </th>
								<th align="left" colspan="2">Descrição da amostra </th>
								<th align="left" colspan="3">Método aplicado </th>
								<th align="left" colspan="2">Desfechos analisados </th>
								<th align="left">Conclusões finais</th>
							</tr>
							<tr>
								<th align="left">Autor, ano; País</th>
								<th align="left">TC<sup>¶¶</sup></th>
								<th align="left">Objetivos</th>
								<th align="left">Tamanho(n)</th>
								<th align="left">Características (linha de base dos STUI<sup>‡‡‡</sup>; idade média ±desvio padrão)</th>
								<th align="left">Intervenção (GI<sup>||</sup>)</th>
								<th align="left">Controle (GC<sup>§</sup>)</th>
								<th align="left">Duração (meses)</th>
								<th align="left">Questionários de avaliação</th>
								<th align="left">Parâmetros da Urodinâmica</th>
								<th align="left">
								</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left">Gerber, et al. (2001)<sup>(19)</sup>; EUA</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Avaliar os efeitos do extrato de <italic>Saw palmetto</italic> (<italic>S. palmetto)</italic> em sintomas urinários, função sexual, e taxa de fluxo urinário em homens com STUI<sup>‡‡‡</sup>.</td>
								<td align="left">n: 85 GI<sup>||</sup>: 41 GC<sup>§</sup>: 44</td>
								<td align="left">Escore I-PSS<sup>††</sup> &gt; 8 sem histórico cirúrgico em próstata; 64,5 (±9,9) anos (GI<sup>||</sup>); 65,3 (±9,7) anos (GC<sup>§</sup>).</td>
								<td align="left">Cápsula 160mg de <italic>S. palmetto</italic> (distribuído pela Nutraceutical), 2x/dia (320 mg diários).</td>
								<td align="left">Cápsula de placebo (azeite de oliva extra virgem, gelatina e glicerina), 2x/dia.</td>
								<td align="left">6</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax<sup>||||</sup></td>
								<td align="left">GI<sup>||</sup> teve uma redução (melhora) média de 4,4 (±5,9) pontos no escore I-PSS<sup>††</sup> demonstrando uma diferença significativa (<italic>p</italic> = 0,038) em comparação com o GC<sup>§</sup>. Qmax<sup>||||</sup> melhorou levemente em ambos os grupos, mas as mudanças não foram significativas (<italic>p</italic> = 0,75). </td>
							</tr>
							<tr>
								<td align="left">Bent, et al. (2006)<sup>(21)</sup>; EUA</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Determinar a eficácia do extrato de <italic>S. palmetto</italic> para o tratamento de HPB<sup>¶</sup>.</td>
								<td align="left">n: 225 GI<sup>||</sup>: 112 GC<sup>§</sup>: 113</td>
								<td align="left">HPB determinada pelo escore *AUASI &gt; 8, sem histórico cirúrgico em próstata; 62,9 (±8,7) anos (GI<sup>||</sup>); 63,0 (±7,4) anos (GC<sup>§</sup>).</td>
								<td align="left">Cápsula 160 mg de <italic>S. palmetto</italic> (distribuído pela Rexall-Sundown, Inc), 2x/dia (320 mg diários).</td>
								<td align="left">Cápsula placebo (polietilenoglicol 400, líquido amargo com aspecto oleoso sem ácidos graxos livres e corante marrom), 2x/dia.</td>
								<td align="left">12</td>
								<td align="left">*AUASI</td>
								<td align="left">Qmax<sup>||||||</sup>, voume prostático e VRP</td>
								<td align="left">Redução (melhora) discreta no escore AUASI*, 0,72 (±0,35) pontos no GC§ e 0,68 (±0,35) pontos no GI<sup>||</sup>, mas sem diferença significativa entre os grupos (IC**95%: -0,93 a 1,01). Alterações não foram observadas na Qmax<sup>||||</sup>, volume prostático e VRP.</td>
							</tr>
							<tr>
								<td align="left">Barry, et al. (2011)<sup>(22)</sup>; Estados Unidos da América</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Determinar o efeito do extrato de <italic>S. palmetto</italic>, em até três vezes a dose padrão, nos STUI<sup>‡‡‡</sup> atribuídos à HPB<sup>¶</sup>.</td>
								<td align="left">n: 357 GI<sup>||</sup>: 176 GC<sup>§</sup>: 181</td>
								<td align="left">Escore AUASI entre 8 e 24, sem histórico cirúrgico em próstata; 61,3 ± 8,7 anos (GI<sup>||</sup>); 60,7 ± 8,1 anos (GC<sup>§</sup>).</td>
								<td align="left">Cápsula 320 mg de <italic>S. palmetto</italic> (distribuído pela Rottapharm) Aumento progressivo da dosagem: -1 cápsula/dia da 1ª a 23ª semana (320 mg diários); -2 cápsulas/dia da 24ª e a 48ª semana (640 mg diários); -3 cápsulas/dia da 48ª e a 72ª semana (960 mg diários).</td>
								<td align="left">Cápsulas placebo (375 mg de polietilenoglicol, 25 mg de glicerol e 75 mg de gelatina) seguindo aumento progressivo de número de cápsulas como no GI.</td>
								<td align="left">18</td>
								<td align="left"> AUASI*</td>
								<td align="left">Qmax<sup>||||</sup> e VRP<sup>||||||</sup></td>
								<td align="left">Escore médio AUASI* reduziu (melhorou) 2,99 pontos (IC**95%: -3,81 a -2,17) no GC e 2,20 pontos (IC95%: -3,04 a -0,36) no GI<sup>||</sup>, uma diferença de 0,79 pontos entre os dois grupos a favor do GC<sup>§</sup>. Comparação da dose-resposta demonstrou que não houve melhora no GI<sup>||</sup> em nenhuma das doses quando comparado ao GC§. Alterações não foram observadas na Qmax e VRP<sup>||||||</sup>.</td>
							</tr>
							<tr>
								<td align="left">Ye, et al. (2019)<sup>(26)</sup>; China</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Avaliar a eficácia e a segurança do <italic>S. palmetto</italic> entre pacientes com STUI<sup>‡‡‡</sup>/ HPB<sup>¶</sup>.</td>
								<td align="left">n: 325 GI<sup>||</sup>: 159 GC<sup>§</sup>: 166</td>
								<td align="left">HPB<sup>¶</sup> com escore I-PSS &lt; 19; 61,5 (± 5,2) anos (GI<sup>||</sup>); 60,3 (± 6,0) anos (GC<sup>§</sup>).</td>
								<td align="left">Cápsula 160 mg de <italic>S. palmetto</italic> (distribuído pela Tad Pharma GmbH)<italic>,</italic> 2x/dia (320mg diários).</td>
								<td align="left">Cápsula placebo (composição não descrita), 2x/dia.</td>
								<td align="left">6</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax<sup>‡‡</sup>, volume prostático e frequência de micções</td>
								<td align="left">O escore I-PSS<sup>††</sup> reduziu (melhorou) em ambos os grupos, mas a redução foi significativamente maior após 24 semanas no GI<sup>||</sup> (<italic>p</italic> &lt; 0,001). O GI<sup>||</sup> demonstrou aumento (melhora) significativo na Qmax<sup>‡‡</sup> a partir da 4ª semana (<italic>p</italic> = 0,011) até a 24ª semana (<italic>p</italic> &lt; 0,001). Alterações não foram observadas no volume prostático e frequência urinária.</td>
							</tr>
							<tr>
								<td align="left">Noguchi, et al. (2008)<sup>(23)</sup>; Japão</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Avaliar a segurança e eficácia do extrato de <italic>Ganoderma lucidum (G. lucidum),</italic> em homens com sintomas do trato urinário inferior, a partir de um estudo com doses escalonadas.</td>
								<td align="left">n: 50 GI<sup>||</sup>/0,6: 12 GI<sup>||</sup>/6: 12 GI<sup>||</sup>/60: 14 GC<sup>§</sup>: 12</td>
								<td align="left">Escore I-PSS<sup>††</sup> &gt; 5, sem histórico cirúrgico em próstata; 59,1 (51-70) anos (GI<sup>||</sup>/0,6); 59,2 (50-72) anos (GI<sup>||</sup>/6); 59,4 (50-70) anos (GI<sup>||</sup>/60); 59,7 (50-67) anos (GC<sup>§</sup>). </td>
								<td align="left">GI<sup>||</sup>/0,6: Comprimido 0,6 mg <italic>G. lucidum</italic>, 1x/dia; GI<sup>||</sup>/6: Comprimido 6 mg <italic>G. lucidum</italic>, 1x/dia; GI<sup>||</sup>/60: Comprimido 60 mg <italic>G. lucidum</italic>, 1x/dia. (Todos comprimidos distribuídos pela Chlorella Industry).</td>
								<td align="left">Comprimido placebo (83,75% maltitol, 10% amido de milho, 3% vitamina C, 0,2% de gardênia amarela e 3% éster de ácido graxo de sacarose), 1x/dia.</td>
								<td align="left">2</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax<sup>||||</sup>, volume prostático e VRP<sup>||||||</sup></td>
								<td align="left">Na 4ª semana, mudança média no escore I-PSS<sup>††</sup> foi significantemente maior no GI<sup>||</sup>/60, em comparação ao GC<sup>§</sup> (<italic>p</italic> = 0,012) e GI<sup>||</sup>/0,6 (<italic>p</italic> &lt; 0,001). Na 8ª semana, mudança média do GI<sup>||</sup>/0,6 foi significantemente menor que o GI<sup>||</sup>/6 (<italic>p</italic> = 0,016) e GI<sup>||</sup>/60 (p = 0,005). Melhora discreta da Qmax<sup>||||</sup>, mas sem diferenças significativas entre os grupos. Alterações não foram observadas no volume prostático e VRP<sup>||||||</sup>.</td>
							</tr>
							<tr>
								<td align="left">Noguchi, et al. (2008)<sup>(24)</sup>; Japão</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Avaliar a segurança e eficácia em homens com sintomas do trato urinário inferior leves a moderados, do extrato de <italic>G. lucidum,</italic> que demonstrou a maior atividade inibitória da 5α-redutase dentre os extratos de 19 cogumelos, comestíveis e medicinais.</td>
								<td align="left">n: 88 GI<sup>||</sup> <sub>:</sub> 44 GC<sup>§</sup>: 44</td>
								<td align="left">Escore I-PSS<sup>††</sup> entre 5 a 19, sem histórico cirúrgico em próstata; 64,0 (± 6,9) anos (GI<sup>||</sup>); 64,0 (± 8,0) anos (GC<sup>§</sup>).</td>
								<td align="left">2 comprimidos 3 mg de <italic>G. lucidum</italic> (distribuídos pela Chlorella Industry), 1x/dia (6mg diários).</td>
								<td align="left">2 comprimidos placebos (83,75% maltitol, 10% amido de milho, 3% vitamina C, 0,2% de gardênia amarela e 3% éster de ácido graxo de sacarose), 1x/dia.</td>
								<td align="left">3</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, volume prostático e VRP<sup>||||||</sup></td>
								<td align="left">Escore I-PSS<sup>††</sup> reduziu (melhorou) mais acentuadamente no GI<sup>||</sup> até a 12ª semana, demonstrando uma diferença significativa (<italic>p</italic> &lt; 0,001) na mudança média do escore entre os dois grupos. A Qmax<sup>||||</sup> (<italic>p</italic> = 0,400) e Qave<sup>‡‡</sup> (<italic>p</italic> = 0,080) demonstraram aumento (melhora) no GI<sup>||</sup> na 4ª e 8ª semana, mas sem diferença significativa entre os grupos na 12ª semana. Alterações não foram observadas no volume prostático e VPR<sup>||||||</sup>.</td>
							</tr>
							<tr>
								<td align="left">Vidlar, et al. (2010)<sup>(27)</sup>; República Tcheca</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Avaliar a eficácia e tolerância do pó de <italic>cranberry</italic> em homens com sintomas do trato urinário inferior, PSA<sup>§§</sup> elevado, HPB¶ e prostatite crônica não bacteriana.</td>
								<td align="left">n: 42 GI<sup>||</sup>: 21 GC<sup>§</sup>: 21</td>
								<td align="left">Achados histológicos de prostatite não bacteriana, aguda ou crônica; 62,0 (± 5,4) anos (GI<sup>||</sup>); 64,0 (± 5,4) anos (GC<sup>§</sup>);</td>
								<td align="left">Cápsula 500mg de <italic>cranberry</italic> em pó (distribuídas por Decas Botanical Synergies). 3x/dia, (1500mg diários).</td>
								<td align="left">Cápsula placebo (composição não descrita), 3x/dia.</td>
								<td align="left">6</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax, Qave, e VRP<sup>||||||</sup></td>
								<td align="left">Escore I-PSS<sup>††</sup> significativamente menor (melhor) no GI|| em comparação ao GC<sup>§</sup> (<italic>p</italic> &lt; 0,050). Melhora significativa (p &lt; 0,050) da Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, e VRP<sup>||||||</sup> em pelo menos 70% dos participantes do GI<sup>||</sup>, e piora significativa (<italic>p</italic> &lt; 0,050) do VRP<sup>||||||</sup> no GC<sup>§</sup>.</td>
							</tr>
							<tr>
								<td align="left">Vidlar, et al. (2015)<sup>(28)</sup>; República Tcheca</td>
								<td align="left">FT<sup>‡</sup></td>
								<td align="left">Avaliar o efeito de <italic>cranberry</italic> em homens com sintomas do trato urinário inferior moderado a severo.</td>
								<td align="left">n: 122 GI<sup>||</sup>/500: 38 GI<sup>||</sup>/250: 43 GC<sup>§</sup>: 41</td>
								<td align="left">Escore I-PSS<sup>††</sup> &gt; 8, sem histórico cirúrgico em próstata; 52,5 (± 5,4) anos (GI<sup>||</sup>/500); 53,3 (± 5,2) anos (GI<sup>||</sup>/250); 54,0 (±5,1) anos (GC§).</td>
								<td align="left">GI<sup>||</sup>/500: 2 cápsulas 250 mg de <italic>cranberry</italic> 1x/dia (500 mg diários); GI<sup>||</sup>/250: 1 cápsula 250mg de <italic>cranberry</italic> e 1 cápsula placebo, 1x/dia (250 mg diários); (todas cápsulas distribuídas por Decas Botanical Synergies).</td>
								<td align="left">2 cápsulas placebo (maltodextrina de baixa densidade, óleo de canola, silicato de alumínio e sódio, vermelho 40 lago e azul 1 lago), 1x/dia.</td>
								<td align="left">6</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, VRP<sup>||||||</sup> e volume de esvaziamento da bexiga</td>
								<td align="left">Redução (melhora) significativa no escore I-PSS<sup>††</sup> do GI<sup>||</sup>/500 e GI<sup>||/</sup>250, de -4,1 (± 1,9) (<italic>p</italic> &lt; 0,001) e -3,1 (± 3,0) (<italic>p</italic> = 0,050) pontos respectivamente. Qmax<sup>||||</sup> (<italic>p</italic> = 0,018), Qave<sup>‡‡</sup> (<italic>p</italic> = 0,040), VRP<sup>||||||</sup> (<italic>p</italic> = 0,027) e volume de esvaziamento da bexiga (<italic>p</italic> = 0,014) melhoraram significativamente no GI<sup>||</sup>/500. </td>
							</tr>
							<tr>
								<td align="left">Johnstone, et al. (2003)<sup>(20)</sup>; Estado Unidos da América</td>
								<td align="left">EA<sup>†</sup></td>
								<td align="left">Avaliar a resposta dos sintomas do trato urinário inferior e do nível de PSA<sup>§§</sup> a EA<sup>†</sup> em uma população de pacientes com biopsia negativa para câncer de próstata.</td>
								<td align="left">n: 30 (Não especifíca amostra em cada grupo do estudo)</td>
								<td align="left">Escore I-PSS<sup>††</sup> &gt; 8; 60,7 (± 8,2) anos (GI<sup>||</sup>); 64,7 (± 5,2) anos (GC<sup>§</sup>/EA<sup>†</sup> placebo); 63,5 (± 3,4) anos (GC<sup>§</sup>/observação).</td>
								<td align="left">PtA***: R10, B40, B32 e B10. Eletroestimulação de 4-5 Hz em R10 e B40. Sessões 3x/semana na 1ª e 2ª semana, e posteriormente 1x/semana na 3ª, 4ª e 8ª semana, 20 min/sessão.</td>
								<td align="left">GC<sup>§</sup>/EA<sup>†</sup> placebo: inserção de 5 agulhas na região posterior dos ombros, áreas sem relação aos PtA*** e sem eletroestimulação. GC<sup>§</sup>/observação: nenhuma intervenção durante o estudo.</td>
								<td align="left">3 (9 sessões)</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Não foi avaliado</td>
								<td align="left">Alterações não foram observadas no escore I-PSS<sup>††</sup> (<italic>p</italic> = 0,063).</td>
							</tr>
							<tr>
								<td align="left">Ricci, et al. (2004)<sup>(29)</sup>; Itália</td>
								<td align="left">EA<sup>†</sup></td>
								<td align="left">Avaliar se a EA<sup>†</sup> na reflexoterapia /acupuntura é capaz de tratar os componentes irritativos sensoriais dos sintomas do trato urinário inferior que persistem após a RTU<sup>†††</sup></td>
								<td align="left">n: 42 GI<sup>||</sup>:13 GC<sup>§</sup>/placebo: 14 GC<sup>§</sup>/conv: 15</td>
								<td align="left">Persistência de sintomas irritativos sensoriais do trato urinário inferior após RTU<sup>†††</sup>; 64,76 anos (52-78 anos).</td>
								<td align="left">PtA somáticos: Vaso concepção: 1, 2, 4, 5; Bexiga 21, 23 e 32; PtA*** auriculares: próstata e genitália externa. Eletroestimulação de 5-10 Hz, com maior intensidade tolerada pelo paciente. Sessões 3x /sem, mais sessões de manutenção cada 15 dias, a partir da 4ª semana, 20 min/sessão.</td>
								<td align="left">CG<sup>§</sup>/placebo: comprimido placebo (não define composição, número de comprimidos, e nem repetições ao dia); GC<sup>§</sup>/conv: Comprimido de oxibutinina 5 mg, 2x/dia (10 mg diários).</td>
								<td align="left">3 (12 sessões)</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax<sup>||||</sup>, volume prostático, frequência de micções e noctúria</td>
								<td align="left">Escore I-PSS<sup>††</sup> reduziu (melhorou) no GC<sup>§</sup> e no GI<sup>||</sup> durante os primeiros 3 meses, mas a diferença foi significativa apenas no GI<sup>||</sup> (<italic>p</italic>&lt;0,001). Alterações não foram observadas na Qmax<sup>||||</sup> e volume prostático. Redução na frequência de micções diurnas de 20% e 8% nos GI<sup>||</sup> e GC<sup>§</sup>, respectivamente. Os relatos de nocturia também reduziram 60% e 20% no GI<sup>||</sup> e GC<sup>§</sup>, respectivamente.</td>
							</tr>
							<tr>
								<td align="left">Yu, et al. (2011)<sup>(30)</sup>; Taiwan</td>
								<td align="left">EA<sup>†</sup></td>
								<td align="left">Avaliar o efeito da EA<sup>†</sup> nos sintomas do trato urinário inferior em homens com HPB<sup>¶</sup>.</td>
								<td align="left">n: 37 GI<sup>||</sup>: 18 GC<sup>§</sup>: 19</td>
								<td align="left">HPB<sup>¶</sup> confirmada por US<sup>§§§</sup> transretal com escore I-PSS<sup>††</sup> &gt; 8, sem histórico cirúrgico em próstata; 63,2 (± 10,0) anos (GI<sup>||</sup>); 59,8 (± 9,0) anos (GC<sup>§</sup>).</td>
								<td align="left">PtA***: Vaso concepção 3 e 4; Estômago 36 e Baço-Pâncreas 6. Agulhas inseridas e manipuladas por 3-5 minutos até atingir Qi. Eletroestimulação de 2Hz com intensidade de 2- 2,5 mA. Sessões 2x/sem, 20 min/sessão.</td>
								<td align="left">Agulhas inseridas superficialmente (tecido subcutâneo), 1 cm lateral aos PtA*** do GI||, sem manipulação manual e nem eletroestimulação. Mesma frequência de sessões que GI<sup>||</sup>.</td>
								<td align="left">1,5 (12 sessões)</td>
								<td align="left">I-PSS††</td>
								<td align="left">Qmax||||, Qave‡‡ e volume de esvaziamento da bexiga</td>
								<td align="left">Alterações não foram observadas no escore I-PSS†† entre os grupos. Aumento (melhora) na Qmax|||| (<italic>p</italic> = 0,030), Qave<sup>‡‡</sup> (<italic>p</italic> = 0,026) volume de esvaziamento (<italic>p</italic> = 0,038) significativo no GI<sup>||</sup>.</td>
							</tr>
							<tr>
								<td align="left">Wang, et al. (2013)<sup>(25)</sup>; China</td>
								<td align="left">EA†</td>
								<td align="left">Avaliar os efeitos da EA<sup>†</sup> no escore I-PSS<sup>††</sup>, no VRP<sup>||||||</sup>, e na Qmax<sup>||||</sup>, bem como explorar as diferenças entre a EA<sup>†</sup> em PtA*** e pontos não relacionados a esses, em pacientes com HPB<sup>¶</sup> moderada ou severa.</td>
								<td align="left">n: 100 GI<sup>||</sup>: 50 GC<sup>§</sup>: 50</td>
								<td align="left">HPB<sup>¶</sup> determinada pelo escore I-PSS<sup>††</sup> &gt; 8; 64,8 (±7,1) anos (GI<sup>||</sup>); 65,9 (±6,7) anos (GC<sup>§</sup>);</td>
								<td align="left">PtA***: Bexiga 33, com manipulação até o paciente sentir a sensação de peso e dormência. Eletroestimulação de 20 Hz, com intensidade máxima tolerada pelo paciente. Sessões 1x/dia completando 5 sessões/semana durante a 1ª e 2ª semana, e posteriormente 3 sessões/semana na 3ª e 4ª semana</td>
								<td align="left">Agulhas inseridas em dois pontos aproximadamente 6,7 cm lateral aos PtA***, sem manipulação, com eletroestimulação igual ao grupo intervenção. Mesma frequência de sessões que GI<sup>||</sup>.</td>
								<td align="left">1 (16 sessões)</td>
								<td align="left">I-PSS<sup>††</sup></td>
								<td align="left">Qmax<sup>||||</sup> e VRP<sup>||||||</sup></td>
								<td align="left">Escore I-PSS<sup>††</sup> teve uma redução (melhora) de 3,2 pontos a mais no GI<sup>||</sup> que no GC<sup>§</sup> na 18ª semana (<italic>p</italic> = 0,001). Alterações não foram observadas na Qmax<sup>||||</sup> ou VRP<sup>||||||</sup>.</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN1">
							<p>*AUASI = <italic>American Urological Association Symptom Index</italic>; <sup>†</sup>EA = Aletroacupuntura; <sup>‡</sup>FT = Fitoterapia; <sup>§</sup>GC = Grupo controle; <sup>||</sup>GI = Grupo intervenção; <sup>¶</sup>HPB = Hiperplasia prostática benigna; **IC = Intervalo de confiança; <sup>††</sup>I-PSS = <italic>International Prostate Symptom Score</italic>; <sup>‡‡</sup>Qave = Taxa de fluxo urinário médio; <sup>§§</sup>PSA = Antígeno prostático específico; <sup>||||</sup>Qmax = Taxa de pico do fluxo urinário; <sup>¶¶</sup>TC = Terapias complementares; ***PtA = Pontos de acupuntura; <sup>†††</sup>RTUP = Ressecção transuretral da próstata; <sup>‡‡‡</sup>STUI = Sintomas do trato urinário inferior; <sup>§§§</sup>US = Ultrassom; <sup>||||||</sup>VRP = Volume residual pós-micção</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>Foram avaliados 1503 homens nos estudos inclusos nesta revisão, dos quais 1294 fizeram parte dos ensaios clínicos de fitoterapia e 209 dos ensaios clínicos de eletroacupuntura. Ao considerar os estudos individualmente, esse número variou de 30<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> a 357 participantes<xref ref-type="bibr" rid="B31"><sup>31</sup></xref>. A média de idade dos participantes foi 60,7 anos (±5,6). O tempo de seguimento variou entre dois e 18 meses para os ensaios clínicos de fitoterapia (±5,1) e um a três meses para os de eletroacupuntura (±4,7).</p>
			<p>Para avaliar a efetividade das TCs, os estudos utilizaram parâmetros subjetivos e objetivos. Foram considerados os questionários <italic>American Urological Association Symptom Index</italic> (AUASI)<xref ref-type="bibr" rid="B31"><sup>31</sup></xref> e <italic>International Prostate Symptom Score</italic> (I-PSS)<xref ref-type="bibr" rid="B32"><sup>32</sup></xref> que classificam subjetivamente a gravidade dos STUI (quadros leves 0-7 pontos, moderados 8-19 pontos ou severos 20-35 pontos)<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. Como parâmetros objetivos, foram utilizados os seguintes desfechos da urodinâmica: frequência de micções, noctúria, taxa de pico do fluxo urinário (Qmax), taxa do fluxo médio urinário (Qave), volume residual pós-miccional (VRP), volume prostático e volume de esvaziamento da bexiga.</p>
			<p>Dentre os estudos incluídos nesta revisão, dois utilizaram o questionário AUASI<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref> e dez o I-PSS para avaliação dos STUI<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Apenas um estudo<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> não incluiu nenhum parâmetro da urodinâmica como um dos desfechos de avaliação dos STUI. A maioria (n=7) considerou pelo menos a Qmax e o VRP<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. </p>
			<p>Quatro estudos de fitoterapia avaliaram a efetividade do <italic>Saw palmetto</italic> (<italic>S. palmetto</italic>) para o controle dos STUI. O fitoterápico foi comparado ao placebo nas doses diárias de 320 mg<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, 640 mg<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> e 960 mg<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>. A dose de 320 mg diários, fracionada em duas vezes ao dia melhorou significativamente (<italic>p</italic> &lt; 0,001) o escore I-PSS após 24 semanas de tratamento<xref ref-type="bibr" rid="B26"><sup>26</sup></xref> e mostrou redução média de 4,4 (± 5,9) pontos no grupo intervenção, com uma diferença significativa (<italic>p</italic> = 0,038) em relação ao placebo após seis meses<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>. Essa mesma dose também reduziu 0,68 (± 0,35) pontos no escore médio AUASI do grupo intervenção, mas sem diferença estatisticamente significativa com o grupo placebo (IC95%: -0,93 a 1,01)<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>. Doses diárias mais elevadas de 640 mg e 960 mg reduziram 2,20 pontos (IC95%: -3,04 a -0,36 pontos) no escore médio AUASI, mas a melhora também foi observada no grupo placebo<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>. Nenhuma das doses avaliadas de <italic>S. palmetto</italic> melhorou os parâmetros da urodinâmica, Qmax, VRP e volume prostático<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
			<p>Outros dois ensaios clínicos avaliaram a efetividade do fitoterápico <italic>Ganoderma lucidum</italic> (<italic>G. lucidum</italic>)<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>. O fitoterápico foi avaliado nas doses diárias de 0,6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>, 6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> e 60 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>. Em comparação ao placebo, as doses diárias de 6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> e 60 mg<xref ref-type="bibr" rid="B24"><sup>24</sup></xref> reduziram significativamente (<italic>p</italic> &lt; 0,001; <italic>p</italic> = 0,012; respectivamente) os escores I-PSS e melhoraram discretamente a Qmax e Qave<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, mas sem diferenças significativas entre os grupos.</p>
			<p>Ademais, dois estudos de fitoterapia avaliaram a efetividade do uso de <italic>cranberry</italic> no controle dos STUI<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. O fitoterápico foi comparado ao placebo nas doses diárias de 250 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, 500 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> e 1500 mg<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. Na dose mais elevada de 1500 mg, fracionada em três vezes ao dia, houve redução significativa (<italic>p</italic> &lt; 0,050) do escore I-PSS do grupo intervenção, bem como melhora dos parâmetros da urodinâmica, Qmax, Qave e VRP, em 70% dos participantes desse grupo<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. No estudo que avaliou as doses de 500 e 250 mg, observou-se uma redução de 4,1 (± 1,9) e 3,1 (± 3,0) pontos nos escores I-PSS, respectivamente<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. Os parâmetros da urodinâmica, Qmax (<italic>p</italic> = 0,018), Qave (<italic>p</italic> = 0,040), VPR (<italic>p</italic> = 0,027) e volume de esvaziamento da bexiga (<italic>p</italic> = 0,014) também indicaram melhora significativa no grupo que recebeu 500 mg de <italic>cranberry</italic><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. </p>
			<p>No que tange aos estudos que avaliaram a efetividade da eletroacupuntura, três contemplaram pontos de acupuntura (PtA) pertencentes ao meridiano da bexiga<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. O ponto B32, que pertence a esse meridiano, foi o PtA mais utilizado<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Ressalta-se que em comparação ao medicamento convencional (Oxibutinina 5 mg) e ao comprimido placebo, a eletroestimulação de 5 a 10 Hz na maior intensidade tolerada do PtA B32, promoveu controle dos STUI com melhora significativa do escore I-PSS (<italic>p</italic> &lt; 0,001) e redução na frequência das micções e noctúria de 20 e 60%, respectivamente<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. </p>
			<p>Outros PtA do meridiano da bexiga foram B10 e B40<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>, B21 e B23<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> e B33<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. O PtA B33 foi o único que apontou uma redução de 3,2 pontos no escore I-PSS do grupo intervenção, demonstrando uma melhora significativa (<italic>p</italic> = 0,001) em comparação à eletroacupuntura placebo quando estimulado à 20 Hz na maior intensidade tolerada<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. </p>
			<p>Outro estudo de eletroacupuntura avaliou a efetividade dos PtA pertencentes aos meridianos distintos baço-pâncreas (BP6), estômago (E36) e vaso concepção (VC3 e VC4)<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Os pontos desses meridianos, ao serem estimulados com 3 Hz e intensidade de 2 a 2,5 mA, mostraram melhora significativa dos parâmetros da urodinâmica Qmax (<italic>p</italic> = 0,030), Qave (<italic>p</italic> = 0,026) e volume de esvaziamento da bexiga (<italic>p</italic> = 0,038) em comparação à eletroacupuntura placebo<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. No entanto, não houve redução do escore I-PSS<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
			<p>Os estudos incluídos nesta revisão foram submetidos a análise de qualidade metodológica, a partir do <italic>Joanna Briggs Institute</italic> (JBI) <italic>Critical Appraisal Tool</italic> - <italic>checklist</italic> para ensaios clínicos randomizados<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>. Nessa avaliação, seis estudos foram classificados como baixo risco de viés, sendo cinco de fitoterapia<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> e um de eletroacupuntura<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. </p>
			<p>Três estudos foram classificados como moderado risco de viés, sendo um de fitoterapia<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> e dois de eletroacupuntura<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Os estudos foram classificados como moderado risco de viés por não terem descrito as perdas ocorridas durante o seguimento e nem sobre o cegamento da equipe de pesquisa responsável pela análise dos desfechos<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. No estudo de fitoterapia<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> não foi informado o método de cegamento dos pesquisadores que aplicaram a intervenção. Já nos estudos de eletroacupuntura foram observadas falhas na descrição do processo de alocação dos participantes<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>, além da ausência de duplo-cegamento<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. </p>
			<p>O alto risco de viés foi identificado em três estudos, dois de fitoterapia<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref> e um de eletroacupuntura<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Como itens de fragilidades metodológicas têm-se a descrição incompleta do método de randomização, as diferenças entre os grupos no início do estudo, a ausência de descrição do cegamento e das perdas amostrais durante o seguimento<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Os resultados da avaliação de risco dos estudos incluídos são apresentados na <xref ref-type="table" rid="t3">Figura 4</xref>.</p>
			<p>
				<table-wrap id="t3">
					<label>Figura 4</label>
					<caption>
						<title>Classificação do risco de viés dos estudos incluídos (N=12)</title>
					</caption>
					<table>
						<colgroup>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">Autor, ano</th>
								<th align="left">Q1<sup>||</sup></th>
								<th align="left">Q2<sup>||</sup></th>
								<th align="left">Q3<sup>||</sup></th>
								<th align="left">Q4<sup>||</sup></th>
								<th align="left">Q5<sup>||</sup></th>
								<th align="left">Q6<sup>||</sup></th>
								<th align="left">Q7<sup>||</sup></th>
								<th align="left">Q8<sup>||</sup></th>
								<th align="left">Q9<sup>||</sup></th>
								<th align="left">Q10<sup>||</sup></th>
								<th align="left">Q11<sup>||</sup></th>
								<th align="left">Q12<sup>||</sup></th>
								<th align="left">Q13<sup>||</sup></th>
								<th align="left">Total</th>
								<th align="left">Risco de viés</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left">Gerber, et al., 2001<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">I</td>
								<td align="left">S</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">76,92%</td>
								<td align="left">Baixo</td>
							</tr>
							<tr>
								<td align="left">Bent, et al., 2006<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">100%</td>
								<td align="left">Baixo</td>
							</tr>
							<tr>
								<td align="left">Barry, et al., 2011<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">100%</td>
								<td align="left">Baixo</td>
							</tr>
							<tr>
								<td align="left">Ye, et al., 2019(26)</td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">46,15%</td>
								<td align="left">Alto</td>
							</tr>
							<tr>
								<td align="left">Noguchi, et al., 2008<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">92,31%</td>
								<td align="left">Baixo</td>
							</tr>
							<tr>
								<td align="left">Noguchi, et al., 2008<xref ref-type="bibr" rid="B24"><sup>24</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">92,31%</td>
								<td align="left">Baixo</td>
							</tr>
							<tr>
								<td align="left">Vidlar, et al., 2010<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>
								</td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">38,46%</td>
								<td align="left">Alto</td>
							</tr>
							<tr>
								<td align="left">Vidlar, et al., 2015<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">69,23%</td>
								<td align="left">Moderado</td>
							</tr>
							<tr>
								<td align="left">Johnstone, et al., 2003<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">S*</td>
								<td align="left">NA<sup>§</sup></td>
								<td align="left">NA<sup>§</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">53,85%</td>
								<td align="left">Moderado</td>
							</tr>
							<tr>
								<td align="left">Ricci, et al., 2004<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>
								</td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">NA<sup>§</sup></td>
								<td align="left">NA<sup>§</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">38,46%</td>
								<td align="left">Alto</td>
							</tr>
							<tr>
								<td align="left">Yu, et al., 2011<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">NA<sup>§</sup></td>
								<td align="left">I<sup>‡</sup></td>
								<td align="left">S*</td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">N<sup>†</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">69,23%</td>
								<td align="left">Moderado</td>
							</tr>
							<tr>
								<td align="left">Wang, et al., 2013<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>
								</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">NA<sup>§</sup></td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">S*</td>
								<td align="left">92,31%</td>
								<td align="left">Baixo</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN2">
							<p>*S = Sim; <sup>†</sup>N = Não; <sup>‡</sup>I = Incerto; <sup>§</sup>NA = Não se aplica; <sup>||</sup>Q = Questão</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
		</sec>
		<sec sec-type="discussion">
			<title>Discussão</title>
			<p>A presente revisão sistemática buscou identificar e avaliar a efetividade das TCs empregadas para o controle dos STUI na população masculina. Dentre os 12 ensaios clínicos incluídos, oito abordaram o uso da fitoterapia<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> e quatro a eletroacupuntura<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. </p>
			<p>Para a análise da efetividade das TCs, um dos métodos adotados considerou a avaliação subjetiva dos STUI. Dessa forma, foram utilizados questionários autoaplicáveis e internacionalmente validados<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref> que classificam e padronizam o registro dos STUI, sendo uma importante ferramenta para determinação de gravidade deste acometimento<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B34"><sup>34</sup></xref>.</p>
			<p>Dentre os questionários para avaliação dos STUI, destacam-se os questionários AUASI do comitê do <italic>American Urological Association</italic><xref ref-type="bibr" rid="B31"><sup>31</sup></xref> e o questionário I-PSS<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>, que se refere a uma adaptação do AUASI com a inclusão de um item que avalia qualidade de vida ao classificar o impacto do incômodo provocado pelos STUI em uma escala de zero a seis<xref ref-type="bibr" rid="B33"><sup>33</sup></xref>. Os dois instrumentos avaliam a gravidade dos STUI a partir de sete perguntas relacionadas a: sensação de esvaziamento incompleto da bexiga, micções frequentes, fluxo intermitente, fluxo fraco, dor ou dificuldade na micção, noctúria e urgência<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. A frequência de cada sintoma recebe uma pontuação de zero a cinco, cujo somatório determina a gravidade (quadros leves 0-7 pontos, moderados 8-19 pontos ou severos 20-35 pontos)<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. </p>
			<p>Outro método de avaliação dos STUI apresentado pelos estudos baseou-se no estudo urodinâmico. Trata-se de um teste objetivo de avaliação da função do trato urinário inferior considerado como padrão-ouro no contexto da prática clínica<xref ref-type="bibr" rid="B35"><sup>35</sup></xref>. Dentre os parâmetros do estudo urodinâmico considerados pelos estudos predominou a taxa de pico do fluxo urinário (Qmax), volume prostático e volume residual pós-miccional (VRP). Ressalta-se que apenas um estudo não considerou a efetividade da intervenção aplicada a partir da avaliação urodinâmica<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>.</p>
			<p>Quanto à efetividade das TCs, nove estudos as apontaram como uma alternativa efetiva para o controle de STUI na população masculina<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Destaca-se a fitoterapia, apontada como uma das TCs de maior uso pela população geral<xref ref-type="bibr" rid="B16"><sup>16</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B36"><sup>36</sup></xref>. A fitoterapia baseia-se no uso das plantas medicinais para o tratamento de determinados sintomas, sendo uma prática bastante reconhecida e difundida pela Organização Mundial de Saúde<xref ref-type="bibr" rid="B37"><sup>37</sup></xref>. Nesta revisão foram analisados os fitoterápicos <italic>S. palmetto</italic><xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, <italic>G. lucidum</italic><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> e <italic>cranberry</italic><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
			<p>Dentre os quatro estudos que avaliaram a efetividade do <italic>S. palmetto</italic><xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, metade<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref> concluiu que esse fitoterápico na dosagem de 320 mg diários foi efetivo no controle dos STUI em homens. Ambos os estudos apontaram uma redução estatisticamente significativa dos escores I-PSS no grupo intervenção quando comparado ao grupo placebo<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Um deles<xref ref-type="bibr" rid="B26"><sup>26</sup></xref> mostrou que o <italic>S. palmetto</italic> também foi capaz de melhorar a Qmax, corroborando com outros estudos que também apontam melhora da Qmax, além da redução da noctúria<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B38"><sup>38</sup></xref>.</p>
			<p>O <italic>S. palmetto</italic>, nome científico <italic>Serenoa repens</italic>, é um fitoterápico da família das palmeiras que devido às suas propriedades anti-inflamatórias e anti-androgênicas tem sido comumente utilizado para o controle de STUI, especialmente aqueles associados à HPB<xref ref-type="bibr" rid="B39"><sup>39</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B40"><sup>40</sup></xref>. Apesar de evidências favoráveis à sua utilização, sua aplicabilidade e efetividade na prática clínica ainda são questionadas<xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Em parte, a grande variabilidade na concentração e biodisponibilidade dos componentes, a depender do laboratório responsável pela produção do extrato, podem justificar a dificuldade em definir sua efetividade<xref ref-type="bibr" rid="B41"><sup>41</sup></xref>. Além disso, a ausência de padronização das concentrações dificulta o estabelecimento de comparações entre os ensaios clínicos<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. </p>
			<p>Em relação a dois estudos que não constataram efetividade do fitoterápico <italic>S. palmetto</italic>, variáveis como o tipo de extrato<xref ref-type="bibr" rid="B21"><sup>21</sup></xref> e a dosagem administrada<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> podem justificar os resultados obtidos. Existe mais de um tipo de extrato de <italic>S. palmetto</italic>, sendo que as formas de extração etanólico e hexânico apresentam maior efetividade clínica do composto<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. Nesse contexto, enfatiza-se que em um dos estudos<xref ref-type="bibr" rid="B21"><sup>21</sup></xref> adotou-se o extrato do tipo dióxido de carbono cuja efetividade é inferior<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. Nenhum dos outros estudos especificou o tipo de extrato de <italic>S</italic>. <italic>palmetto</italic> avaliado<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
			<p>Quanto à dosagem do fitoterápico <italic>S. palmetto</italic>, um dos estudos incluídos<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> concluiu que o <italic>S. palmetto</italic> não foi superior ao placebo. Esse ensaio clínico<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> avaliou a efetividade do <italic>S. palmetto</italic> em doses escalonadas de 320 mg, 640 mg e 960 mg diários, ou seja, considerou o dobro e o triplo da dose empregada nos outros estudos<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Desta forma, ao considerar a discrepância entre as dosagens estabelecidas sugere-se ressalvas para a interpretação dos resultados e a relevância de estudos futuros. </p>
			<p>O <italic>G. lucidum</italic>, fitoterápico de escolha em outros dois estudos desta revisão<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, consiste em um tipo de cogumelo muito conhecido em países asiáticos, cujos componentes bioativos de destaque são os triterpenos e os polissacarídeos<xref ref-type="bibr" rid="B43"><sup>43</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B44"><sup>44</sup></xref>. Apesar dos mecanismos que justificam seu efeito antitumoral, antioxidante e antibacteriano não serem completamente elucidados<xref ref-type="bibr" rid="B44"><sup>44</sup></xref>, ressalta-se os resultados satisfatórios apresentados pelos estudos incluídos<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> em que houve melhora significativa nos escores I-PSS no grupo intervenção. Dessa forma, as evidências<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> sugerem a efetividade do <italic>G</italic>. <italic>lucidum</italic>, na dosagem de 6 mg diários, para o controle de STUI em homens.</p>
			<p>Esta revisão contempla ainda dois estudos<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> que analisaram o <italic>cranberry</italic>, nome científico <italic>Vaccinium</italic> spp., fruta muito consumida nos países da América do Norte para controle de infecções do trato urinário inferior<xref ref-type="bibr" rid="B45"><sup>45</sup></xref>. O pó de <italic>cranberry</italic> analisado em ambos os estudos foi fornecido pelo mesmo laboratório, o que favorece a comparação dos resultados. Na dosagem de 250 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> e de 1500 mg diário<xref ref-type="bibr" rid="B27"><sup>27</sup></xref> esse fitoterápico reduziu significativamente o escore I-PSS no grupo intervenção<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. No entanto, ao considerar a avaliação urodinâmica, resultados mais efetivos foram melhores em dosagens mais elevadas, por exemplo, de 1500 mg diários<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. Sugere-se que o ácido siálico encontrado no extrato de <italic>cranberry</italic> possui efeito anti-inflamatório e analgésico, especialmente pela capacidade de diminuir a adesão de microrganismos na parede da bexiga<xref ref-type="bibr" rid="B45"><sup>45</sup></xref>.</p>
			<p>A eletroacupuntura foi outra TC avaliada em quatro ensaios clínicos desta revisão<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Os efeitos terapêuticos da acupuntura são obtidos a partir da ativação do fluxo de energia ou <italic>Qi</italic>, por meio da inserção de agulhas em determinados PtA com o objetivo de restaurar o equilíbrio homeostático<xref ref-type="bibr" rid="B46"><sup>46</sup></xref>. Neste contexto, a eletroacupuntura representa uma variação da acupuntura em que uma corrente elétrica é aplicada às agulhas buscando acentuar e potencializar os efeitos terapêuticos<xref ref-type="bibr" rid="B47"><sup>47</sup></xref>. O fluxo da corrente elétrica através de um meio condutor biológico desencadeia efeitos fisiológicos, envolvendo fenômenos eletroquímicos, eletrofísicos e eletrotérmicos. Dentre os parâmetros físicos mais relevantes e estudados na eletroacupuntura, destaca-se a frequência estimulatória, em especial, suas relações com a liberação de opioides endógenos em processos analgésicos e anti-inflamatórios<xref ref-type="bibr" rid="B48"><sup>48</sup></xref>. </p>
			<p>Quanto ao cegamento, os métodos de eletroacupuntura placebo empregados nos estudos incluídos foram: uso de pontos não associados aos PtA<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>, profundidade mais superficial<xref ref-type="bibr" rid="B30"><sup>30</sup></xref> e ausência de eletroestimulação<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Devido à dificuldade de cegamento dos estudos clínicos nessa área<xref ref-type="bibr" rid="B47"><sup>47</sup></xref>, acredita-se que este fato possa justificar o desenho uni cego dos quatro estudos que avaliaram o efeito desta terapia<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
			<p>Quanto aos PtA utilizados na eletroacupuntura, a maioria incluiu pelo menos um ponto referente ao meridiano da bexiga<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>, com destaque para o PtA B32 (<italic>Ciliao</italic>)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Estudos recentes identificaram resultados significativos para o tratamento de sintomas da HPB em homens<xref ref-type="bibr" rid="B49"><sup>49</sup></xref> e de sintomas de bexiga hiperativa (BH) em ratos a partir da estimulação do PtA B32<xref ref-type="bibr" rid="B50"><sup>50</sup></xref>. Sabe-se que o PtA B32 é um dos quatro pontos localizados nos quatro forames sacrais, sendo considerado o mais importante por possuir indicações amplas (disfunções miccionais, dismenorreia, dor lombar e ciática e infertilidade) e ser um dos pontos que produz maior efeito tonificante do Rim e Essência<xref ref-type="bibr" rid="B51"><sup>51</sup></xref>.</p>
			<p>Apenas um estudo incluído nesta revisão optou por utilizar PtA de outros meridianos que não condizem ao da bexiga<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>, sendo estes: baço pâncreas (BP6 - <italic>Sanyinjiao</italic>), estômago (E36 - <italic>Zusanli</italic>) e vaso concepção (VC3 - <italic>Zhongji</italic>; VC4 - <italic>Guanyuan</italic>). Estudo conduzido em ratos com bexiga hiperativa evidenciou que o ponto B33 (<italic>Zhongliao</italic>) apresentou efeito superior aos pontos BP6 (<italic>Sanyinjiao</italic>) e B40 (<italic>Weizhong</italic>) no que diz respeito ao aumento do intervalo entre as contrações<xref ref-type="bibr" rid="B52"><sup>52</sup></xref>. Portanto, sugere-se que este fato possa justificar o predomínio de protocolos que adotem PtA associados ao meridiano da bexiga em comparação aos demais. </p>
			<p>Quanto à heterogeneidade dos critérios de inclusão estabelecidos pelos estudos, dentre os ensaios clínicos de fitoterapia, três consideraram escores I-PSS ou AUASI maiores que oito para a inclusão dos participantes<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, dois definiram uma pontuação máxima de 19 no escore I-PSS<xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, um definiu um limite máximo de 24 pontos no escore AUASI<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> e outro estudo considerou uma pontuação mínima de cinco no escore I-PSS<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>. Apenas um estudo<xref ref-type="bibr" rid="B27"><sup>27</sup></xref> não considerou a pontuação em questionários de avaliação dos STUI para definir a amostra. </p>
			<p>Ademais, dois ensaios clínicos de fitoterapia utilizaram o escore AUASI e I-PSS para definir o diagnóstico de HPB entre seus participantes<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref> e a maioria considerou a participação apenas de homens sem histórico cirúrgico da próstata<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. Esta heterogeneidade para definição da causa base e da gravidade dos STUI pode influenciar na avaliação da efetividade das intervenções, visto que não está definido na literatura qual a influência da gravidade dos STUI na resposta às TCs. </p>
			<p>Da mesma forma, os participantes dos ensaios clínicos de eletroacupuntura apresentaram características distintas de seleção. Três estudos consideraram homens com escores I-PSS acima de oito pontos<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref> e um estudo não considerou nenhum escore para definição da amostra<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Em relação à causa de base para os STUI, dois estudos incluíram na amostra homens com HPB, sendo que um estudo definiu o diagnóstico com base no escore I-PSS<xref ref-type="bibr" rid="B25"><sup>25</sup></xref> e outro fez o diagnóstico a partir de um ultrassom transretal<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Além disso, um dos estudos de eletroacupuntura incluiu homens que já foram submetidos à ressecção transuretral da próstata<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>, enquanto outro estudo<xref ref-type="bibr" rid="B30"><sup>30</sup></xref> teve uma amostra apenas com homens sem histórico cirúrgico da próstata. </p>
			<p>Outro fato relevante refere-se à diferença do tempo de seguimento nos estudos, que variou entre dois e 18 meses para fitoterapia e um a três meses para eletroacupuntura. Um dos grandes desafios na realização de estudos clínicos que avaliam a efetividade das TC baseia-se na dificuldade em estabelecer protocolos fixos de tratamento. Sabe-se que este é um método que se contrapõe aos preceitos básicos da grande maioria das TC. Contudo, há de se considerar que a padronização quanto ao tempo de seguimento ideal a partir de estudos clínicos pode favorecer a replicabilidade dos protocolos e alcance dos mesmos resultados em futuras investigações. </p>
			<p>Quanto às perspectivas de inclusão dessas terapias na assistência de enfermagem, sabe-se que a Classificação das Intervenções de Enfermagem (NIC) contempla as intervenções “fitoterapia” (2420) e “estimulação cutânea” (1340)<xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. Os enfermeiros são profissionais de destaque na implementação e utilização de diversas TCs, uma vez que os princípios de sua formação são semelhantes aos paradigmas das racionalidades médicas que envolvem a medicina integrativa. Contudo, ainda é reduzido o contingente desses profissionais que atuam com essas terapias ou que possuem conhecimento para prescrever e encaminhar os usuários para esse tipo de atendimento. Destaca-se um movimento, ainda que incipiente, de enfermeiros que buscam cursos de especialização nesta área, o que contribui para a disseminação dessas terapias à comunidade e, consequente, com o aperfeiçoamento do cuidado de enfermagem<xref ref-type="bibr" rid="B54"><sup>54</sup></xref>.</p>
			<p>Destaca-se como limitação da presente revisão a seleção de estudos do tipo ensaio clínico. Dessa forma, sugere-se a ampliação futura considerando diferentes desenhos metodológicos. Outra limitação pautou-se nas evidências identificadas e que não puderam ser incluídas devido ao efeito de as TCs estarem associadas a outros tratamentos convencionais como medicamentosos ou cirúrgicos. Como resultado, as evidências apresentadas devem ser consideradas preliminares, geradoras de hipóteses e um recurso para orientar pesquisas futuras com base nas lacunas de conhecimento identificadas.</p>
		</sec>
		<sec sec-type="conclusions">
			<title>Conclusão</title>
			<p>A presente revisão sistemática identificou e avaliou doze ensaios clínicos que analisaram a efetividade de TCs para o controle dos STUI em homens. A maioria desses estudos avaliou a fitoterapia, que foi apontada como uma alternativa efetiva em seis dos oito ensaios clínicos, uma vez que reduziu a frequência de STUI a partir da redução dos escores I-PSS e parâmetros da urodinâmica. Ressaltamos ainda que, dentre os estudos de fitoterapia, predominaram aqueles classificados como baixo risco de viés. Dessa forma, ao considerar a efetividade apontada por metade dos estudos e a boa qualidade metodológica deles, sustenta-se a indicação da fitoterapia para o controle dos STUI em homens. </p>
			<p>No que diz respeito à eletroacupuntura, apesar dos resultados promissores, sugere-se o desenvolvimento de pesquisas mais robustas e com metodologias de maior nível de evidência, visto que apenas um dos ensaios clínicos foi classificado como baixo risco de viés. Sabe-se que este fato pode impactar na veracidade da efetividade da terapia implementada.</p>
			<p>No contexto dos STUI o não tratamento dos casos leves ou tratamento convencional a base de medicamentos e cirurgias para casos refratários ainda são alternativas predominantes. No entanto, considerando os possíveis efeitos das TCs, especialmente no que diz respeito ao controle de STUI, torna-se fundamental a realização de futuras investigações que possam gerar recomendações mais consistentes. De forma geral, sabe-se que as TCs são minimamente invasivas, o que implica em menor risco de sequelas, quando comparadas aos procedimentos cirúrgicos, além de terem poucos relatos de eventos adversos, ao contrário dos medicamentos.</p>
		</sec>
	</body>
	<back>
		<ref-list>
			<title>Referências</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. D'Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433-77. doi: http://doi.org/10.1002/nau.23897</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>D'Ancona</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Haylen</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Oelke</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Abranches-Monteiro</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Arnold</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Goldman</surname>
							<given-names>H</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction</article-title>
					<source>Neurourol Urodyn</source>
					<year>2019</year>
					<volume>38</volume>
					<issue>2</issue>
					<fpage>433</fpage>
					<lpage>477</lpage>
					<pub-id pub-id-type="doi">10.1002/nau.23897</pub-id>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. Cameron AP, Lewicky-Gaupp C, Smith AR, Helfand BT, Gore JL, Clemens JQ, et al. Baseline lower urinary tract symptoms in patients enrolled in lurn: a prospective, observational cohort study. J Urol. 2018;199(4):1023-31. doi: http://10.1016/j.juro.2017.10.035</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cameron</surname>
							<given-names>AP</given-names>
						</name>
						<name>
							<surname>Lewicky-Gaupp</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Smith</surname>
							<given-names>AR</given-names>
						</name>
						<name>
							<surname>Helfand</surname>
							<given-names>BT</given-names>
						</name>
						<name>
							<surname>Gore</surname>
							<given-names>JL</given-names>
						</name>
						<name>
							<surname>Clemens</surname>
							<given-names>JQ</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Baseline lower urinary tract symptoms in patients enrolled in lurn: a prospective, observational cohort study</article-title>
					<source>J Urol</source>
					<year>2018</year>
					<volume>199</volume>
					<issue>4</issue>
					<fpage>1023</fpage>
					<lpage>1031</lpage>
					<pub-id pub-id-type="doi">http://10.1016/j.juro.2017.10.035</pub-id>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Rohrmann S, Katzke V, Kaaks R. Prevalence and progression of lower urinary tract symptoms in aging population. Urology. 2016;95:158-63. doi: http://10.1016/j.urology.2016.06.021</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rohrmann</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Katzke</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Kaaks</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Prevalence and progression of lower urinary tract symptoms in aging population</article-title>
					<source>Urology</source>
					<year>2016</year>
					<volume>95</volume>
					<fpage>158</fpage>
					<lpage>163</lpage>
					<pub-id pub-id-type="doi">http://10.1016/j.urology.2016.06.021</pub-id>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Liu SP, Chuang YC, Sumarsono B, Chang HC. The prevalence and bother of lower urinary tract symptoms in men and women aged 40 years or over in Taiwan. J Formos Med Assoc. 2019;181(1):170-8. doi: http://10.1016/j.jfma.2018.03.006</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liu</surname>
							<given-names>SP</given-names>
						</name>
						<name>
							<surname>Chuang</surname>
							<given-names>YC</given-names>
						</name>
						<name>
							<surname>Sumarsono</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Chang</surname>
							<given-names>HC</given-names>
						</name>
					</person-group>
					<article-title>The prevalence and bother of lower urinary tract symptoms in men and women aged 40 years or over in Taiwan</article-title>
					<source>J Formos Med Assoc</source>
					<year>2019</year>
					<volume>181</volume>
					<issue>1</issue>
					<fpage>170</fpage>
					<lpage>178</lpage>
					<pub-id pub-id-type="doi">http://10.1016/j.jfma.2018.03.006</pub-id>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Mourad S, Shokeir A, Ayoub N, Ibrahim M, Reynolds N, Donde S, et al. Prevalence and impact of lower urinary tract symptoms: results of the Epic Survey in Turkey. Neurourol Urodyn. 2019;38(2):637-43. doi: http://doi.org/10.1002/nau.23875</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mourad</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Shokeir</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Ayoub</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Ibrahim</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Reynolds</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Donde</surname>
							<given-names>S</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Prevalence and impact of lower urinary tract symptoms: results of the Epic Survey in Turkey</article-title>
					<source>Neurourol Urodyn</source>
					<year>2019</year>
					<volume>38</volume>
					<issue>2</issue>
					<fpage>637</fpage>
					<lpage>643</lpage>
					<pub-id pub-id-type="doi">10.1002/nau.23875</pub-id>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. Liao L, Chuang YC, Liu SP, Lee KS, Yoo TK, Chu R, et al. Effect of lower urinary tract symptoms on the quality of life and sexual function of males in China, Taiwan and South Korea: sub-group analysis of a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019;11(2):O78-84. doi: http://doi.org/10.1111/luts.12220</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liao</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Chuang</surname>
							<given-names>YC</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>SP</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>KS</given-names>
						</name>
						<name>
							<surname>Yoo</surname>
							<given-names>TK</given-names>
						</name>
						<name>
							<surname>Chu</surname>
							<given-names>R</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Effect of lower urinary tract symptoms on the quality of life and sexual function of males in China, Taiwan and South Korea: sub-group analysis of a cross-sectional, population-based study</article-title>
					<source>Low Urin Tract Symptoms</source>
					<year>2019</year>
					<volume>11</volume>
					<issue>2</issue>
					<fpage>O78</fpage>
					<lpage>O84</lpage>
					<pub-id pub-id-type="doi">10.1111/luts.12220</pub-id>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Rhee SJ, Kim EY, Kim SW, Kim SH, Lee HJ, Yoon DH, et al. Longitudinal study of the relationship between lower urinary tract symptoms and depressive symptoms. J Psychosom Res. 2019;116:100-5. doi: http://doi.org/10.1016/j.jpsychores.2018.11.015</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rhee</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>EY</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>SW</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>SH</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>HJ</given-names>
						</name>
						<name>
							<surname>Yoon</surname>
							<given-names>DH</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Longitudinal study of the relationship between lower urinary tract symptoms and depressive symptoms</article-title>
					<source>J Psychosom Res</source>
					<year>2019</year>
					<volume>116</volume>
					<fpage>100</fpage>
					<lpage>105</lpage>
					<pub-id pub-id-type="doi">10.1016/j.jpsychores.2018.11.015</pub-id>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>8. Song Q, Abrams P, Sun Y. Beyond prostate, beyond surgery and beyond urology: the &quot;3bs&quot; of managing non-neurogenic male lower urinary tract symptoms. Asian J Urol. 2019;6(2):169-73. doi: http://doi.org/10.1016/j.ajur.2017.11.002</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Song</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Abrams</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Sun</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Beyond prostate, beyond surgery and beyond urology: the &quot;3bs&quot; of managing non-neurogenic male lower urinary tract symptoms</article-title>
					<source>Asian J Urol</source>
					<year>2019</year>
					<volume>6</volume>
					<issue>2</issue>
					<fpage>169</fpage>
					<lpage>173</lpage>
					<pub-id pub-id-type="doi">10.1016/j.ajur.2017.11.002</pub-id>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>9. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019; 8(5): 529-39. doi: 10.21037/tau.2019.10.01</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lokeshwar</surname>
							<given-names>SD</given-names>
						</name>
						<name>
							<surname>Harper</surname>
							<given-names>BT</given-names>
						</name>
						<name>
							<surname>Webb</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Jordan</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Dykes</surname>
							<given-names>TA</given-names>
						</name>
						<name>
							<surname>Neal</surname>
							<given-names>DE</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Epidemiology and treatment modalities for the management of benign prostatic hyperplasia</article-title>
					<source>Transl Androl Urol</source>
					<year>2019</year>
					<volume>8</volume>
					<issue>5</issue>
					<fpage>529</fpage>
					<lpage>539</lpage>
					<pub-id pub-id-type="doi">10.21037/tau.2019.10.01</pub-id>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>10. Bechis SK, Kim MM, Wintner A, Kreydin EI. Differential response to medical therapy for male lower urinary tract symptoms. Curr Bladder Dysfunct Rep. 2015;10:177-85. doi: http://doi.org/10.1007/s11884-015-0295-6</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bechis</surname>
							<given-names>SK</given-names>
						</name>
						<name>
							<surname>Kim</surname>
							<given-names>MM</given-names>
						</name>
						<name>
							<surname>Wintner</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kreydin</surname>
							<given-names>EI</given-names>
						</name>
					</person-group>
					<article-title>Differential response to medical therapy for male lower urinary tract symptoms</article-title>
					<source>Curr Bladder Dysfunct Rep</source>
					<year>2015</year>
					<volume>10</volume>
					<fpage>177</fpage>
					<lpage>185</lpage>
					<pub-id pub-id-type="doi">10.1007/s11884-015-0295-6</pub-id>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>11. World Health Organization. WHO Traditional medicine strategy: 2014-2023 [Internet]. Geneva: WHO; 2013 [cited 2021 Jan 30]. Available from: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/92455/9789241506090_eng.pdf?sequence=1">https://apps.who.int/iris/bitstream/handle/10665/92455/9789241506090_eng.pdf?sequence=1 </ext-link>
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<collab>World Health Organization</collab>
					</person-group>
					<source>WHO Traditional medicine strategy: 2014-2023</source>
					<year>2013</year>
					<publisher-loc>Geneva</publisher-loc>
					<publisher-name>WHO</publisher-name>
					<date-in-citation content-type="access-date" iso-8601-date="2021-01-30">2021 Jan 30</date-in-citation>
					<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/92455/9789241506090_eng.pdf?sequence=1">https://apps.who.int/iris/bitstream/handle/10665/92455/9789241506090_eng.pdf?sequence=1 </ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>12. Novara G, Giannarini G, Alcaraz A, Cózar-Omo JM, Descazeaud A, Montorsi F, et al. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus. 2016;2(5):553-61. doi: http://doi.org/10.1016/j.euf.2016.04.002</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Novara</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Giannarini</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Alcaraz</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Cózar-Omo</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Descazeaud</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Montorsi</surname>
							<given-names>F</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials</article-title>
					<source>Eur Urol Focus</source>
					<year>2016</year>
					<volume>2</volume>
					<issue>5</issue>
					<fpage>553</fpage>
					<lpage>561</lpage>
					<pub-id pub-id-type="doi">10.1016/j.euf.2016.04.002</pub-id>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>13. Zhang W, Ma L, Bauer BA, Liu Z, Lu Y. Acupuncture for benign prostatic hyperplasia: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0174586. doi: http://doi.org/10.1371/journal.pone.0174586</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhang</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Ma</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Bauer</surname>
							<given-names>BA</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Lu</surname>
							<given-names>Y</given-names>
						</name>
					</person-group>
					<article-title>Acupuncture for benign prostatic hyperplasia: a systematic review and meta-analysis</article-title>
					<source>PLoS One</source>
					<year>2017</year>
					<volume>12</volume>
					<issue>4</issue>
					<elocation-id>e0174586</elocation-id>
					<pub-id pub-id-type="doi">10.1371/journal.pone.0174586</pub-id>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>14. Fusco F, Creta M, Nunzio C, Gacci M, Marzi VL, Agro EF. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: a systematic review and meta-analysis of urodynamic studies. Neurourol Urodyn. 2018;37(6):1865-74. doi: http://doi.org/10.1002/nau.23554</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fusco</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Creta</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Nunzio</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Gacci</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Marzi</surname>
							<given-names>VL</given-names>
						</name>
						<name>
							<surname>Agro</surname>
							<given-names>EF</given-names>
						</name>
					</person-group>
					<article-title>Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: a systematic review and meta-analysis of urodynamic studies</article-title>
					<source>Neurourol Urodyn</source>
					<year>2018</year>
					<volume>37</volume>
					<issue>6</issue>
					<fpage>1865</fpage>
					<lpage>1874</lpage>
					<pub-id pub-id-type="doi">10.1002/nau.23554</pub-id>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>15. Russo GI, Scandura C, Mauro M, Cacciamani G, Albersen M, Hatzichristodoulou G, et al. Clinical efficacy of Serenoa repens versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review and network meta-analysis of randomized placebo-controlled clinical trials. Eur Urol Focus. 2021;7(2):420-31. doi: http://doi.org/10.1016/j.euf.2020.01.002</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Russo</surname>
							<given-names>GI</given-names>
						</name>
						<name>
							<surname>Scandura</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Mauro</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Cacciamani</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Albersen</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Hatzichristodoulou</surname>
							<given-names>G</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Clinical efficacy of Serenoa repens versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review and network meta-analysis of randomized placebo-controlled clinical trials</article-title>
					<source>Eur Urol Focus</source>
					<year>2021</year>
					<volume>7</volume>
					<issue>2</issue>
					<fpage>420</fpage>
					<lpage>431</lpage>
					<pub-id pub-id-type="doi">10.1016/j.euf.2020.01.002</pub-id>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>16. Balneaves LG, Watling CZ, Hayward EN, Ross B, Taylor-Brown J, Porcino A, et al. Addressing Complementary and Alternative Medicine Use Among Individuals with Cancer: An Integrative Review and Clinical Practice Guideline. J Natl Cancer Inst. 2022 Jan 11;114(1):25-37. doi: http://doi.org/10.1093/jnci/djab048. PMID: 33769512</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Balneaves</surname>
							<given-names>LG</given-names>
						</name>
						<name>
							<surname>Watling</surname>
							<given-names>CZ</given-names>
						</name>
						<name>
							<surname>Hayward</surname>
							<given-names>EN</given-names>
						</name>
						<name>
							<surname>Ross</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Taylor-Brown</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Porcino</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Addressing Complementary and Alternative Medicine Use Among Individuals with Cancer: An Integrative Review and Clinical Practice Guideline</article-title>
					<source>J Natl Cancer Inst</source>
					<year>2022</year>
					<volume>114</volume>
					<issue>1</issue>
					<fpage>25</fpage>
					<lpage>37</lpage>
					<pub-id pub-id-type="doi">10.1093/jnci/djab048</pub-id>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: http://doi.org/10.1136/ bmj.n71</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Page</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>McKenzie</surname>
							<given-names>JE</given-names>
						</name>
						<name>
							<surname>Bossuyt</surname>
							<given-names>PM</given-names>
						</name>
						<name>
							<surname>Boutron</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Hoffmann</surname>
							<given-names>TC</given-names>
						</name>
						<name>
							<surname>Mulrow</surname>
							<given-names>CD</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>
					<source>BMJ</source>
					<year>2021</year>
					<volume>372</volume>
					<fpage>n71</fpage>
					<lpage>n71</lpage>
					<pub-id pub-id-type="doi">10.1136/</pub-id>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>18. Joanna Briggs Institute. The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews: checklist for randomized controlled trials. Adelaide: JBI; 2017 [cited 2021 Apr 30]. Available from: <ext-link ext-link-type="uri" xlink:href="https://jbi.global/sites/default/files/2019-05/JBI_RCTs_Appraisal_tool2017_0.pdf">https://jbi.global/sites/default/files/2019-05/JBI_RCTs_Appraisal_tool2017_0.pdf </ext-link>
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<collab>Joanna Briggs Institute</collab>
					</person-group>
					<source>The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews: checklist for randomized controlled trials</source>
					<year>2017</year>
					<publisher-loc>Adelaide</publisher-loc>
					<publisher-name>JBI</publisher-name>
					<date-in-citation content-type="access-date" iso-8601-date="2021-04-30">2021 Apr 30</date-in-citation>
					<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://jbi.global/sites/default/files/2019-05/JBI_RCTs_Appraisal_tool2017_0.pdf">https://jbi.global/sites/default/files/2019-05/JBI_RCTs_Appraisal_tool2017_0.pdf </ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>19. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of Saw Palmetto in men with lower urinary tract symptom. Urology. 2001;58(6):960-3. doi: http://doi.org/10.1016/S0090-4295(01)01442-X</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gerber</surname>
							<given-names>GS</given-names>
						</name>
						<name>
							<surname>Kuznetsov</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Johnson</surname>
							<given-names>BC</given-names>
						</name>
						<name>
							<surname>Burstein</surname>
							<given-names>JD</given-names>
						</name>
					</person-group>
					<article-title>Randomized, double-blind, placebo-controlled trial of Saw Palmetto in men with lower urinary tract symptom</article-title>
					<source>Urology</source>
					<year>2001</year>
					<volume>58</volume>
					<issue>6</issue>
					<fpage>960</fpage>
					<lpage>963</lpage>
					<pub-id pub-id-type="doi">10.1016/S0090-4295(01)01442-X</pub-id>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>20. Johnstone PA, Bloom TL, Niemtzow RC, Crain D, Riffenburgh RH, Amling CL. A prospective, randomized pilot trial of acupuncture of the kidney-bladder distinct meridian for lower urinary tract symptoms. J Urol. 2003;169(3):1037-9. doi: http://doi.org/10.1097/01.ju.0000044925.03113.ab</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Johnstone</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Bloom</surname>
							<given-names>TL</given-names>
						</name>
						<name>
							<surname>Niemtzow</surname>
							<given-names>RC</given-names>
						</name>
						<name>
							<surname>Crain</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Riffenburgh</surname>
							<given-names>RH</given-names>
						</name>
						<name>
							<surname>Amling</surname>
							<given-names>CL</given-names>
						</name>
					</person-group>
					<article-title>A prospective, randomized pilot trial of acupuncture of the kidney-bladder distinct meridian for lower urinary tract symptoms</article-title>
					<source>J Urol</source>
					<year>2003</year>
					<volume>169</volume>
					<issue>3</issue>
					<fpage>1037</fpage>
					<lpage>1039</lpage>
					<pub-id pub-id-type="doi">10.1097/01.ju.0000044925.03113.ab</pub-id>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>21. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw Palmetto for benign prostatic hyperplasia. N Eng J Med. 2006;354(6):557-66. doi: http://doi.org/10.1056/NEJMoa053085</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bent</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Kane</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Shinohara</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Neuhaus</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Hudes</surname>
							<given-names>ES</given-names>
						</name>
						<name>
							<surname>Goldberg</surname>
							<given-names>H</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Saw Palmetto for benign prostatic hyperplasia</article-title>
					<source>N Eng J Med</source>
					<year>2006</year>
					<volume>354</volume>
					<issue>6</issue>
					<fpage>557</fpage>
					<lpage>566</lpage>
					<pub-id pub-id-type="doi">10.1056/NEJMoa053085</pub-id>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>22. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-51. doi: http://doi.org/10.1001/jama.2011.1364</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barry</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Meleth</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>JY</given-names>
						</name>
						<name>
							<surname>Kreder</surname>
							<given-names>KJ</given-names>
						</name>
						<name>
							<surname>Avins</surname>
							<given-names>AL</given-names>
						</name>
						<name>
							<surname>Nickel</surname>
							<given-names>JC</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial</article-title>
					<source>JAMA</source>
					<year>2011</year>
					<volume>306</volume>
					<issue>12</issue>
					<fpage>1344</fpage>
					<lpage>1351</lpage>
					<pub-id pub-id-type="doi">10.1001/jama.2011.1364</pub-id>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>23. Noguchi M, Kakuma T, Tomiyasu K, Kurita Y, Kukihara H, Konishi K, et al. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-raging study. Asian J Androl. 2008;10(4):651-8. doi: http://doi.org/10.1111/j.1745-7262.2008.00336.x</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Noguchi</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kakuma</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Tomiyasu</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Kurita</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Kukihara</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Konishi</surname>
							<given-names>K</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-raging study</article-title>
					<source>Asian J Androl</source>
					<year>2008</year>
					<volume>10</volume>
					<issue>4</issue>
					<fpage>651</fpage>
					<lpage>658</lpage>
					<pub-id pub-id-type="doi">10.1111/j.1745-7262.2008.00336.x</pub-id>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>24. Noguchi M, Kakuma T, Tomiyasu K, Yamada A, Itoh K, Konishi F, et al. Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. Asian J Androl. 2008;10(5):777-85. doi: http://doi.org/10.1111/j.1745-7262.2008.00361.x</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Noguchi</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kakuma</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Tomiyasu</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Yamada</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Itoh</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Konishi</surname>
							<given-names>F</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms</article-title>
					<source>Asian J Androl</source>
					<year>2008</year>
					<volume>10</volume>
					<issue>5</issue>
					<fpage>777</fpage>
					<lpage>785</lpage>
					<pub-id pub-id-type="doi">10.1111/j.1745-7262.2008.00361.x</pub-id>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>25. Wang Y, Liu B, Yu J, Wu J, Wang J, Liu Z. Electroacupuncture for Moderate and Severe Benign Prostatic Hyperplasia: A Randomized Controlled Trial. PLoS One. 2013;8(4):e59449. doi: http://doi.org/10.1371/journal.pone.0059449</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Z</given-names>
						</name>
					</person-group>
					<article-title>Electroacupuncture for Moderate and Severe Benign Prostatic Hyperplasia: A Randomized Controlled Trial</article-title>
					<source>PLoS One</source>
					<year>2013</year>
					<volume>8</volume>
					<issue>4</issue>
					<elocation-id>e59449</elocation-id>
					<pub-id pub-id-type="doi">10.1371/journal.pone.0059449</pub-id>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>26. Ye Z, Huang J, Zhou L, Chen S, Wang Z, Ma L, et al. Efficacy and safety of Serenoa repens extract among patients with benign prostatic hyperplasia in China: a multicenter, randomized, double-blind, placebo-controlled trial. Urology. 2019;129:172-9. doi: http://doi.org/10.1016/j.urology.2019.02.030</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ye</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Zhou</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Ma</surname>
							<given-names>L</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Efficacy and safety of Serenoa repens extract among patients with benign prostatic hyperplasia in China: a multicenter, randomized, double-blind, placebo-controlled trial</article-title>
					<source>Urology</source>
					<year>2019</year>
					<volume>129</volume>
					<fpage>172</fpage>
					<lpage>179</lpage>
					<pub-id pub-id-type="doi">10.1016/j.urology.2019.02.030</pub-id>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>27. Vidlar A, Vostalova J, Ulrichova J, Student V, Stejskal D, Reichenbach R, et al. The effectiveness of dried cranberries (Vaccinium macrocarpon) in men with lower urinary tract symptoms. Br J Nutr. 2010;104(8):1181-9. doi: http://doi.org/10.1017/S0007114510002059</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Vidlar</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Vostalova</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ulrichova</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Student</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Stejskal</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Reichenbach</surname>
							<given-names>R</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The effectiveness of dried cranberries (Vaccinium macrocarpon) in men with lower urinary tract symptoms</article-title>
					<source>Br J Nutr</source>
					<year>2010</year>
					<volume>104</volume>
					<issue>8</issue>
					<fpage>1181</fpage>
					<lpage>1189</lpage>
					<pub-id pub-id-type="doi">10.1017/S0007114510002059</pub-id>
				</element-citation>
			</ref>
			<ref id="B28">
				<label>28</label>
				<mixed-citation>28. Vidlar A, Student V, Vostalova J, Fromentin E, Roller M, Simanek V, et al. Cranberry fruit powder (Flowens(tm)) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study. World J Urol. 2016;34(3):419-24. doi: http://doi.org/10.1007/s00345-015-1611-7</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Vidlar</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Student</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Vostalova</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Fromentin</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Roller</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Simanek</surname>
							<given-names>V</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Cranberry fruit powder (Flowens(tm)) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study</article-title>
					<source>World J Urol</source>
					<year>2016</year>
					<volume>34</volume>
					<issue>3</issue>
					<fpage>419</fpage>
					<lpage>424</lpage>
					<pub-id pub-id-type="doi">10.1007/s00345-015-1611-7</pub-id>
				</element-citation>
			</ref>
			<ref id="B29">
				<label>29</label>
				<mixed-citation>29. Ricci L, Minardi D, Romoli M, Galosi AB, Muzzonigro G. Acupuncture reflexotherapy in the treatment of sensory urgency that persists after transurethral resection of the prostate: a preliminary report. Neurourol Urodyn. 2004;23(1):58-62. doi: http://doi.org/10.1002/nau.10105</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ricci</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Minardi</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Romoli</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Galosi</surname>
							<given-names>AB</given-names>
						</name>
						<name>
							<surname>Muzzonigro</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>Acupuncture reflexotherapy in the treatment of sensory urgency that persists after transurethral resection of the prostate: a preliminary report</article-title>
					<source>Neurourol Urodyn</source>
					<year>2004</year>
					<volume>23</volume>
					<issue>1</issue>
					<fpage>58</fpage>
					<lpage>62</lpage>
					<pub-id pub-id-type="doi">10.1002/nau.10105</pub-id>
				</element-citation>
			</ref>
			<ref id="B30">
				<label>30</label>
				<mixed-citation>30. Yu JS, Shen KH, Chen WC, Her JS, Hsieh CL. Effects of electroacupuncture on benign prostate hyperplasia patients with lower urinary tract symptoms: A single-blinded, randomized controlled trial. Evid Based Complement Alternat Med. 2011;2011:303198. doi: http://doi.org/10.1155/2011/303198</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yu</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Shen</surname>
							<given-names>KH</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>WC</given-names>
						</name>
						<name>
							<surname>Her</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Hsieh</surname>
							<given-names>CL</given-names>
						</name>
					</person-group>
					<article-title>Effects of electroacupuncture on benign prostate hyperplasia patients with lower urinary tract symptoms: A single-blinded, randomized controlled trial</article-title>
					<source>Evid Based Complement Alternat Med</source>
					<year>2011</year>
					<volume>2011</volume>
					<fpage>303198</fpage>
					<lpage>303198</lpage>
					<pub-id pub-id-type="doi">10.1155/2011/303198</pub-id>
				</element-citation>
			</ref>
			<ref id="B31">
				<label>31</label>
				<mixed-citation>31. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 2017;192(2S):S189-S197. doi: http://doi.org/10.1016/j.juro.2016.10.071</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barry</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Fowler</surname>
							<given-names>FJ</given-names>
						</name>
						<name>
							<surname>O'Leary</surname>
							<given-names>MP</given-names>
						</name>
						<name>
							<surname>Bruskewitz</surname>
							<given-names>RC</given-names>
						</name>
						<name>
							<surname>Holtgrewe</surname>
							<given-names>HL</given-names>
						</name>
						<name>
							<surname>Mebust</surname>
							<given-names>WK</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The American Urological Association Symptom Index for benign prostatic hyperplasia</article-title>
					<source>J Urol</source>
					<year>2017</year>
					<volume>192</volume>
					<issue>2S</issue>
					<fpage>S189</fpage>
					<lpage>S197</lpage>
					<pub-id pub-id-type="doi">10.1016/j.juro.2016.10.071</pub-id>
				</element-citation>
			</ref>
			<ref id="B32">
				<label>32</label>
				<mixed-citation>32. Harley SJD, Wittert G, Brook NR, Secombe P, Campbell J, Lockwood C. Identifying predictors of change in the severity of untreated lower urinary tract symptoms in men: a systematic review protocol. JBI Database System Rev Implement Rep. 2017;15(6):1585-92. doi: http://doi.org/10.11124/JBISRIR-2016-003129</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Harley</surname>
							<given-names>SJD</given-names>
						</name>
						<name>
							<surname>Wittert</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Brook</surname>
							<given-names>NR</given-names>
						</name>
						<name>
							<surname>Secombe</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Campbell</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Lockwood</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Identifying predictors of change in the severity of untreated lower urinary tract symptoms in men a systematic review protocol</article-title>
					<source>JBI Database System Rev Implement Rep</source>
					<year>2017</year>
					<volume>15</volume>
					<issue>6</issue>
					<fpage>1585</fpage>
					<lpage>1592</lpage>
					<pub-id pub-id-type="doi">10.11124/JBISRIR-2016-003129</pub-id>
				</element-citation>
			</ref>
			<ref id="B33">
				<label>33</label>
				<mixed-citation>33. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) [Internet]. Arnhem: Netherlands; 2018 [cited 2021 Apr 30]. Available from: <ext-link ext-link-type="uri" xlink:href="https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#9">https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#9 </ext-link>
				</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Gravas</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Cornu</surname>
							<given-names>JN</given-names>
						</name>
						<name>
							<surname>Gacci</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Gratzke</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Herrmann</surname>
							<given-names>TRW</given-names>
						</name>
						<name>
							<surname>Mamoulakis</surname>
							<given-names>C</given-names>
						</name>
						<etal/>
					</person-group>
					<source>EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)</source>
					<year>2018</year>
					<publisher-loc>Arnhem</publisher-loc>
					<publisher-name>Netherlands</publisher-name>
					<date-in-citation content-type="access-date" iso-8601-date="2021-04-30">2021 Apr 30</date-in-citation>
					<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#9">https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#9 </ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B34">
				<label>34</label>
				<mixed-citation>34. Parsons JK, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol. 2020;204:799-804. doi: http://doi.org/10.1097/JU.0000000000001298</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Parsons</surname>
							<given-names>JK</given-names>
						</name>
						<name>
							<surname>Barry</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Dahm</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Gandhi</surname>
							<given-names>MC</given-names>
						</name>
						<name>
							<surname>Kaplan</surname>
							<given-names>SA</given-names>
						</name>
						<name>
							<surname>Kohler</surname>
							<given-names>TS</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia AUA guideline amendment 2020</article-title>
					<source>J Urol</source>
					<year>2020</year>
					<volume>204</volume>
					<fpage>799</fpage>
					<lpage>804</lpage>
					<pub-id pub-id-type="doi">10.1097/JU.0000000000001298</pub-id>
				</element-citation>
			</ref>
			<ref id="B35">
				<label>35</label>
				<mixed-citation>35. Rosier PFWM, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, et al. International Continence Society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243-60. doi: http://doi.org/10.1002/nau.23124</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rosier</surname>
							<given-names>PFWM</given-names>
						</name>
						<name>
							<surname>Schaefer</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Lose</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Goldman</surname>
							<given-names>HB</given-names>
						</name>
						<name>
							<surname>Guralnick</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Eustice</surname>
							<given-names>S</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>International Continence Society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study</article-title>
					<source>Neurourol Urodyn</source>
					<year>2017</year>
					<volume>36</volume>
					<issue>5</issue>
					<fpage>1243</fpage>
					<lpage>1260</lpage>
					<pub-id pub-id-type="doi">10.1002/nau.23124</pub-id>
				</element-citation>
			</ref>
			<ref id="B36">
				<label>36</label>
				<mixed-citation>36. Boing AC, Santiago PHR, Tesser CD, Furlan IL, Bertoldi AD, Boing AF. Prevalence and associated factors with integrative and complementary practices use in Brazil. Complement Ther Clin Pract. 2019;37:1-5. doi: http://doi.org/10.1016/j.ctcp.2019.07.009</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Boing</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Santiago</surname>
							<given-names>PHR</given-names>
						</name>
						<name>
							<surname>Tesser</surname>
							<given-names>CD</given-names>
						</name>
						<name>
							<surname>Furlan</surname>
							<given-names>IL</given-names>
						</name>
						<name>
							<surname>Bertoldi</surname>
							<given-names>AD</given-names>
						</name>
						<name>
							<surname>Boing</surname>
							<given-names>AF</given-names>
						</name>
					</person-group>
					<article-title>Prevalence and associated factors with integrative and complementary practices use in Brazil</article-title>
					<source>Complement Ther Clin Pract</source>
					<year>2019</year>
					<volume>37</volume>
					<fpage>1</fpage>
					<lpage>5</lpage>
					<pub-id pub-id-type="doi">10.1016/j.ctcp.2019.07.009</pub-id>
				</element-citation>
			</ref>
			<ref id="B37">
				<label>37</label>
				<mixed-citation>37. Falzon CC, Balabanova A. Phytotherapy: An introduction to herbal medicine. Prim Care. 2017;44(2):217-27. doi: http://doi.org/10.1016/j.pop.2017.02.001</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Falzon</surname>
							<given-names>CC</given-names>
						</name>
						<name>
							<surname>Balabanova</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Phytotherapy: An introduction to herbal medicine</article-title>
					<source>Prim Care</source>
					<year>2017</year>
					<volume>44</volume>
					<issue>2</issue>
					<fpage>217</fpage>
					<lpage>227</lpage>
					<pub-id pub-id-type="doi">10.1016/j.pop.2017.02.001</pub-id>
				</element-citation>
			</ref>
			<ref id="B38">
				<label>38</label>
				<mixed-citation>38. Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, López BM, Fernández-Gómez JM, Angulo JC, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon(r)) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049-65. doi: http://doi.org/10.1111/bju.14362</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Vela-Navarrete</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Alcaraz</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Rodríguez-Antolín</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>López</surname>
							<given-names>BM</given-names>
						</name>
						<name>
							<surname>Fernández-Gómez</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Angulo</surname>
							<given-names>JC</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Efficacy and safety of a hexanic extract of Serenoa repens (Permixon(r)) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies</article-title>
					<source>BJU Int</source>
					<year>2018</year>
					<volume>122</volume>
					<issue>6</issue>
					<fpage>1049</fpage>
					<lpage>1065</lpage>
					<pub-id pub-id-type="doi">10.1111/bju.14362</pub-id>
				</element-citation>
			</ref>
			<ref id="B39">
				<label>39</label>
				<mixed-citation>39. Latil A, Pétrissans MT, Rouquet J, Robert G, Taille A. Effects of hexanic extract of Serenoa repens (Permixon(r) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75(16):1857-67. doi: http://doi.org/10.1002/pros.23059</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Latil</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Pétrissans</surname>
							<given-names>MT</given-names>
						</name>
						<name>
							<surname>Rouquet</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Robert</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Taille</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Effects of hexanic extract of Serenoa repens (Permixon(r) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia</article-title>
					<source>Prostate</source>
					<year>2015</year>
					<volume>75</volume>
					<issue>16</issue>
					<fpage>1857</fpage>
					<lpage>1867</lpage>
					<pub-id pub-id-type="doi">10.1002/pros.23059</pub-id>
				</element-citation>
			</ref>
			<ref id="B40">
				<label>40</label>
				<mixed-citation>40. Gravas S, Samarinas M, Zacharouli K, Karatzas A, Tzortzis V, Koukoulis G, et al. The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol. 2019;37(3):539-44. doi: http://doi.org/10.1007/s00345-018-2409-1</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gravas</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Samarinas</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Zacharouli</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Karatzas</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Tzortzis</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Koukoulis</surname>
							<given-names>G</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study</article-title>
					<source>World J Urol</source>
					<year>2019</year>
					<volume>37</volume>
					<issue>3</issue>
					<fpage>539</fpage>
					<lpage>544</lpage>
					<pub-id pub-id-type="doi">10.1007/s00345-018-2409-1</pub-id>
				</element-citation>
			</ref>
			<ref id="B41">
				<label>41</label>
				<mixed-citation>41. Giammarioli S, Boniglia C, Stasio L, Gargiulo R, Mosca M, Carratu B. Phytosterols in supplements containing Serenoa repens: an example of variability of active principles in commercial plant-based products. Nat Prod Res. 2019;33(15):2257-61. doi: http://doi.org/10.1080/14786419.2018.1490910</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Giammarioli</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Boniglia</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Stasio</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Gargiulo</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Mosca</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Carratu</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<article-title>Phytosterols in supplements containing Serenoa repens: an example of variability of active principles in commercial plant-based products</article-title>
					<source>Nat Prod Res</source>
					<year>2019</year>
					<volume>33</volume>
					<issue>15</issue>
					<fpage>2257</fpage>
					<lpage>2261</lpage>
					<pub-id pub-id-type="doi">10.1080/14786419.2018.1490910</pub-id>
				</element-citation>
			</ref>
			<ref id="B42">
				<label>42</label>
				<mixed-citation>42. Gorne RC, Wegener T, Kelber O, Feistel B, Reichling J. Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms: an overview. Wien Med Wochenshr. 2017;167(7-8):177-82. doi: http://doi.org/10.1007/s10354-016-0526-2</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gorne</surname>
							<given-names>RC</given-names>
						</name>
						<name>
							<surname>Wegener</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kelber</surname>
							<given-names>O</given-names>
						</name>
						<name>
							<surname>Feistel</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Reichling</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms: an overview</article-title>
					<source>Wien Med Wochenshr</source>
					<year>2017</year>
					<volume>167</volume>
					<issue>7-8</issue>
					<fpage>177</fpage>
					<lpage>182</lpage>
					<pub-id pub-id-type="doi">10.1007/s10354-016-0526-2</pub-id>
				</element-citation>
			</ref>
			<ref id="B43">
				<label>43</label>
				<mixed-citation>43. Qu L, Li S, Zhou Y, Chen J, Qin X, et al. Anticancer effect of triterpenes from Ganoderma lucidum in human prostate cancer cell. Oncol Lett. 2017;14(6):7467-72. doi: http://doi.org/10.3892/ol.2017.7153</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Qu</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Zhou</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Qin</surname>
							<given-names>X</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Anticancer effect of triterpenes from Ganoderma lucidum in human prostate cancer cell</article-title>
					<source>Oncol Lett</source>
					<year>2017</year>
					<volume>14</volume>
					<issue>6</issue>
					<fpage>7467</fpage>
					<lpage>7472</lpage>
					<pub-id pub-id-type="doi">10.3892/ol.2017.7153</pub-id>
				</element-citation>
			</ref>
			<ref id="B44">
				<label>44</label>
				<mixed-citation>44. Cor D, Knez Z, Hrncic MK. Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of Ganoderma lucidum terpenoids and polysaccharides: a review. Molecules. 2018;23(3):649. doi: http://doi.org/10.3390/molecules23030649</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cor</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Knez</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Hrncic</surname>
							<given-names>MK</given-names>
						</name>
					</person-group>
					<article-title>Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of Ganoderma lucidum terpenoids and polysaccharides: a review</article-title>
					<source>Molecules</source>
					<year>2018</year>
					<volume>23</volume>
					<issue>3</issue>
					<fpage>649</fpage>
					<lpage>649</lpage>
					<pub-id pub-id-type="doi">10.3390/molecules23030649</pub-id>
				</element-citation>
			</ref>
			<ref id="B45">
				<label>45</label>
				<mixed-citation>45. Shaheen G, Akram M, Jabeen F, Shah SMA, Munir N, Daniyal M, et al. Therapeutic potential of medicinal plants for the management of urinary tract infections: a systematic review. Clin Exp Pharmacol Physiol. 2019;46(7):613-24. doi: http://doi.org/10.1111/1440-1681.13092</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Shaheen</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Akram</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Jabeen</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Shah</surname>
							<given-names>SMA</given-names>
						</name>
						<name>
							<surname>Munir</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Daniyal</surname>
							<given-names>M</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Therapeutic potential of medicinal plants for the management of urinary tract infections: a systematic review</article-title>
					<source>Clin Exp Pharmacol Physiol</source>
					<year>2019</year>
					<volume>46</volume>
					<issue>7</issue>
					<fpage>613</fpage>
					<lpage>624</lpage>
					<pub-id pub-id-type="doi">10.1111/1440-1681.13092</pub-id>
				</element-citation>
			</ref>
			<ref id="B46">
				<label>46</label>
				<mixed-citation>46. Liu BP, Wang YT, Chen S. Effect of acupuncture on clinical symptoms and laboratory indicators for chronic prostatitis/ chronic pelvic pain syndrome: A systematic review and meta-analysis. Int Urol Nephrol. 2016;48(12):1977-91. doi: http://doi.org/10.1007/s11255-016-1403-z</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liu</surname>
							<given-names>BP</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>YT</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Effect of acupuncture on clinical symptoms and laboratory indicators for chronic prostatitis/ chronic pelvic pain syndrome: A systematic review and meta-analysis</article-title>
					<source>Int Urol Nephrol</source>
					<year>2016</year>
					<volume>48</volume>
					<issue>12</issue>
					<fpage>1977</fpage>
					<lpage>1991</lpage>
					<pub-id pub-id-type="doi">10.1007/s11255-016-1403-z</pub-id>
				</element-citation>
			</ref>
			<ref id="B47">
				<label>47</label>
				<mixed-citation>47. Chen ZX, Li Y, Zhang XG, Chen S, Yang WT, Zheng XW, et al. Sham eletroacupuncture methods in randomized controlled trials. Sci Rep. 2017;7(40837). doi: http://doi.org/10.1038/srep40837</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chen</surname>
							<given-names>ZX</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>XG</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>WT</given-names>
						</name>
						<name>
							<surname>Zheng</surname>
							<given-names>XW</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Sham eletroacupuncture methods in randomized controlled trials</article-title>
					<source>Sci Rep</source>
					<year>2017</year>
					<volume>7</volume>
					<issue>40837</issue>
					<pub-id pub-id-type="doi">10.1038/srep40837</pub-id>
				</element-citation>
			</ref>
			<ref id="B48">
				<label>48</label>
				<mixed-citation>48. Yamamoto H, Kawada T, Kamiya A, Miyazaki S, Sugimachi M. Involvement of the mechanoreceptors in the sensory mechanisms of manual and electrical acupuncture. Auton Neurosci. 2011 Feb 24;160(1-2):27-31. doi: http://doi.org/10.1016/j.autneu.2010.11.004</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yamamoto</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Kawada</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kamiya</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Miyazaki</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Sugimachi</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Involvement of the mechanoreceptors in the sensory mechanisms of manual and electrical acupuncture</article-title>
					<source>Auton Neurosci</source>
					<year>2011</year>
					<volume>160</volume>
					<issue>1-2</issue>
					<fpage>27</fpage>
					<lpage>31</lpage>
					<pub-id pub-id-type="doi">10.1016/j.autneu.2010.11.004</pub-id>
				</element-citation>
			</ref>
			<ref id="B49">
				<label>49</label>
				<mixed-citation>49. Yuan H, Wei N, Li Y, Yu L, Zhang Y, Ong WL, et al. Effect of depth of electroacupuncture on the IPSS of patients with benign prostatic hyperplasia. Evid Based Complement Alternat Med. 2019;2019(1439141). doi: http://doi.org/10.1155/2019/1439141</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yuan</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Wei</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Ong</surname>
							<given-names>WL</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Effect of depth of electroacupuncture on the IPSS of patients with benign prostatic hyperplasia</article-title>
					<source>Evid Based Complement Alternat Med</source>
					<year>2019</year>
					<volume>2019</volume>
					<issue>1439141</issue>
					<pub-id pub-id-type="doi">10.1155/2019/1439141</pub-id>
				</element-citation>
			</ref>
			<ref id="B50">
				<label>50</label>
				<mixed-citation>50. Feng QF, Zhang AD, Xing M, Wang X, Ming SR, Chen YI. Electroacupuncture alleviates bladder overactivity via inhabiting bladder P2X3 receptor. Evid Based Complement Alternat Med. 2020;2020(4080891). doi: http://doi.org/10.1155/2020/4080891</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Feng</surname>
							<given-names>QF</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>AD</given-names>
						</name>
						<name>
							<surname>Xing</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Ming</surname>
							<given-names>SR</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>YI</given-names>
						</name>
					</person-group>
					<article-title>Electroacupuncture alleviates bladder overactivity via inhabiting bladder P2X3 receptor</article-title>
					<source>Evid Based Complement Alternat Med</source>
					<year>2020</year>
					<volume>2020</volume>
					<issue>4080891</issue>
					<pub-id pub-id-type="doi">10.1155/2020/4080891</pub-id>
				</element-citation>
			</ref>
			<ref id="B51">
				<label>51</label>
				<mixed-citation>51. Maciocia G. The Foundations of Chinese Medicine. 3. ed. Rio de Janeiro: Roca; 2017.</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Maciocia</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<source>The Foundations of Chinese Medicine</source>
					<year>2017</year>
					<edition>3</edition>
					<publisher-loc>Rio de Janeiro</publisher-loc>
					<publisher-name>Roca</publisher-name>
				</element-citation>
			</ref>
			<ref id="B52">
				<label>52</label>
				<mixed-citation>52. Yang L, Wang Y, Mo Q, Liu Z. A comparative study of electroacupuncture at Zhongliao (BL33) and other acupoints for overactive bladder symptoms. Front Med. 2017;11(1):129-36. doi: http://doi.org/10.1007/s11684-016-0491-6</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Yang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Mo</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>Z</given-names>
						</name>
					</person-group>
					<article-title>A comparative study of electroacupuncture at Zhongliao (BL33) and other acupoints for overactive bladder symptoms</article-title>
					<source>Front Med</source>
					<year>2017</year>
					<volume>11</volume>
					<issue>1</issue>
					<fpage>129</fpage>
					<lpage>136</lpage>
					<pub-id pub-id-type="doi">10.1007/s11684-016-0491-6</pub-id>
				</element-citation>
			</ref>
			<ref id="B53">
				<label>53</label>
				<mixed-citation>53. Butcher HK, Bulechek GM, Dochterman JM, Wagner CM. Nursing Intervention Classification. 7. ed. Maryland Heights (MO): Elsevier; 2018.</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Butcher</surname>
							<given-names>HK</given-names>
						</name>
						<name>
							<surname>Bulechek</surname>
							<given-names>GM</given-names>
						</name>
						<name>
							<surname>Dochterman</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Wagner</surname>
							<given-names>CM</given-names>
						</name>
					</person-group>
					<source>Nursing Intervention Classification</source>
					<year>2018</year>
					<edition>7</edition>
					<publisher-loc>Maryland Heights(MO)</publisher-loc>
					<publisher-name>Elsevier</publisher-name>
				</element-citation>
			</ref>
			<ref id="B54">
				<label>54</label>
				<mixed-citation>54. Azevedo C, Moura CC, Corrêa HP, Mata LRF, Chaves ECL, Chianca TCM. Complementary and integrative therapies in the scope of nursing: legal aspects and academic assistance panorama. Esc Anna Nery. 2019;23(2):e20180389. doi: http://doi.org/10.1590/2177-9465-EAN-2018-0389</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Azevedo</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Moura</surname>
							<given-names>CC</given-names>
						</name>
						<name>
							<surname>Corrêa</surname>
							<given-names>HP</given-names>
						</name>
						<name>
							<surname>Mata</surname>
							<given-names>LRF</given-names>
						</name>
						<name>
							<surname>Chaves</surname>
							<given-names>ECL</given-names>
						</name>
						<name>
							<surname>Chianca</surname>
							<given-names>TCM</given-names>
						</name>
					</person-group>
					<article-title>Complementary and integrative therapies in the scope of nursing: legal aspects and academic assistance panorama</article-title>
					<source>Esc Anna Nery</source>
					<year>2019</year>
					<volume>23</volume>
					<issue>2</issue>
					<elocation-id>e20180389</elocation-id>
					<pub-id pub-id-type="doi">10.1590/2177-9465-EAN-2018-0389</pub-id>
				</element-citation>
			</ref>
		</ref-list>
		<fn-group>
			<fn fn-type="financial-disclosure" id="fn4">
				<label>Apoio financeiro</label>
				<p> Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), processo nº 429958/2018-8 e da Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), processo APQ 01034-21, Brasil.</p>
			</fn>
		</fn-group>
	</back>
	<sub-article article-type="translation" id="s1" xml:lang="en">
		<front-stub>
			<article-id pub-id-type="doi">10.1590/1518-8345.5897.3543</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Review Article</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Complementary therapies in the control of male lower urinary tract symptoms: A systematic review</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-5080-4643</contrib-id>
					<name>
						<surname>Mata</surname>
						<given-names>Luciana Regina Ferreira da</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-7881-0519</contrib-id>
					<name>
						<surname>Motter</surname>
						<given-names>Paula Giuliana Rodrigues</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5881-5710</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Cissa</given-names>
					</name>
					<xref ref-type="aff" rid="aff5"><sup>2</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-5051-4910</contrib-id>
					<name>
						<surname>Bernardes</surname>
						<given-names>Mariana Ferreira Vaz Gontijo</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-8313-2791</contrib-id>
					<name>
						<surname>Chianca</surname>
						<given-names>Tânia Couto Machado</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-9586-9486</contrib-id>
					<name>
						<surname>Vasques</surname>
						<given-names>Christiane Inocêncio</given-names>
					</name>
					<xref ref-type="aff" rid="aff6"><sup>3</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff4">
				<label>1</label>
				<institution content-type="original"> Universidade Federal de Minas Gerais, Escola de Enfermagem, Belo Horizonte, MG, Brazil.</institution>
			</aff>
			<aff id="aff5">
				<label>2</label>
				<institution content-type="original"> Universidade Federal de Viçosa, Departamento de Medicina e Enfermagem, Viçosa, MG, Brazil.</institution>
			</aff>
			<aff id="aff6">
				<label>3</label>
				<institution content-type="original"> Universidade de Brasília, Faculdade de Ciências da Saúde, Brasília, DF, Brazil.</institution>
			</aff>
			<author-notes>
				<corresp id="c2">
					<label>Corresponding author</label> Christiane Inocêncio Vasques E-mail: <email>chvasques@unb.br</email>
				</corresp>
				<fn fn-type="edited-by" id="fn5">
					<label>Associate Editor</label>
					<p> Maria Lúcia Zanetti</p>
				</fn>
				<fn fn-type="con" id="fn6">
					<label>Authors’ contribution</label>
					<p><bold>Study concept and design:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Christiane Inocêncio Vasques. <bold>Obtaining data:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. <bold>Data analysis and interpretation:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. <bold>Obtaining financing:</bold> Luciana Regina Ferreira da Mata, Tânia Couto Machado Chianca. <bold>Drafting the manuscript:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes. <bold>Critical review of the manuscript as to its relevant intellectual content:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. All authors approved the final version of the text.</p>
				</fn>
				<fn fn-type="conflict" id="fn7">
					<label>Conflict of interest</label>
					<p> The authors have declared that there is no conflict of interest.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>Abstract</title>
				<sec>
					<title>Objective:</title>
					<p> to evaluate diverse scientific evidence on the effectiveness of complementary therapies in the control of lower urinary tract symptoms in the adult and aged male population.</p>
				</sec>
				<sec>
					<title>Method:</title>
					<p> a systematic review developed according to the PRISMA checklist. The search was performed in the CINAHL, <italic>Embase</italic>, LILACS, PEDro, PubMed, Web of Science and Google Scholar databases.</p>
				</sec>
				<sec>
					<title>Results:</title>
					<p> a total of 585 records were identified and 12 clinical trials were selected that met the inclusion criteria. The outcomes considered by the studies for analyzing effectiveness of the complementary therapies were validated questionnaires to assess the severity of the lower urinary tract symptoms (sensation of incomplete bladder emptying, frequent urination, intermittent flow, weak flow, pain or difficulty urinating, nocturia and urgency) and urodynamics parameters. The studies analyzed the complementary phytotherapy (n=8) and electroacupuncture (n=4) therapies. Six studies related to phytotherapy showed statistical significance. Electroacupuncture showed a significant improvement in the symptoms in two studies. </p>
				</sec>
				<sec>
					<title>Conclusion:</title>
					<p> pytotherapy was effective to control the simptoms related to frequency, urgency, nocturia, incomplete emptying, intermittence, weak flow and effort to initiate urination. To confirm the effectiveness of electroacupuncture, research studies with well-designed methodologies will also be necessary to resolve the divergences between the studies of this review. </p>
				</sec>
			</abstract>
			<kwd-group xml:lang="en">
				<title>Descriptors:</title>
				<kwd>Complementary Therapies</kwd>
				<kwd>Lower Urinary Tract Symptoms</kwd>
				<kwd>Systematic Review</kwd>
				<kwd>Men’s Health</kwd>
				<kwd>Phytotherapy</kwd>
				<kwd>Electroacupuncture</kwd>
			</kwd-group>
			<funding-group>
				<award-group award-type="contract">
					<funding-source>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</funding-source>
					<award-id>429958/2018-8</award-id>
				</award-group>
				<award-group award-type="contract">
					<funding-source>Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)</funding-source>
					<award-id>APQ 01034-21</award-id>
				</award-group>
				<funding-statement>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Grant #429958/2018-8 and by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Grant APQ 01034-21, Brazil.</funding-statement>
			</funding-group>
		</front-stub>
		<body>
			<boxed-text id="bx2">
				<sec>
					<title>Highlights</title>
					<p>(1) Complementary therapies can be effective in male urinary symptoms.</p>
					<p>(2) Phytotherapy was effective in six of the eight studies included.</p>
					<p>(3) Studies with electroacupuncture and more robust methodologies are needed.</p>
				</sec>
			</boxed-text>
			<sec sec-type="intro">
				<title>Introduction</title>
				<p>According to the International Continence Society (ICS), lower urinary tract symptoms (LUTS) can be categorized according to the urination phase: storage, emptying and post-urination<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Storage LUTS, such as nocturia and urinary incontinence, are the most reported by the general population, followed by post-urination drip, reduction in urinary flow and sensation of incomplete bladder emptying, which are also common complaints<xref ref-type="bibr" rid="B2"><sup>2</sup></xref>.</p>
				<p>LUTS are more frequent with advancing age<xref ref-type="bibr" rid="B3"><sup>3</sup></xref>. In men there are different clinical presentations of LUTS, which are related to the bladder, prostate, urethra, pelvic floor and/or adjacent pelvic organs<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Epidemiological studies conducted with the adult and aged male population indicate that prevalence can range from 60% to 84%<xref ref-type="bibr" rid="B4"><sup>4</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. The etiology most frequently associated with LUTS occurrence in men is benign prostatic hyperplasia (BPH)<xref ref-type="bibr" rid="B3"><sup>3</sup></xref>. Although it is not a morbidity that determines severity associated with mortality, these symptoms exert negative impacts on the daily lives of their patients, as they affect quality of life, cause sexual dissatisfaction and increase the risk of depressive disorders<xref ref-type="bibr" rid="B6"><sup>6</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
				<p>There is a variety of treatment strategies for controlling LUTS<xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. The conventional treatment usually involves behavior changes, such as reduced caffeine and alcohol consumption, increased physical activity, and reduced body weight. In some cases, such treatment can be associated with pharmacological measures, with an emphasis on alpha-blockers and 5-alpha-reductase inhibitors<xref ref-type="bibr" rid="B9"><sup>9</sup></xref>. However, there is a percentage of men whose response to the conventional treatment is unsatisfactory and who end up requiring surgical measures<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>. Both options imply medical costs and possible harms associated with adverse effects of the medications or sequelae after invasive interventions<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>.</p>
				<p>In this context, interventions based on complementary therapies (CTs) can be an effective strategy to control LUTS in men, especially because they are of lower cost and with minimal adverse effects. The CTs, also called Traditional and Complementary Medicine, are a set of knowledge, skills and practices that originate from the experiences and beliefs of different cultures that complement conventional medicine practices<xref ref-type="bibr" rid="B11"><sup>11</sup></xref>. </p>
				<p>Phytotherapy and acupuncture have been evaluated individually through systematic reviews regarding their effectiveness<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref> and compared to the conventional treatments to control LUTS<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Nevertheless, it is observed that CTs indication often occur empirically<xref ref-type="bibr" rid="B16"><sup>16</sup></xref>. Therefore, it is expected that a systematic review will be able to summarize the available evidence on the effectiveness of different CTs to control LUTS in the male population and thus favor its implementation in the clinical practice.</p>
				<p>Considering popularization of the CTs, there is a need to develop a systematic review that aims at evaluating the diverse scientific evidence on the effectiveness of complementary therapies in the control of lower urinary tract symptoms in the adult and aged male population.</p>
			</sec>
			<sec sec-type="methods">
				<title>Method</title>
				<sec>
					<title>Study design</title>
					<p>This is a systematic literature review, registered in the International Prospective Register of Systematic Reviews (PROSPERO) platform (Registration number: CRD42021226480), and developed according to the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist<xref ref-type="bibr" rid="B17"><sup>17</sup></xref> to report systematic reviews. </p>
				</sec>
				<sec>
					<title>Selection criteria</title>
					<p>The PICO strategy was used to establish the guiding question, in which the letter P refers to the population or group of patients (men with LUTS), I to the intervention (CTs), C to the comparison (comparison with other interventions) and O to the outcomes (LUTS control). Therefore, this systematic review sought to answer the following question: How effective are CTs in controlling LUTS in the male population?</p>
					<p>Only clinical trials evaluating the use of CTs to control LUTS in adult men (18 years old or more) were eligible for the systematic review. There were no restrictions on eligibility regarding language or year of publication.</p>
				</sec>
				<sec>
					<title>Sample definition and period</title>
					<p>By reading the titles and abstracts, studies with samples consisting of mixed populations, children and animals were excluded, as well as original research studies whose design was not clinical trial; publications such as reviews, letters, editorials, protocols and case reports; and records that did not have an online summary available. From the full reading, clinical trials that associated conventional treatment with CTs in the intervention group and publications of the clinical trial protocol type were excluded. It is also noted that studies which, although eligible in terms of their titles and abstracts, were not located in full online or made available by the corresponding authors, through email contact.</p>
					<p>The search was carried out in the following databases: Index to Nursing &amp; Allied Health Literature (CINAHL) via the CAPES Journals Portal, Embase, <italic>Literatura Latino-Americana e do Caribe em Ciências da Saúde</italic> (LILACS), Physiotherapy Evidence Database (PEDro), PubMed, and Web of Science. The studies were identified from search strategies specifically adapted to each of the databases using terminologies defined by the Medical Subject Headings (MeSH/PubMed) and the Descriptors in Health Science (<italic>Descritores em Ciência da Saúde</italic>, DeCS), as presented in <xref ref-type="table" rid="t4">Figure 1</xref>. The searches in the databases were conducted in May 2021. The researchers manually searched the reference lists of the studies selected to identify possible references that were missed in the electronic search. Finally, Google Scholar was also considered as a complementary search method.</p>
					<p>
						<table-wrap id="t4">
							<label>Figure 1</label>
							<caption>
								<title>Search strategy and results in each database. Belo Horizonte, MG, Brazil, 2021</title>
							</caption>
							<table>
								<colgroup>
									<col/>
									<col/>
								</colgroup>
								<thead>
									<tr>
										<th align="left">Databases</th>
										<th align="left">Search strategy</th>
									</tr>
								</thead>
								<tbody>
									<tr>
										<td align="left">CINAHL</td>
										<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
									</tr>
									<tr>
										<td align="left">Embase</td>
										<td align="left"><italic>(‘lower urinary tract symptom’/exp OR ‘lower urinary tract symptom’) AND (‘chinese medicine’/exp OR ‘chinese medicine’)</italic></td>
									</tr>
									<tr>
										<td align="left">LILACS</td>
										<td align="left"><italic>(tw:(((“Terapias Complementares” OR “Medicina Alternativa” OR “Medicina Complementar” OR “Terapias Alternativas” OR “Práticas Integrativas e Complementares” OR auriculoterapia OR “Acupuntura Auricular” OR “Terapia por Acupuntura” OR eletroacupuntura OR “Pontos de Acupuntura” OR moxibustão OR Medicina Tradicional Chinesa OR Meridianos OR Acupressão OR Orelha Externa OR “Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR electroacupuncture OR “Acupuncture Points” OR moxibustion OR “Medicine, chinese traditional” OR Meridians OR Acupressure OR “Ear, external”)))) AND (tw:(((“Incontinência Urinária” OR “Transtornos Urinários” OR “Incontinência Urinária por Estresse” OR “Urinary Incontinence” OR “Urination Disorders” OR “Urinary incontinence, stress”))))</italic></td>
									</tr>
									<tr>
										<td align="left">PEDro</td>
										<td align="left"><italic>Therapy: acupuncture; Problem: incontinence</italic></td>
									</tr>
									<tr>
										<td align="left">PubMed</td>
										<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
									</tr>
									<tr>
										<td align="left">Web of Science</td>
										<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
									</tr>
									<tr>
										<td align="left">Google Scholar</td>
										<td align="left"><italic>Advanced search With all the words: Complementary Alternative Medicine With the exact phrase: Lower urinary tract symptomsWithout the words: Female; Children</italic></td>
									</tr>
								</tbody>
							</table>
						</table-wrap>
					</p>
				</sec>
				<sec>
					<title>Data collection</title>
					<p>The web version of EndNoteBasic<sup>®</sup> was used to groupe the searches and exclude the duplicates. Subsequently, all the references underwent a manual screening to extract key information from the studies (authors; year; country; CTs; objective; sample size; characteristics of the sample; characteristics of the intervention and control groups; treatment and follow-up time; assessment instruments and other outcomes; and conclusions), which were transcribed and organized into a Microsoft Excel spreadsheet that facilitated development of the selection stage.</p>
					<p>Selection of the studies was carried out by two researchers, PhD students in Nursing (P1 and P2), independently and in two phases. In the first phase, from the reading of titles and abstracts, those studies potentially eligible for systematic review were identified, considering the inclusion and exclusion criteria defined. In the second phase, the studies selected were read in full and those that did not meet the inclusion criteria were excluded. The selection divergences between both researchers (P1 and P2) were discussed and, when there was no consensus, they were evaluated by a third researcher, PhD in Nursing (P3), who decided on the inclusion or exclusion of the studies.</p>
					<p>Two researchers (P1 and P2) independently extracted the relevant data from the articles selected to a Microsoft Excel spreadsheet. The extracted data were as follows: general characteristics of the study (author, year and country of publication), objectives, sample characteristics (number of participants and mean age), characteristics of the intervention [phytotherapy (dose and duration)], acupuncture/electroacupuncture (acupuncture points, manipulation procedures, electrostimulation frequency and intensity, duration and number of sessions), other arms of the study, results (main outcomes analyzed and instruments used) and the conclusion. A third reviewer (P3) evaluated the accuracy of the data collected.</p>
				</sec>
				<sec>
					<title>Data analysis</title>
					<p>The quality evaluation of the studies selected was carried out based on the Joanna Briggs Institute (JBI) Critical Appraisal Tool - Checklist for randomized clinical trials. This is an instrument that evaluates the methodological quality and the approach of possible bias in the design, conduction and analysis of data from randomized clinical trials. This checklist consists of 13 questions with four answer options (yes, no, uncertain or not applied)<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>.</p>
					<p>In relation to the categorization of the methodological quality of the clinical trials from the instrument applied, studies that had 70% or more “yes” answers were classified as with low risk of bias, with 50% to 69% of “yes” as with moderate risk, and with 49% or fewer “yes” answers as with high risk. </p>
					<p>The risk of bias assessment was performed independently by two researchers (P1 and P2). A third researcher (P3) was considered for evaluating possible divergences. </p>
				</sec>
			</sec>
			<sec sec-type="results">
				<title>Results</title>
				<p>A total of 585 records were identified in the searches conducted in the databases, among which 96 duplicates were removed. After reading titles and abstracts, 478 records were excluded in the first phase and 11 articles were selected for full reading. In addition to these, the search using other methods resulted in the selection of three articles, and another four articles were selected from the reference lists. </p>
				<p>Considering the inclusion and exclusion criteria established, of the 18 articles selected and read in full during the second phase, six were excluded. The final sample consisted of 12 studies that met the selection criteria. The process for identification, inclusion and exclusion of the studies is described in <xref ref-type="fig" rid="f2">Figure 2</xref>.</p>
				<p>
					<fig id="f2">
						<label>Figure 2</label>
						<caption>
							<title>Flowchart corresponding to the searches in the databases and to the selection criteria</title>
						</caption>
						<graphic xlink:href="1518-8345-rlae-30-e3597-gf2.png"/>
					</fig>
				</p>
				<p>All the studies were published in English between 2001 and 2019. As for the country of origin, four studies were carried out in the United States<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref>, two in Japan<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, two in China<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, two in the Czech Republic<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, one in Italy<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> and one in Taiwan<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. </p>
				<p>Most of the clinical trials evaluated phytotherapy (n=8) to control LUTS in the male population<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. The other clinical trials in this review addressed electroacupuncture (n=4)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. The description of each article is detailed in <xref ref-type="table" rid="t5">Figure 3</xref>.</p>
				<p>
					<table-wrap id="t5">
						<label>Figure 3</label>
						<caption>
							<title>Description of the characteristics of the studies included in the systematic review (n=12)</title>
						</caption>
						<table>
							<colgroup>
								<col span="3"/>
								<col span="2"/>
								<col span="3"/>
								<col span="2"/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" colspan="3">Characteristics of the study </th>
									<th align="left" colspan="2">Description of the sample </th>
									<th align="left" colspan="3">Method applied </th>
									<th align="left" colspan="2">Outcomes analyzed </th>
									<th align="left">Final conclusions</th>
								</tr>
								<tr>
									<th align="left">Author(s) (Year); Country</th>
									<th align="left">CT<sup>¶¶</sup></th>
									<th align="left">Objectives</th>
									<th align="left">Size(n)</th>
									<th align="left">Characteristics (LUTS<sup>‡‡‡</sup> baseline; mean age ± standard deviation)</th>
									<th align="left">Intervention (IG<sup>||</sup>)</th>
									<th align="left">Control (CG<sup>§</sup>)</th>
									<th align="left">Duration (months)</th>
									<th align="left">Assessment questionnaires</th>
									<th align="left">Urodynamics parameters</th>
									<th align="left">
									</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left">Gerber, et al. (2001)<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>; USA</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To evaluate the effects of <italic>Saw palmetto</italic> (<italic>S. palmetto</italic>) extract on urinary symptoms, sexual function, and urinary flow rate in men with LUTS<sup>‡‡‡</sup>.</td>
									<td align="left">n: 85 IG<sup>||</sup>: 41 CG<sup>§</sup>: 44</td>
									<td align="left">I-PSS<sup>††</sup> score &gt; 8 without history of prostate surgery; 64.5 (±9.9) years old (IG<sup>||</sup>); 65.3 (±9.7) years old (CG<sup>§</sup>).</td>
									<td align="left">160 mg <italic>S. palmetto</italic> capsule (distributed by Nutraceutical), 2x/day (320 mg a day).</td>
									<td align="left">Placebo capsule (extra virgin olive oil, gelatin and glycerin), 2x/day.</td>
									<td align="left">6</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup></td>
									<td align="left">IG<sup>||</sup> had a mean reduction (improvement) of 4.4 (±5.9) points in the I-PSS score<sup>††</sup>, showing a significant difference (<italic>p</italic> = 0.038) when compared to the CG<sup>§</sup>. Qmax<sup>||||</sup> improved slightly in both groups, but the changes were not significant (<italic>p</italic> = 0.75). </td>
								</tr>
								<tr>
									<td align="left">Bent, et al. (2006)<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>; USA</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To determine the efficacy of <italic>S. palmetto</italic> extract for the treatment of BPH<sup>¶</sup>.</td>
									<td align="left">n: 225 IG<sup>||</sup>: 112 CG<sup>§</sup>: 113</td>
									<td align="left">BPH determined by AUASI* score &gt; 8, without history of prostate surgery; 62.9 (±8.7) years old (IG<sup>||</sup>); 63.0 (±7.4) years old (CG<sup>§</sup>).</td>
									<td align="left">160 mg <italic>S. palmetto</italic> capsule (distributed by Rexall-Sundown, Inc), 2x/day (320 mg a day).</td>
									<td align="left">Placebo capsule (polyethylene glycol 400, bitter liquid with oily aspect without free fatty acids and brown dye), 2x/day.</td>
									<td align="left">12</td>
									<td align="left">AUASI*</td>
									<td align="left">Qmax<sup>||||||</sup>, prostatic volume and PURV</td>
									<td align="left">Slight reduction (improvement) in the AUASI* score, 0.72 (±0.35) points in the CG<sup>§</sup> and 0.68 (±0.35) points in the IG<sup>||</sup>, but without significant difference between the groups (95% CI**: -0.93 to 1.01). Changes were not observed in Qmax<sup>||||</sup>, prostatic volume or PURV.</td>
								</tr>
								<tr>
									<td align="left">Barry, et al. (2011)<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>; United States of America</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To determine the effect of <italic>S. palmetto</italic> extract, up to three times the standard dose, in LUTS<sup>‡‡‡</sup> attributed to BPH<sup>¶</sup>.</td>
									<td align="left">n: 357 IG<sup>||</sup>: 176 CG<sup>§</sup>: 181</td>
									<td align="left">AUASI* score between 8 and 24, without history of prostate surgery; 61.3 ± 8.7 years old (IG<sup>||</sup>); 60.7 ± 8.1 years old (CG<sup>§</sup>).</td>
									<td align="left">320 mg <italic>S. palmetto</italic> capsule (distributed by Rottapharm). Progressive increase in dosage: -1 capsule/day from the 1<sup>st</sup> to the 23<sup>rd</sup> week (320 mg a day); -2 capsules/day from the 24<sup>th</sup> to the 48<sup>th</sup>week (640 mg a day); -3 capsules/day from the 48<sup>th</sup> to the 72<sup>th</sup>week (960 mg a day).</td>
									<td align="left">Placebo capsules (375 mg polyethylene glycol, 25 mg glycerol and 75 mg gelatin) following a progressive increase in the number of capsules as in the IG.</td>
									<td align="left">18</td>
									<td align="left">AUASI*</td>
									<td align="left">Qmax<sup>||||</sup> and PURV<sup>||||||</sup></td>
									<td align="left">The mean AUASI* score decreased (improved) by 2.99 points (95% CI**: -3.81 to -2.17) in the CG and by 2.20 points (95% CI: -3.04 to -0.36) in the IG<sup>||</sup>, a difference of 0.79 points between the two groups in favor of the CG<sup>§</sup>. The dose-response comparison showed that there was no improvement in the IG<sup>||</sup> in any of the doses when compared to the CG<sup>§</sup>. Changes were not observed in Qmax and PURV<sup>||||||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Ye, et al. (2019)<xref ref-type="bibr" rid="B26"><sup>26</sup></xref>; China</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To assess the efficacy and safety of <italic>S. palmetto</italic> among patients with LUTS<sup>‡‡‡</sup>/ BPH<sup>¶</sup>.</td>
									<td align="left">n: 325 IG<sup>||</sup>: 159 CG<sup>§</sup>: 166</td>
									<td align="left">BPH<sup>¶</sup> with I-PSS score &lt; 19; 61.5 (±5.2) years old (IG<sup>||</sup>); 60.3 (±6.0) years old (CG<sup>§</sup>).</td>
									<td align="left">160 mg <italic>S. palmetto</italic> capsule (distributed by Tad Pharma GmbH)<italic>,</italic> 2x/day (320 mg a day).</td>
									<td align="left">Placebo capsule (composition not described), 2x/day.</td>
									<td align="left">6</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>‡‡</sup>, prostate volume and urination frequency</td>
									<td align="left">The I-PSS<sup>††</sup> score decreased (improved) in both groups, but the reduction was significantly greater after 24 weeks in the IG<sup>||</sup> (<italic>p</italic> &lt; 0.001). The IG <sup>||</sup> presented a significant increase (improvement) in Qmax<sup>‡‡</sup> from the 4<sup>th</sup> week (<italic>p</italic> = 0.011) to the 24<sup>th</sup> week (p &lt; 0.001). Changes were not observed in prostate volume or urinary frequency.</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al. (2008)<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>; Japan</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To evaluate the safety and efficacy of the <italic>Ganoderma lucidum (G. lucidum)</italic> extract in men with lower urinary tract symptoms from a dose-escalation study.</td>
									<td align="left">n: 50 IG<sup>||</sup>/0.6: 12 IG<sup>||</sup>/6: 12 IG<sup>||</sup>/60: 14 CG<sup>§</sup>: 12</td>
									<td align="left">I-PSS<sup>††</sup> score &gt; 5 without history of prostate surgery; 59.1 (51-70) years old (IG<sup>||</sup>/0.6); 59.2 (50-72) years old (IG<sup>||</sup>/6); 59.4 (50-70) years old (IG<sup>||</sup>/60); 59.7 (50-67) years old (CG<sup>§</sup>). </td>
									<td align="left">IG<sup>||</sup>/0.6: 0.6 mg <italic>G.</italic> <italic>Lucidum</italic> tablet, 1x/day; IG<sup>||</sup>/6: 6 mg <italic>G. Lucidum</italic> tablet, 1x/day; IG<sup>||</sup>/60: 60 mg <italic>G.</italic> <italic>Lucidum</italic> tablet, 1x/day. (All tablets distributed by Chlorella Industry).</td>
									<td align="left">Placebo tablet (83.75% maltitol, 10% corn starch, 3% vitamin C, 0.2% yellow gardenia and 3% sucrose fatty acid ester), 1x/day.</td>
									<td align="left">2</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, prostatic volume and PURV<sup>||||||</sup></td>
									<td align="left">In the 4<sup>th</sup> week, the mean change in the I-PSS<sup>††</sup> score was significantly higher in IG<sup>||</sup>/60, when compared to the CG<sup>§</sup> (<italic>p</italic> = 0.012) and to the IG<sup>||</sup>/0.6 (p &lt; 0.001). In the 8<sup>th</sup> week, the mean change in IG<sup>||</sup>/0.6 was significantly lower than in IG<sup>||</sup>/6 (<italic>p</italic> = 0.016) and IG<sup>||</sup>/60 (p = 0.005). Slight improvement of Qmax<sup>||||</sup>, but without significant differences between the groups. No changes were observed in prostatic volume or PURV<sup>||||||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al. (2008)<xref ref-type="bibr" rid="B24"><sup>24</sup></xref>; Japan</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To evaluate the safety and efficacy in men with mild to moderate lower urinary tract symptoms of the <italic>G. Lucidum</italic> extract, which showed the highest 5α-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms.</td>
									<td align="left">n: 88 IG<sup>||</sup><sub>:</sub> 44 CG<sup>§</sup>: 44</td>
									<td align="left">I-PSS<sup>††</sup> score between 5 and 19, with no history of prostate surgery; 64.0 (±6.9) years old (IG<sup>||</sup>); 64.0 (±8.0) years old (CG<sup>§</sup>).</td>
									<td align="left">2 tablets with 3 mg of <italic>G. Lucidum</italic> (distributed by Chlorella Industry), 1x/day (6 mg a day).</td>
									<td align="left">2 placebo tablets (83.75% maltitol, 10% corn starch, 3% vitamin C, 0.2% yellow gardenia and 3% sucrose fatty acid ester), 1x/day.</td>
									<td align="left">3</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, prostate volume and PURV<sup>||||||</sup></td>
									<td align="left">The I-PSS<sup>††</sup> score decreased (improved) more markedly in the IG<sup>||</sup> up to the 12<sup>th</sup> week, showing a significant difference (<italic>p</italic> &lt; 0.001) in the mean change in the score between the two groups. Qmax<sup>||||</sup> (<italic>p</italic> = 0.400) and Qave<sup>‡‡</sup> (<italic>p</italic> = 0.080) showed an increase (improvement) in the IG<sup>||</sup> at the 4<sup>th</sup> and 8<sup>th</sup> weeks, but with no significant difference between the groups at the 12<sup>th</sup> week. Changes were not observed in prostate volume or PURV<sup>||||||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al. (2010)<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>; Czech Republic</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To evaluate the efficacy and tolerance of cranberry powder in men with lower urinary tract symptoms, elevated PSA<sup>§§</sup>, BPH<sup>¶</sup> and chronic nonbacterial prostatitis.</td>
									<td align="left">n: 42 IG<sup>||</sup>: 21 CG<sup>§</sup>: 21</td>
									<td align="left">Histological findings of nonbacterial, acute or chronic prostatitis; 62.0 (±5.4) years old (IG<sup>||</sup>); 64.0 (±5.4) years old (CG<sup>§</sup>);</td>
									<td align="left">500 mg cranberry powder capsule (distributed by Decas Botanical Synergies). 3x/day, (1,500 mg a day).</td>
									<td align="left">Placebo capsule (composition not described), 3x/day.</td>
									<td align="left">6</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax, Qave and PURV<sup>||||||</sup></td>
									<td align="left">I-PSS<sup>††</sup> score significantly lower (better) in the IG<sup>||</sup> when compared to the CG<sup>§</sup> (<italic>p</italic> &lt; 0.050). Significant improvement (p &lt; 0.050) of Qmax<sup>||||</sup>, Qave<sup>‡‡</sup> and PURV<sup>||||||</sup> in at least 70% of the IG participants<sup>||</sup>, and significant worsening (p &lt; 0.050) of PURV<sup>||||||</sup> in the CG<sup>§</sup>.</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al. (2015)<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>; Czech Republic</td>
									<td align="left">PhT<sup>‡</sup></td>
									<td align="left">To evaluate the effect of cranberry in men with moderate to severe lower urinary tract symptoms.</td>
									<td align="left">n: 122 IG<sup>||</sup>/500: 38 IG<sup>||</sup>/250: 43 CG<sup>§</sup>: 41</td>
									<td align="left">I-PSS<sup>††</sup> score &gt; 8 without history of prostate surgery; 52.5 (±5.4) years old (IG<sup>||</sup>/500); 53.3 (±5.2) years old (IG<sup>||</sup>/250); 54.0 (±5.1) years old (CG<sup>§</sup>).</td>
									<td align="left">IG<sup>||</sup>/500: 2 x 250 mg cranberry capsules 1x/day (500 mg a day); IG<sup>||</sup>/250: 1 250 mg cranberry capsule and 1 placebo capsule, 1x/day (250 mg a day); (all capsules distributed by Decas Botanical Synergies).</td>
									<td align="left">2 placebo capsules (low density maltodextrin, canola oil, sodium aluminum silicate, lake red 40 and lake blue 1), 1x/day.</td>
									<td align="left">6</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, PURV<sup>||||||</sup> and bladder emptying volume</td>
									<td align="left">Significant reductions (improvement) in the I-PSS<sup>††</sup> score of IG<sup>||</sup>/500 and IG<sup>||</sup>/250, of -4.1 (±1.9) (<italic>p</italic> &lt; 0.001) and -3.1 (±3.0) (<italic>p</italic> = 0.050) points respectively. Qmax<sup>||||</sup> (<italic>p</italic> = 0.018), Qave<sup>‡‡</sup> (<italic>p</italic> = 0.040), PURV<sup>||||||</sup> (<italic>p</italic> = 0.027) and bladder emptying volume (<italic>p</italic> = 0.014) significantly improved in IG<sup>||</sup>/500. </td>
								</tr>
								<tr>
									<td align="left">Johnstone, et al. (2003)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>; United States of America</td>
									<td align="left">EA<sup>†</sup></td>
									<td align="left">To assess the response of lower urinary tract symptoms and PSA<sup>§§</sup> to EA<sup>†</sup> in a population of patients with a negative biopsy for prostate cancer.</td>
									<td align="left">n: 30 (It does not specify the sample in each study group)</td>
									<td align="left">I-PSS<sup>††</sup> score &gt; 8; 60.7 (±8.2) years old (IG<sup>||</sup>); 64.7 (±5.2) years old (CG<sup>§</sup>/EA<sup>†</sup> placebo); 63.5 (±3.4) years old (CG<sup>§</sup>/observation).</td>
									<td align="left">AcPts***: R10, B40, B32 and B10. 4-5 Hz electrostimulation on R10 and B40. Sessions 3x/week in the 1<sup>st</sup> and 2<sup>nd</sup> weeks, and later 1x/week in the 3<sup>rd</sup>, 4<sup>th</sup> and 8<sup>th</sup> weeks, 20 min/session.</td>
									<td align="left">CG<sup>§</sup>/EA<sup>†</sup> placebo: insertion of 5 needles in the posterior region of the shoulders, areas unrelated to AcPts*** and without electrostimulation. CG<sup>§</sup>/observation: no intervention during the study.</td>
									<td align="left">3 (9 sessions)</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Not evaluated</td>
									<td align="left">No changes were observed in the I-PSS<sup>††</sup> score (<italic>p</italic> = 0.063).</td>
								</tr>
								<tr>
									<td align="left">Ricci, et al. (2004)<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>; Italy</td>
									<td align="left">EA<sup>†</sup></td>
									<td align="left">To assess whether EA<sup>†</sup> in reflex therapy/acupuncture is able to treat the sensory irritating components of lower urinary tract symptoms that persist after TURP<sup>†††</sup></td>
									<td align="left">n: 42 IG<sup>||</sup>:13 CG<sup>§</sup>/ placebo: 14 CG<sup>§</sup>/ conv: 15</td>
									<td align="left">Persistence of sensory irritative symptoms of the lower urinary tract after TURP<sup>†††</sup>; 64.76 years old (52-78 years old).</td>
									<td align="left">Somatic AcPts: Conception vessel: 1, 2, 4, 5; Bladder 21, 23 and 32; Auricular AcPts***: prostate and external genitalia. 5-10 Hz electrostimulation, with greater intensity tolerated by the patient. 3 sessions/week, plus maintenance sessions every 15 days, starting from the 4<sup>th</sup> week, 20 min/session.</td>
									<td align="left">CG<sup>§</sup>/placebo: placebo tablet (it does not define composition, number of tablets, or repetitions <italic>per</italic> day); CG<sup>§</sup>/conv: Oxybutynin 5 mg tablet, 2x/day (10 mg a day).</td>
									<td align="left">3 (12 sessions)</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, prostate volume, urination frequency and nocturia</td>
									<td align="left">The I-PSS score<sup>††</sup> decreased (improved) in the CG<sup>§</sup> and IG<sup>||</sup> during the first 3 months, but the difference was only significant in the IG<sup>||</sup> (<italic>p</italic>&lt;0.001). Changes were not observed in Qmax<sup>||||</sup> and prostate volume. Reductions in daytime urination frequency of 20% and 8% in the IG<sup>||</sup> and CG<sup>§</sup>, respectively. The nocturia reports were also reduced 60% and 20% in the IG<sup>||</sup> and CG<sup>§</sup>, respectively.</td>
								</tr>
								<tr>
									<td align="left">Yu, et al. (2011)<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>; Taiwan</td>
									<td align="left">EA<sup>†</sup></td>
									<td align="left">To evaluate the effect of EA<sup>†</sup> on lower urinary tract symptoms in men with BPH<sup>¶</sup>.</td>
									<td align="left">n: 37 IG<sup>||</sup>: 18 CG<sup>§</sup>: 19</td>
									<td align="left">BPH<sup>¶</sup> confirmed by transrectal US<sup>§§§</sup> with I-PSS<sup>††</sup> score &gt; 8, with no history of prostate surgery; 63.2 (±10.0) years old (IG<sup>||</sup>); 59.8 (±9.0) years old (CG<sup>§</sup>).</td>
									<td align="left">AcPts***: Conception Vessels 3 and 4; Stomach 36 and Spleen-Pancreas 6. Needles inserted and handled for 3-5 minutes until reaching Qi. 2 Hz electrostimulation with 2-2.5 mA intensity. 2 sessions/week, 20 min/session.</td>
									<td align="left">Needles inserted superficially (subcutaneous tissue), 1 cm lateral to the AcPt*** of the IG<sup>||</sup>, without manual handling or electrostimulation. Same frequency of sessions as in the IG<sup>||</sup>.</td>
									<td align="left">1.5 (12 sessions)</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>,Qave<sup>‡‡</sup> and bladder emptying volume</td>
									<td align="left">Changes were not observed in the I-PSS<sup>††</sup> score between the groups. Increase (improvement) in Qmax<sup>||||</sup> (<italic>p</italic> = 0.030), Qave<sup>‡‡</sup> (<italic>p</italic> = 0.026), significant emptying volume (<italic>p</italic> = 0.038) in the IG<sup>||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Wang, et al. (2013)<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>; China</td>
									<td align="left">EA<sup>†</sup></td>
									<td align="left">To evaluate the effects of EA<sup>†</sup> on the I-PSS<sup>††</sup> score, PURV<sup>|||||</sup>, and Qmax<sup>||||</sup>, as well as to explore the differences between AE<sup>†</sup> in AcPts*** and unrelated points in patients with moderate or severe BPH<sup>¶</sup>.</td>
									<td align="left">n: 100 IG<sup>||</sup>: 50 CG<sup>§</sup>: 50</td>
									<td align="left">BPH<sup>¶</sup> determined by I-PSS<sup>††</sup> score &gt; 8; 64.8 (±7.1) years old (IG<sup>||</sup>); 65.9 (±6.7) years old (CG<sup>§</sup>);</td>
									<td align="left">AcPts***: Bladder 33, with manipulation until the patient feels a sensation of weight and numbness. 20 Hz electrostimulation, with maximum intensity tolerated by the patient. 1 session/day completing 5 sessions/week during the 1<sup>st</sup> and 2<sup>nd</sup> weeks, and then 3 sessions/week in the 3<sup>rd</sup> and 4<sup>th</sup> weeks</td>
									<td align="left">Needles inserted at two points approximately 6.7 cm lateral to the AcPts***, without manipulation, with the same electrostimulation as in the intervention group. Same frequency of sessions as in the IG<sup>||</sup>.</td>
									<td align="left">1 (16 sessions)</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup> and PURV<sup>||||||</sup></td>
									<td align="left">The I-PSS<sup>††</sup> score had a 3.2-point higher reduction (improvement) in the IG<sup>||</sup> than in the CG<sup>§</sup>at week 18 (<italic>p</italic> = 0.001). No changes were observed in Qmax<sup>||||</sup> or PURV<sup>|||||</sup>.</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN3">
								<p>*AUASI = American Urological Association Symptom Index; <sup>†</sup>EA = Allethroacupuncture; <sup>‡</sup>Ph = Phytotherapy; <sup>§</sup>CG = Control Group; <sup>||</sup>IG = Intervention Group; <sup>¶</sup>BPH = Benign Prostate Hyperplasia; **CI = Confidence Interval; <sup>††</sup>I-PSS = International Prostate Symptom Score; <sup>‡‡</sup>Qave =Average Urinary Flow Rate; <sup>§§</sup>PSA = Prostate-Specific Antigen; <sup>||||</sup>Qmax = Peak Urinary Flow Rate; <sup>¶¶</sup>CTs = Complementary Therapies; ***AcPts = Acupuncture Points; <sup>†††</sup>TURP = Transurethral Resection of the Prostate; <sup>‡‡‡</sup>LUTS = Lower Urinary Tract Symptoms; <sup>§§</sup>US = Ultrasound; <sup>||||||</sup>PURV = Post-Urination Residual Volume.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>A total of 1,503 men were evaluated in the studies included in this review, of which 1,294 were part of the phytotherapy clinical trials and 209 took part in the electroacupuncture clinical trials. Considering the studies individually, this number varied from 30<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> to 357 participants<xref ref-type="bibr" rid="B31"><sup>31</sup></xref>. The mean age of the participants was 60.7 years old (±5.6). The follow-up time varied from two to 18 months for the phytotherapy clinical trials (±5.1) and from one to three months for electroacupuncture (±4.7).</p>
				<p>To evaluate effectiveness of the CTs, the studies used subjective and objective parameters. The American Urological Association Symptom Index (AUASI)<xref ref-type="bibr" rid="B31"><sup>31</sup></xref> and the International Prostate Symptom Score (I-PSS)<xref ref-type="bibr" rid="B32"><sup>32</sup></xref> questionnaires were considered, which subjectively classify LUTS severity as mild (0-7 points), moderate (8-19 points) or severe conditions (20-35 points)<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. As objective parameters, the following urodynamic outcomes were used: urination frequency, nocturia, peak urinary flow rate (Qmax), average urinary flow rate (Qave), post-urination residual volume (PURV), prostate volume and bladder emptying volume.</p>
				<p>Among the studies included in this review, two used the AUASI questionnaire<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref> and ten resorted to I-PSS for evaluating LUTS<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Only one study<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> did not include any of the urodynamics parameters as one of the outcomes of LUTS evaluation. The majority (n=7) considered at least Qmax and PURV<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. </p>
				<p>Four phytotherapy studies evaluated the effectiveness of <italic>Saw palmetto</italic> (<italic>S. palmetto</italic>) for controlling LUTS. This herbal medication was compared to placebo at daily doses of 320 mg<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, 640 mg<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> and 960 mg<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>. The 320 mg daily dose, fractionated twice a day, significantly improved (<italic>p</italic> &lt; 0.001) the I-PSS score after 24 weeks of treatment<xref ref-type="bibr" rid="B26"><sup>26</sup></xref> and showed a mean reduction of 4.4 (±5.9) points in the intervention group, with a significant difference (<italic>p</italic> = 0.038) when compared to the placebo after six months<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>. This same dose also reduced 0.68 (±0.35) points in the mean AUASI score of the intervention group, but without a statistically significant difference with the placebo group (95% CI: -0.93 to 1.01)<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>. Higher daily doses of 640 mg and 960 mg reduced 2.20 points (95% CI: -3.04 to -0.36 points) in the mean AUASI score, but an improvement was also observed in the placebo group<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>. None of the evaluated doses of <italic>S. palmetto</italic> improved the Qmax, PURV and prostate volume urodynamics parameters<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
				<p>Another two clinical trials evaluated effectiveness of the <italic>Ganoderma lucidum</italic> (<italic>G. lucidum)</italic>) herbal medication<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>. This herbal medication was evaluated at daily doses of 0.6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>, 6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> and 60 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>. When compared to placebo, daily doses of 6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> and 60 mg<xref ref-type="bibr" rid="B24"><sup>24</sup></xref> significantly reduced (<italic>p</italic> &lt; 0.001; <italic>p</italic> = 0.012; respectively) the I-PSS scores and slightly improved Qmax and Qave<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, but without significant differences between the groups.</p>
				<p>In addition, two phytotherapy studies evaluated the effectiveness of using cranberry in LUTS controls<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. This herbal medication was compared to placebo at daily doses of 250 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, 500 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> and 1,500 mg<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. At the highest dose of 1,500 mg, fractionated in three times a day, there was a significant reduction (<italic>p</italic> &lt; 0.050) in the I-PSS score of the intervention group, as well as an improvement of the urodynamic parameters, Qmax, Qave and PURV, in 70% of the participants of this group<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. In the study that evaluated the 500 mg and 250 mg doses there was a reduction of 4.1 (±1.9) and 3.1 (±3.0) points in the I-PSS scores, respectively<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. The Qmax (<italic>p</italic> = 0.018), Qave (<italic>p</italic> = 0.040), PURV (<italic>p</italic> = 0.027) and bladder emptying volume (<italic>p</italic> = 0.014) urodynamics parameters also indicated significant improvements in the group that received 500 mg of cranberry<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. </p>
				<p>Regarding the studies that evaluated the effectiveness of electroacupuncture, three included acupuncture points (AcPts) belonging to the bladder meridian<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Point B32, which belongs to this meridian, was the most used AcPt<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. It is noteworthy that, when compared to the conventional medication (Oxybutynin 5 mg) and the placebo tablet, 5 to 10 Hz electrostimulation at the highest tolerated intensity of AcPt B32, promoted LUTS control with a significant improvement of the I-PSS score (<italic>p</italic> &lt; 0.001) and reductions in the urination frequency and nocturia of 20% and 60%, respectively<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. </p>
				<p>Other AcPts of the bladder meridian were B10 and B40<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>, B21 and B23<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> and B33<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. AcPt B33 was the only one that presented a 3.2-point reduction in the I-PSS score of the intervention group, showing a significant improvement (<italic>p</italic> = 0.001) when compared to placebo electroacupuncture when stimulated at 20 Hz at the highest intensity tolerated<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. </p>
				<p>Another electroacupuncture study evaluated the effectiveness of the AcPts belonging to the different spleen-pancreas (BP6), stomach (E36) and conception vessel (CV3 and CV4) meridians<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. When stimulated with 3 Hz and intensity of 2 to 2.5 mA, the points of these meridians showed a significant improvement in the Qmax (<italic>p</italic> = 0.030), Qave (<italic>p</italic> = 0.026) and bladder emptying volume urodynamics parameters (<italic>p</italic> = 0.038), when compared to placebo electroacupuncture<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. However, there was no reduction in the I-PSS score<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>The studies included in this review were submitted to methodological quality analysis, based <italic>on the Joanna Briggs Institute (JBI</italic>) Critical Appraisal Tool - Checklist for randomized clinical trials<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>. In this evaluation, six studies were classified as withlow risk of bias, five of which were on phytotherapy<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> and another one on electroacupuncture<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. </p>
				<p>Three studies were classified as with moderate risk of bias, one on phytotherapy<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> and the other two on electroacupuncture<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. The studies were classified as with moderate risk of bias because they did not describe the losses that occurred during the follow-up or the blinding of the research team responsible for analyzing the outcomes<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. In the phytotherapy study<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, the method used to blind the researchers who applied the intervention was not informed. In the electroacupuncture studies, failures were observed in the description of the participants’ allocation process<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>, in addition to the absence of double-blinding<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. </p>
				<p>High risk of bias was identified in three studies, two on phytotherapy<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref> and another one on electroacupuncture<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. As items of methodological weaknesses we have the incomplete description of the randomization method, the differences between the groups at the beginning of the study, and non-description of the blinding and of the sample losses during follow-up<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. The results of the risk assessment in the studies included are presented in <xref ref-type="table" rid="t6">Figure 4</xref>.</p>
				<p>
					<table-wrap id="t6">
						<label>Figure 4</label>
						<caption>
							<title>Classification of the risk of bias of the studies included (N=12)</title>
						</caption>
						<table>
							<colgroup>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Author, year</th>
									<th align="left">Q1<sup>||</sup></th>
									<th align="left">Q2<sup>||</sup></th>
									<th align="left">Q3<sup>||</sup></th>
									<th align="left">Q4<sup>||</sup></th>
									<th align="left">Q5<sup>||</sup></th>
									<th align="left">Q6<sup>||</sup></th>
									<th align="left">Q7<sup>||</sup></th>
									<th align="left">Q8<sup>||</sup></th>
									<th align="left">Q9<sup>||</sup></th>
									<th align="left">Q10<sup>||</sup></th>
									<th align="left">Q11<sup>||</sup></th>
									<th align="left">Q12<sup>||</sup></th>
									<th align="left">Q13<sup>||</sup></th>
									<th align="left">Total</th>
									<th align="left">Risk of bias</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left">Gerber, et al., 2001<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">76.92%</td>
									<td align="left">Low</td>
								</tr>
								<tr>
									<td align="left">Bent, et al., 2006<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">100%</td>
									<td align="left">Low</td>
								</tr>
								<tr>
									<td align="left">Barry, et al., 2011<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">100%</td>
									<td align="left">Low</td>
								</tr>
								<tr>
									<td align="left">Ye, et al., 2019<xref ref-type="bibr" rid="B26"><sup>26</sup></xref>
									</td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">46.15%</td>
									<td align="left">High</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al., 2008<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">92.31%</td>
									<td align="left">Low</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al., 2008<xref ref-type="bibr" rid="B24"><sup>24</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">92.31%</td>
									<td align="left">Low</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al., 2010<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>
									</td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">38.46%</td>
									<td align="left">High</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al., 2015<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">69.23%</td>
									<td align="left">Moderate</td>
								</tr>
								<tr>
									<td align="left">Johnstone, et al., 2003<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">53.85%</td>
									<td align="left">Moderate</td>
								</tr>
								<tr>
									<td align="left">Ricci, et al., 2004<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>
									</td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">38.46%</td>
									<td align="left">High</td>
								</tr>
								<tr>
									<td align="left">Yu, et al., 2011<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">U<sup>‡</sup></td>
									<td align="left">Y*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">69.23%</td>
									<td align="left">Moderate</td>
								</tr>
								<tr>
									<td align="left">Wang, et al., 2013<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>
									</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">Y*</td>
									<td align="left">92.31%</td>
									<td align="left">Low</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN4">
								<p>*Y = yES; <sup>†</sup>N = No; <sup>‡</sup>U = Uncertain; <sup>§</sup>NA = Not Applicable; <sup>||</sup>Q = Question.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
			</sec>
			<sec sec-type="discussion">
				<title>Discussion</title>
				<p>This systematic review sought to identify and evaluate effectiveness of the CTs used for LUTS control in the male population. Among the 12 clinical trials included, eight addressed the use of phytotherapy<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> and four dealt with electroacupuncture <xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. </p>
				<p>For the analysis of the effectiveness of the CTs, one of the methods adopted considered the subjective evaluation of LUTS. Thus, self-administered and internationally validated questionnaires<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref> were used to classify and standardize the recording of LUTS, being an important tool to determine the severity of this involvement<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B34"><sup>34</sup></xref>.</p>
				<p>The following stand out among the questionnaires for LUTS evaluation: AUASI questionnaires of the American Urological Association committee<xref ref-type="bibr" rid="B31"><sup>31</sup></xref> and the I-PSS questionnaire<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>, which refers to an adaptation of AUASI with inclusion of an item that evaluates quality of life by classifying the impact of the discomfort caused by the LUTS on a scale from zero to six<xref ref-type="bibr" rid="B33"><sup>33</sup></xref>. The two instruments assess LUTS severity based on seven questions related to the following: sensation of incomplete bladder emptying, frequent urination, intermittent flow, weak flow, pain or difficulty while urinating, nocturia and urgency<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. The frequency of each symptom is attributed a score from zero to five, whose sum determines the severity (mild: 0-7 points, moderate: 8-19 points or severe: 20-35 points)<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. </p>
				<p>Another method for LUTS evaluation presented by the studies was based on the urodynamic study. This is an objective test to evaluate the function of the lower urinary tract considered as the gold standard in the clinical practice context<xref ref-type="bibr" rid="B35"><sup>35</sup></xref>. Among the urodynamic study parameters considered by the studies, the peak rate of urinary flow (Qmax), prostate volume and post-urination residual volume (PURV) predominated. It is emphasized that only one study did not consider the effectiveness of the intervention applied from the urodynamic evaluation<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>.</p>
				<p>As for effectiveness of the CTs, nine studies pointed them as an effective alternative for LUTS control in the male population<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Phytotherapy stands out, pointed out as one of the most used CTs by the general population<xref ref-type="bibr" rid="B16"><sup>16</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B36"><sup>36</sup></xref>. Phytotherapy is based on the use of medicinal plants for the treatment of certain symptoms, being a practice widely recognized and disseminated by the World Health Organization<xref ref-type="bibr" rid="B37"><sup>37</sup></xref>. The following herbal medications were analyzed in this review: <italic>S. palmetto</italic><xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, <italic>G. lucidum</italic><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> and cranberry<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
				<p>Among the four studies that evaluated the effectiveness of <italic>S. palmetto</italic><xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, half<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref> concluded that this herbal medication at a dosage of 320 mg a day was effective in controlling LUTS in men. Both studies indicated a statistically significant reduction in the I-PSS scores in the intervention group when compared to the placebo group<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. One of them<xref ref-type="bibr" rid="B26"><sup>26</sup></xref> showed that <italic>S. palmetto</italic> was also able to improve Qmax, corroborating other studies that also point to an improvement in Qmax, in addition to a reduction in nocturia<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B38"><sup>38</sup></xref>.</p>
				<p><italic>S. palmetto</italic>, scientific name <italic>Serenoa repens</italic>, is a herbal medication of the palm family that, due to its anti-inflammatory and anti-androgenic properties, has been commonly used for LUTS control, especially those associated with BPH<xref ref-type="bibr" rid="B39"><sup>39</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B40"><sup>40</sup></xref>. Despite diverse evidence favorable to its use, its applicability and effectiveness in the clinical practice are still questioned<xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. In part, the significant variability in the components’ concentration and bioavailability, depending on the laboratory responsible for the production of the extract, may justify the difficulty defining its effectiveness<xref ref-type="bibr" rid="B41"><sup>41</sup></xref>. In addition, the absence of standardization of the concentrations makes it difficult to establish comparisons between the clinical trials<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. </p>
				<p>In relation to two studies that did not verify the effectiveness of the <italic>S. palmetto</italic> herbal medication effective, variables such as the type of extract<xref ref-type="bibr" rid="B21"><sup>21</sup></xref> and the dosage administered<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> can justify the results obtained. There is more than one type of <italic>S. palmetto</italic> extract, and the forms of ethanolic and hexane extraction present greater clinical effectiveness of the compound<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. In this context, it is emphasized that one of the studies<xref ref-type="bibr" rid="B21"><sup>21</sup></xref> adopted the carbon dioxide extract, whose effectiveness is lower<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. None of the other studies specified the type of <italic>S. palmetto</italic> extract evaluated<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
				<p>Regarding dosage of the <italic>S. palmetto</italic> herbal medication, one of the studies included<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> concluded that <italic>S. palmetto</italic> was not superior to placebo. This clinical trial<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> evaluated the effectiveness of <italic>S. palmetto</italic> at staggered doses of 320 mg, 640 mg and 960 mg a day, that is, it considered the double and triple of the dose used in the other studies<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Thus, considering the discrepancy between the dosages established, a number of precautions are suggested for the interpretation of the results and the relevance of future studies. </p>
				<p><italic>G. lucidum</italic>, the herbal medication of choice in another two studies of this review<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, consists of a type of mushroom that is well-known in Asian countries, with triterpenes and polysaccharides as its outstanding bioactive components<xref ref-type="bibr" rid="B43"><sup>43</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B44"><sup>44</sup></xref>. Although the mechanisms that justify its antitumor, antioxidant and antibacterial effects are not completely elucidated<xref ref-type="bibr" rid="B44"><sup>44</sup></xref>, the satisfactory results presented by the studies included<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> are noteworthy, in which there was a significant improvement in the I-PSS scores in the intervention group. Thus, the diverse evidence<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> suggests effectiveness of <italic>G</italic>.<italic>lucidum</italic> at a dosage of 6 mg a day for LUTS control in men.</p>
				<p>This review also includes two studies<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> that analyzed cranberry, scientific name <italic>Vaccinium spp.</italic>, a fruit widely consumed in North American countries to control lower urinary tract infections<xref ref-type="bibr" rid="B45"><sup>45</sup></xref>. The cranberry powder analyzed in both studies was provided by the same laboratory, which favors comparison of the results. At dosages of 250 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> and 1,500 mg a day<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>, this herbal medication significantly reduced the I-PSS score in the intervention group<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. However, considering the urodynamic evaluation, more effective results were better at higher dosages, for example, 1,500 mg a day<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. It is suggested that the sialic acid found in cranberry extract has anti-inflammatory and analgesic effects, especially by the ability to decrease adhesion of microorganisms in the bladder wall<xref ref-type="bibr" rid="B45"><sup>45</sup></xref>.</p>
				<p>Electroacupuncture was another CT evaluated in four clinical trials of this review<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. The therapeutic effects of acupuncture are obtained from activation of the energy flow or <italic>Qi</italic>, through the insertion of needles in certain AcPts with the objective of restoring homeostatic balance<xref ref-type="bibr" rid="B46"><sup>46</sup></xref>. In this context, electroacupuncture represents an acupuncture variation in which an electric current is applied to the needles seeking to accentuate and enhance the therapeutic effects<xref ref-type="bibr" rid="B47"><sup>47</sup></xref>. The flow of electric current through a biological conductive medium triggers physiological effects, involving electrochemical, electrophysical and electrothermal phenomena. Stimulatory frequency stands out among the most relevant and studied physical parameters in electroacupuncture, especially its relationship with the release of endogenous opioids in analgesic and anti-inflammatory processes<xref ref-type="bibr" rid="B48"><sup>48</sup></xref>. </p>
				<p>As for blinding, the placebo electroacupuncture methods employed in the studies included were as follows: use of points not associated with the AcPts<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>, more superficial depth<xref ref-type="bibr" rid="B30"><sup>30</sup></xref> and absence of electrostimulation<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Due to the blinding difficulty of the clinical studies in this area<xref ref-type="bibr" rid="B47"><sup>47</sup></xref>, it is believed that this fact may justify the uni-blind design of the four studies that evaluated the effect of this therapy<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>As for the AcPts used in electroacupuncture, the majority included at least one point referring to the bladder meridian<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>, with emphasis on AcPt B32 (<italic>Ciliao</italic>)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Recent studies have identified significant results for the treatment of BPH symptoms in men<xref ref-type="bibr" rid="B49"><sup>49</sup></xref> and overactive bladder (OB) symptoms in rats based on AcPt B32 stimulation<xref ref-type="bibr" rid="B50"><sup>50</sup></xref>. It is known that AcPt B32 is one of the four points located in the four sacral foramina, being considered the most important because it has broad indications (voiding dysfunctions, dysmenorrhea, low back pain and sciatica and infertility) and is one of the points that produces the greatest tonifying effect of the Kidney and Essence<xref ref-type="bibr" rid="B51"><sup>51</sup></xref>.</p>
				<p>Only one study included in this review chose to use AcPts from other meridians that do not match the bladder’s<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>, namely: spleen-pancreas (BP6 - <italic>Sanyinjiao</italic>), stomach (E36 - <italic>Zusanli</italic>) and conception vessels (CV3 - <italic>Zhongji</italic>; CV4 - <italic>Guanyuan</italic>). A study conducted in rats with overactive bladders evidenced that point B33 (<italic>Zhongliao</italic>) presented a superior effect to points BP6 (<italic>Sanyinjiao</italic>) and B40 (<italic>Weizhong</italic>) with regard to the increase in the interval between the contractions<xref ref-type="bibr" rid="B52"><sup>52</sup></xref>. Therefore, it is suggested that this fact may justify the predominance of protocols that adopt AcPts associated with the bladder meridian when compared to the others. </p>
				<p>Regarding the heterogeneity of the inclusion criteria established by the studies, among the phytotherapy clinical trials, three considered I-PSS or AUASI scores above eight for inclusion of the participants<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, two defined a maximum score of 19 in the I-PSS score<xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, one defined a maximum limit of 24 points in the AUASI score<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>, and another study considered a minimum score of five in the I-PSS score<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>. Only one study<xref ref-type="bibr" rid="B27"><sup>27</sup></xref> did not consider the score in the LUTS assessment questionnaires to define the sample. </p>
				<p>In addition, two phytotherapy clinical trials used the AUASI and I-PSS scores to define the BPH diagnosis among their participants<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref> and the majority only considered the participation of men without prostate surgical history<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. This heterogeneity to define the LUTS underlying cause and severity can influence evaluation of the effectiveness of the interventions, as it is not defined in the literature what the influence of LUTS severity is in the response to the CTs. </p>
				<p>Similarly, the participants of the electroacupuncture clinical trials presented different selection characteristics. Three studies considered men with I-PSS scores above eight points<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref> and one study did not consider any score for sample definition<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. In relation to the underlying cause for the LUTS, two studies included men with BPH in their samples, one study defined the diagnosis based on the I-PSS score<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>, and another made the diagnosis from a transrectal ultrasound exam<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. In addition to that, one of the electroacupuncture studies included men who have already undergone transurethral resection of the prostate<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>, while another study<xref ref-type="bibr" rid="B30"><sup>30</sup></xref> had a sample with only men with no prostate surgical history. </p>
				<p>Another relevant fact refers to the difference in the follow-up time in the studies, which varied between two and 18 months for phytotherapy and one to three months for electroacupuncture. One of the major challenges in conducting clinical studies that assess CT effectiveness is based on the difficulty establishing fixed treatment protocols. It is known that this method is opposed to the basic precepts of the vast majority of the CTs. However, it should be considered that standardization of the ideal follow-up time based clinical studies may favor replicability of the protocols and achieve the same results in future research studies. </p>
				<p>As for the perspectives of including these therapies in Nursing care, it is known that the Nursing Interventions Classification (NIC) includes the “phytotherapy” (2420) and “cutaneous stimulation” (1340) interventions<xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. Nurses are prominent professionals in the implementation and use of several CTs, as the principles of their training are similar to the paradigms of the medical rationalities that involve Integrative Medicine. However, the number of these professionals who work with these therapies or who have the knowledge to prescribe and refer users to this type of care is still reduced. There is a movement, albeit incipient, of nurses who seek specialization courses in this area, which contributes to the dissemination of these therapies to the community, with the consequent improvement of Nursing care<xref ref-type="bibr" rid="B54"><sup>54</sup></xref>.</p>
				<p>The selection of clinical trial studies stands out as a limitation of this review. Thus, future expansion is suggested considering different methodological designs. Another limitation was based on the diverse evidence identified and that could not be included due to the effect of the CTs being associated with other conventional treatments such as medical or surgical. As a result, the diverse evidence presented should be considered preliminary, as hypothesis-generating, and as a resource to guide future research studies based on the knowledge gaps identified.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>Conclusion</title>
				<p>This systematic review identified and evaluated twelve clinical trials that analyzed the effectiveness of CTS for LUTS control in men. Most of these studies evaluated phytotherapy, which was indicated as an effective alternative in six of the eight clinical trials, as it reduced LUTS frequency from the reduction of the I-PSS scores and urodynamic parameters. We also emphasize that, among the phytotherapy studies, there was predominance of those classified as with low risk of bias. Thus, considering the effectiveness pointed out by half of the studies and their good methodological quality, the indication of phytotherapy for LUTS control in men is supported.</p>
				<p>With regard to electroacupuncture, despite the promising results, the suggestion is to develop more robust research studies following methodologies with higher levels of evidence, as only one of the clinical trials was classified as with low risk of bias. It is known that this fact can exert an impact on the effectiveness of the therapy implemented.</p>
				<p>In the LUTS context, non-treatment of mild cases or conventional treatment based on medication and surgeries for refractory cases are still predominant alternatives. However, considering the possible effects of the CTs, especially with regard to LUTS control, it becomes fundamental to carry out future research studies capable of generating more consistent recommendations. In general, it is known that CTs are minimally invasive, which implies a lower risk of sequelae when compared to surgical procedures, in addition to having few reports of adverse events, unlike medications. </p>
			</sec>
		</body>
		<back>
			<fn-group>
				<fn fn-type="financial-disclosure" id="fn8">
					<label>Supported by</label>
					<p>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Grant #429958/2018-8 and by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Grant APQ 01034-21, Brazil.</p>
				</fn>
			</fn-group>
		</back>
	</sub-article>
	<sub-article article-type="translation" id="s2" xml:lang="es">
		<front-stub>
			<article-id pub-id-type="doi">10.1590/1518-8345.5897.3596</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Artículo de Revisión</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Terapias complementarias para el control de los síntomas del tracto urinario inferior masculino: revisión sistemática</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-5080-4643</contrib-id>
					<name>
						<surname>Mata</surname>
						<given-names>Luciana Regina Ferreira da</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-7881-0519</contrib-id>
					<name>
						<surname>Motter</surname>
						<given-names>Paula Giuliana Rodrigues</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5881-5710</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Cissa</given-names>
					</name>
					<xref ref-type="aff" rid="aff8"><sup>2</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-5051-4910</contrib-id>
					<name>
						<surname>Bernardes</surname>
						<given-names>Mariana Ferreira Vaz Gontijo</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-8313-2791</contrib-id>
					<name>
						<surname>Chianca</surname>
						<given-names>Tânia Couto Machado</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-9586-9486</contrib-id>
					<name>
						<surname>Vasques</surname>
						<given-names>Christiane Inocêncio</given-names>
					</name>
					<xref ref-type="aff" rid="aff9"><sup>3</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff7">
				<label>1</label>
				<institution content-type="original"> Universidade Federal de Minas Gerais, Escola de Enfermagem, Belo Horizonte, MG, Brasil.</institution>
			</aff>
			<aff id="aff8">
				<label>2</label>
				<institution content-type="original"> Universidade Federal de Viçosa, Departamento de Medicina e Enfermagem, Viçosa, MG, Brasil.</institution>
			</aff>
			<aff id="aff9">
				<label>3</label>
				<institution content-type="original">Universidade de Brasília, Faculdade de Ciências da Saúde, Brasília, DF, Brasil.</institution>
			</aff>
			<author-notes>
				<corresp id="c3">
					<label>Autor de correspondencia</label> Christiane Inocêncio Vasques E-mail: <email>chvasques@unb.br</email>
				</corresp>
				<fn fn-type="edited-by" id="fn9">
					<label>Editora Asociada</label>
					<p> Maria Lúcia Zanetti</p>
				</fn>
				<fn fn-type="con" id="fn10">
					<label>Contribución de los autores</label>
					<p><bold>Concepción y dibujo de la pesquisa:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Christiane Inocêncio Vasques. <bold>Obtención de datos:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. <bold>Análisis e interpretación de los datos:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. <bold>Obtención de financiación:</bold> Luciana Regina Ferreira da Mata, Tânia Couto Machado Chianca. <bold>Redacción del manuscrito:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes. <bold>Revisión crítica del manuscrito en cuanto al contenido intelectual importante:</bold> Luciana Regina Ferreira da Mata, Paula Giuliana Rodrigues Motter, Cissa Azevedo, Mariana Ferreira Vaz Gontijo Bernardes, Tânia Couto Machado Chianca, Christiane Inocêncio Vasques. Todos los autores aprobaron la versión final del texto.</p>
				</fn>
				<fn fn-type="conflict" id="fn11">
					<label>Conflicto de intereses</label>
					<p> Los autores han declarado que no existe ningún conflicto de intereses.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>Resumen</title>
				<sec>
					<title>Objetivo:</title>
					<p> evaluar la evidencia científica sobre la efectividad de las terapias complementarias para el control de los síntomas del tracto urinario inferior en la población masculina adulta y adulta mayor. </p>
				</sec>
				<sec>
					<title>Método:</title>
					<p> revisión sistemática desarrollada según la <italic>checklist</italic> PRISMA. La búsqueda se realizó en las bases de datos CINAHL, <italic>Embase,</italic> LILACS, PEDro, PubMed, <italic>Web of Science</italic> y <italic>Google Scholar</italic>. </p>
				</sec>
				<sec>
					<title>Resultados:</title>
					<p> se identificaron 585 registros y se seleccionaron 12 ensayos clínicos que cumplían con los criterios de inclusión. Los resultados que los estudios consideraron para analizar la efectividad de las terapias complementarias fueron cuestionarios validados que evaluaban la gravedad de los síntomas del tracto urinario inferior (sensación de vaciado incompleto de la vejiga, micción frecuente, flujo intermitente, flujo débil, dolor o dificultad para orinar, nicturia y urgencia) y parámetros urodinámicos. Los estudios analizaron las terapias complementarias fitoterapia (n=8) y electroacupuntura (n=4). Seis estudios relacionados con la fitoterapia demostraron significación estadística. La electroacupuntura demostró una mejoría significativa de los síntomas en dos estudios. </p>
				</sec>
				<sec>
					<title>Conclusión:</title>
					<p> la fitoterapia fue efectiva para controlar los síntomas de frecuencia, urgencia, nicturia, vaciado incompleto, intermitencia, flujo débil y esfuerzo para iniciar la micción. Para confirmar la efectividad de la electroacupuntura, aún es necesario que se realicen investigaciones con metodologías bien diseñadas para resolver las diferencias entre los estudios de esta revisión. </p>
				</sec>
			</abstract>
			<kwd-group xml:lang="es">
				<title>Descriptores:</title>
				<kwd>Terapias Complementarias</kwd>
				<kwd>Síntomas del Sistema Urinario Inferior</kwd>
				<kwd>Revisión Sistemática</kwd>
				<kwd>Salud del Hombre</kwd>
				<kwd>Fitoterapia</kwd>
				<kwd>Electroacupuntura</kwd>
			</kwd-group>
			<funding-group>
				<award-group award-type="contract">
					<funding-source>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</funding-source>
					<award-id>429958/2018-8</award-id>
				</award-group>
				<award-group award-type="contract">
					<funding-source>Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)</funding-source>
					<award-id>APQ 01034-21</award-id>
				</award-group>
				<funding-statement>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), proceso nº 429958/2018-8 y de la Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), proceso APQ 01034-21, Brasil.</funding-statement>
			</funding-group>
		</front-stub>
		<body>
			<boxed-text id="bx3">
				<sec>
					<title>Destacados</title>
					<p>(1) Las terapias complementarias pueden ser efectivas para los síntomas urinarios masculinos.</p>
					<p>(2) La fitoterapia fue efectiva en seis de los ocho estudios incluidos.</p>
					<p>(3) Es necesario realizar estudios con electroacupuntura y metodologías más robustas.</p>
				</sec>
			</boxed-text>
			<sec sec-type="intro">
				<title>Introducción</title>
				<p>Según la <italic>International Continence Society</italic> (ICS), los síntomas del tracto urinario inferior (STUI) se pueden categorizar según la fase de la micción: almacenamiento, vaciado y postmicción<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Los STUI de almacenamiento, como la nicturia y la incontinencia urinaria, son los más relatados por la población general, seguidos del goteo postmiccional, la reducción del flujo urinario y la sensación de vaciado incompleto de la vejiga, que también son quejas frecuentes<xref ref-type="bibr" rid="B2"><sup>2</sup></xref>.</p>
				<p>La frecuencia de los STUI aumenta con la edad<xref ref-type="bibr" rid="B3"><sup>3</sup></xref>. Los hombres, presentan diferentes manifestaciones clínicas de STUI, las cuales están relacionadas con la vejiga, la próstata, la uretra, el suelo pélvico y/o los órganos pélvicos adyacentes<xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Estudios epidemiológicos realizados con población masculina adulta y adulta mayor indican que la prevalencia puede variar entre el 60 y 84%<xref ref-type="bibr" rid="B4"><sup>4</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. La etiología más frecuentemente asociada a la aparición de STUI en los hombres es la hiperplasia prostática benigna (HPB)<xref ref-type="bibr" rid="B3"><sup>3</sup></xref>. Si bien no es una morbilidad grave asociada a la mortalidad, estos síntomas tienen un impacto negativo en la vida cotidiana de los pacientes, dado que afectan su calidad de vida, conducen a la insatisfacción sexual y aumentan el riesgo de trastornos depresivos<xref ref-type="bibr" rid="B6"><sup>6</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
				<p>Hay una variedad de estrategias de tratamiento para controlar los STUI<xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. El tratamiento convencional generalmente implica cambios en el comportamiento, como reducir el consumo de cafeína y alcohol, aumentar la actividad física y reducir el peso corporal. Dicho tratamiento, en algunos casos, puede estar asociado a medidas farmacológicas, especialmente alfabloqueantes e inhibidores de la 5-alfa-reductasa<xref ref-type="bibr" rid="B9"><sup>9</sup></xref>. Sin embargo, una parte de los hombres responde insatisfactoriamente al tratamiento convencional y requiere medidas quirúrgicas<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>. Ambas opciones implican costos médicos y posibles daños asociados a efectos adversos de los medicamentos o secuelas después de intervenciones invasivas<xref ref-type="bibr" rid="B10"><sup>10</sup></xref>.</p>
				<p>En ese caso, las intervenciones basadas en terapias complementarias (TC) pueden ser una estrategia eficaz para controlar los STUI en los hombres, especialmente porque son más económicas y tienen mínimos efectos adversos. Las TC, también llamadas Medicina Tradicional y Complementaria, son un conjunto de conocimientos, habilidades y prácticas que se originan a partir de las experiencias y creencias de diferentes culturas que complementan las prácticas de la medicina convencional<xref ref-type="bibr" rid="B11"><sup>11</sup></xref>. </p>
				<p>La efectividad de la fitoterapia y de la acupuntura ha sido evaluada individualmente por medio de revisiones sistemáticas<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref> y comparada con los tratamientos convencionales para el control de los STUI<xref ref-type="bibr" rid="B14"><sup>14</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Sin embargo, se observa que muchas veces las TC se indican de forma empírica<xref ref-type="bibr" rid="B16"><sup>16</sup></xref>. Por lo tanto, se espera que una revisión sistemática sea capaz de resumir la evidencia disponible sobre la efectividad de las diferentes TC para controlar los STUI en la población masculina y así favorecer su implementación en la práctica clínica.</p>
				<p>Considerando la popularización de las TC, surge la necesidad de desarrollar una revisión sistemática que tenga como objetivo evaluar la evidencia científica sobre la efectividad de las terapias complementarias para el control de los síntomas del tracto urinario inferior en la población masculina adulta y adulta mayor.</p>
			</sec>
			<sec sec-type="methods">
				<title>Método</title>
				<sec>
					<title>Diseño del estudio</title>
					<p>Revisión sistemática de la literatura, registrada en la plataforma <italic>International Prospective Register of Systematic Reviews</italic> (PROSPERO) (Número de registro: CRD42021226480), desarrollada según las recomendaciones de la <italic>Preferred Reporting Items for Systematic Reviews and Meta-Analyses</italic> PRISMA <italic>Checklist</italic><xref ref-type="bibr" rid="B17"><sup>17</sup></xref> para informar revisiones sistemáticas.</p>
				</sec>
				<sec>
					<title>Criterio de selección</title>
					<p>Para elaborar la pregunta orientadora se utilizó la estrategia PICO, en la que P se refiere a la población o grupo de pacientes (hombres con STUI), I a la Intervención (TC), C a la comparación (no se utilizó comparación con otras intervenciones) y O al resultado/<italic>outcomes</italic> (STUI control). Por lo tanto, esta revisión sistemática buscó responder a la siguiente pregunta: ¿Qué efectividad tienen las TC para controlar los STUI en la población masculina?</p>
					<p>Fueron elegibles para la revisión sistemática solo los ensayos clínicos que evaluaron el uso de TC para controlar los STUI en hombres adultos (a partir de los 18 años). No hubo restricciones por idioma o año de publicación.</p>
				</sec>
				<sec>
					<title>Definición de la muestra y el periodo</title>
					<p>Mediante la lectura del título y del resumen, se excluyeron los estudios con muestras compuestas por poblaciones mixtas, niños y animales; las investigaciones originales cuyo diseño no fuera un ensayo clínico; las publicaciones como revisiones, cartas, editoriales, protocolos e informes de caso; los registros que no tenían resumen en línea disponible. Después de la lectura completa se excluyeron los ensayos clínicos que asociaban el tratamiento convencional con TC en el grupo de intervención y publicaciones como protocolos de ensayos clínicos. Cabe señalar que también se excluyeron los estudios que, a pesar de ser elegibles por título y resumen, no se encontraron completos en línea o no fueron enviados por los autores correspondientes por correo electrónico.</p>
					<p>La búsqueda se realizó en las siguientes bases de datos: <italic>Index to Nursing &amp; Allied Health Literature</italic> (CINAHL) a través del Portal de Periódicos CAPES, <italic>Embase, Latin American and Caribbean Health Sciences Literature</italic> (LILACS)<italic>, Physiotherapy Evidence Database</italic> (PEDro), PubMed, y <italic>Web of Science</italic>. Los estudios se identificaron a partir de estrategias de búsqueda adaptadas específicamente para cada una de las bases de datos utilizando terminología definida por el <italic>Medical Subject Headings</italic> (MeSH/PubMed) y los Descriptores en Ciencias de la Salud (DeCS), como se muestra en la <xref ref-type="table" rid="t7">Figura 1</xref>. Los datos se obtuvieron en mayo de 2021. Los investigadores realizaron búsquedas manuales en las listas de referencias de los estudios seleccionados para identificar posibles referencias que no se identificaron en la búsqueda electrónica. Por último, también se utilizó <italic>Google Scholar</italic> como método de búsqueda complementario.</p>
					<p>
						<table-wrap id="t7">
							<label>Figura 1</label>
							<caption>
								<title>Estrategia de búsqueda y resultados en cada base de datos. Belo Horizonte, MG, Brasil, 2021</title>
							</caption>
							<table>
								<colgroup>
									<col/>
									<col/>
								</colgroup>
								<thead>
									<tr>
										<th align="left">Base de datos </th>
										<th align="left">Estrategia de búsqueda</th>
									</tr>
								</thead>
								<tbody>
									<tr>
										<td align="left">CINAHL</td>
										<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
									</tr>
									<tr>
										<td align="left"><italic>Embase</italic></td>
										<td align="left"><italic>(‘lower urinary tract symptom’/exp OR ‘lower urinary tract symptom’) AND (‘chinese medicine’/exp OR ‘chinese medicine’)</italic></td>
									</tr>
									<tr>
										<td align="left">LILACS</td>
										<td align="left"><italic>(tw:(((“Terapias Complementares” OR “Medicina Alternativa” OR “Medicina Complementar” OR “Terapias Alternativas” OR “Práticas Integrativas e Complementares” OR auriculoterapia OR “Acupuntura Auricular” OR “Terapia por Acupuntura” OR eletroacupuntura OR “Pontos de Acupuntura” OR moxibustão OR Medicina Tradicional Chinesa OR Meridianos OR Acupressão OR Orelha Externa OR “Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR electroacupuncture OR “Acupuncture Points” OR moxibustion OR “Medicine, chinese traditional” OR Meridians OR Acupressure OR “Ear, external”)))) AND (tw:(((“Incontinência Urinária” OR “Transtornos Urinários” OR “Incontinência Urinária por Estresse” OR “Urinary Incontinence” OR “Urination Disorders” OR “Urinary incontinence, stress”))))</italic></td>
									</tr>
									<tr>
										<td align="left">PEDro</td>
										<td align="left"><italic>Therapy: acupuncture; Problem: incontinence</italic></td>
									</tr>
									<tr>
										<td align="left">PubMed</td>
										<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
									</tr>
									<tr>
										<td align="left"><italic>Web of Science</italic></td>
										<td align="left"><italic>((“Complementary Therapies” OR “Alternative Medicine” OR “Alternative Therapies” OR “Complementary Medicine” OR “Complementary and Integrative Practices” OR “Medicine, Chinese Traditional” OR Acupressure OR Auriculotherapy OR “Acupuncture, Ear” OR “Acupuncture Therapy” OR “Ear, external” OR Electroacupuncture OR “Acupuncture Points” OR Moxibustion OR Reflexotherapy OR “Foot reflexology” OR “Zone Therapy” OR Meridians) AND (“Urinary Incontinence” OR “Urination Disorders” OR “Urinary Dysfunction” OR “Urinary Symptoms” OR “Urinary Incontinence, Stress”))</italic></td>
									</tr>
									<tr>
										<td align="left"><italic>Google Scholar</italic></td>
										<td align="left"><italic>Advanced searchWith all the words: Complementary Alternative Medicine With the exact phrase: Lower urinary tract symptomsWithout the words: Female; Children</italic></td>
									</tr>
								</tbody>
							</table>
						</table-wrap>
					</p>
				</sec>
				<sec>
					<title>Recolección de datos</title>
					<p>Para agrupar las búsquedas y excluir duplicados se utilizó <italic>EndNoteBasic</italic><sup>®</sup>, versión <italic>web</italic>. Posteriormente, todas las referencias se sometieron a una selección manual para extraer información clave de los estudios (autores; año; país; TC; objetivo; tamaño de la muestra; características de la muestra; características de la intervención y del control; tiempo de tratamiento y seguimiento; evaluación de instrumentos y otros resultados; conclusiones), las cuales fueron transcritas y organizadas en una planilla de Microsoft Excel que facilitó el desarrollo de la etapa de selección.</p>
					<p>La selección de estudios fue realizada por dos investigadoras, estudiantes de doctorado en enfermería (P1 y P2), de forma independiente en dos fases. En la primera fase, después de la lectura del título y el resumen, se identificaron aquellos estudios potencialmente elegibles para revisión sistemática, considerando los criterios de inclusión y exclusión definidos. En la segunda fase, los estudios seleccionados se leyeron en su totalidad y se excluyeron aquellos que no cumplían con los criterios de inclusión. Las diferencias de selección entre las dos investigadoras (P1 y P2) fueron discutidas y cuando no hubo consenso, fueron evaluadas por un tercer investigador, doctor en enfermería (P3), quien decidió la inclusión o exclusión de los estudios.</p>
					<p>Dos investigadoras (P1 y P2) extrajeron de forma independiente los datos relevantes de los artículos seleccionados en una hoja de cálculo creada en Microsoft Excel. Los datos extraídos fueron: características generales del estudio (autor, año y país de publicación), objetivos, características de la muestra (número de participantes y edad media), características de la intervención [fitoterapia (dosis y duración)], acupuntura/electroacupuntura (puntos de acupuntura, procedimientos de manipulación, frecuencia e intensidad de la electroestimulación, duración y número de sesiones), otros brazos del estudio], resultados (principales resultados analizados e instrumentos utilizados) y conclusión. Una tercera revisora (P3) evaluó la precisión de los datos recolectados.</p>
				</sec>
				<sec>
					<title>Análisis de los datos</title>
					<p>La evaluación de la calidad de los estudios seleccionados se realizó según la <italic>Joanna Briggs Institute</italic> (JBI) <italic>Critical Appraisal Tool</italic> - <italic>checklist</italic> para ensayos clínicos aleatorizados. Es un instrumento que evalúa la calidad metodológica y el abordaje de posibles sesgos en el diseño, realización y análisis de los datos de ensayos clínicos aleatorizados. Esta <italic>checklist</italic> consta de 13 preguntas con cuatro opciones de respuesta (sí, no, incierto o no se aplica)<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>.</p>
					<p>En cuanto a la categorización de la calidad metodológica de los ensayos según el instrumento aplicado, los estudios que tuvieron 70% o más de respuestas afirmativas fueron clasificados como con bajo riesgo de sesgo, del 50 a 69% de respuestas afirmativas fueron clasificados como con riesgo moderado y con un 49 % o menos de respuestas afirmativas fueron clasificados como con alto riesgo.</p>
					<p>La evaluación del riesgo de sesgo fue realizada de forma independiente por dos investigadoras (P1 y P2). Se consideró a una tercera investigadora (P3) para la evaluación de posibles divergencias.</p>
				</sec>
			</sec>
			<sec sec-type="results">
				<title>Resultados</title>
				<p>En las búsquedas realizadas en las bases de datos se identificaron 585 registros, de los cuales se eliminaron 96 duplicados. Después de la lectura de títulos y resúmenes, 478 registros fueron excluidos en la primera fase y 11 artículos fueron seleccionados para lectura completa. Además de estos, la búsqueda de otros métodos dio como resultado la selección de tres artículos y se seleccionaron otros cuatro artículos de las listas de referencias.</p>
				<p>Considerando los criterios de inclusión y exclusión establecidos, de los 18 artículos seleccionados y leídos en su totalidad durante la segunda fase, seis fueron excluidos. La muestra final estuvo compuesta por 12 estudios que cumplieron con los criterios de selección. El proceso de identificación, inclusión y exclusión de estudios se describe en <xref ref-type="fig" rid="f3">Figura 2</xref>.</p>
				<p>
					<fig id="f3">
						<label>Figura 2</label>
						<caption>
							<title>Diagrama de flujo de búsquedas en bases de datos y criterios de selección</title>
						</caption>
						<graphic xlink:href="1518-8345-rlae-30-e3597-gf3.png"/>
					</fig>
				</p>
				<p>Todos los estudios fueron publicados en inglés entre 2001 y 2019. En cuanto al país de origen, cuatro estudios se realizaron en Estados Unidos<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref>, dos en Japón<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, dos en China<xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, dos en la República Checa<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, uno en Italia<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> y uno en Taiwán<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>La mayoría de los ensayos clínicos evaluaron la fitoterapia (n=8) para el control de STUI en la población masculina<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. El resto de los ensayos clínicos de esta revisión abordaron la electroacupuntura (n=4)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. La descripción de cada elemento se detalla en la <xref ref-type="table" rid="t8">Figura 3</xref>.</p>
				<p>
					<table-wrap id="t8">
						<label>Figura 3</label>
						<caption>
							<title>Descripción de las características de los estudios incluidos en la revisión sistemática (n=12)</title>
						</caption>
						<table>
							<colgroup>
								<col span="3"/>
								<col span="2"/>
								<col span="3"/>
								<col span="2"/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" colspan="3">Características del estudio </th>
									<th align="left" colspan="2">Descripción de la muestra </th>
									<th align="left" colspan="3">Método aplicado </th>
									<th align="left" colspan="2">Resultados analizados </th>
									<th align="left">Conclusiones finales</th>
								</tr>
								<tr>
									<th align="left">Autor, año; País</th>
									<th align="left">TC<sup>¶¶</sup></th>
									<th align="left">Objetivos</th>
									<th align="left">Tamaño (n)</th>
									<th align="left">Características (línea de base de STUI<sup>‡‡‡</sup>; edad media ±desviación estándar)</th>
									<th align="left">Intervención (GI<sup>||</sup>)</th>
									<th align="left">Control (GC<sup>§</sup>)</th>
									<th align="left">Duración (meses)</th>
									<th align="left">Cuestionarios de evaluación</th>
									<th align="left">Parámetros de Urodinámica</th>
									<th align="left">
									</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left">Gerber, et al. (2001)<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>; EE. UU.</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Evaluar los efectos del extracto de <italic>Saw palmetto</italic> (<italic>S. palmetto)</italic> sobre los síntomas urinarios, la función sexual y el flujo urinario en hombres con STUI<sup>‡‡‡</sup>.</td>
									<td align="left">n: 85 GI<sup>||</sup>: 41 GC<sup>§</sup>: 44</td>
									<td align="left">Puntaje I-PSS<sup>††</sup> &gt; 8 sin antecedentes de cirugía de próstata; 64,5 (±9,9) años (GI<sup>||</sup>); 65,3 (±9,7) años (GC<sup>§</sup>).</td>
									<td align="left">Cápsula 160mg de <italic>S. palmetto</italic> (distribuido por Nutraceutical), 2x/día (320 mg diarios).</td>
									<td align="left">Cápsula de placebo (aceite de oliva extra virgen, gelatina y glicerina), 2x/día.</td>
									<td align="left">6</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup></td>
									<td align="left">GI<sup>||</sup> tuvo una reducción (mejoría) promedio de 4.4 (±5.9) puntos en el puntaje I-PSS<sup>††</sup> lo que demuestra una diferencia significativa (<italic>p</italic> = 0,038) al compararlo con el GC<sup>§</sup>. Qmax<sup>||||</sup> mejoró ligeramente en ambos grupos, pero los cambios no fueron significativos (<italic>p</italic> = 0,75). </td>
								</tr>
								<tr>
									<td align="left">Bent, et al. (2006)<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>; EE. UU.</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Determinar la eficacia del extracto de <italic>S. palmetto</italic> para el tratamiento de HPB<sup>¶</sup>.</td>
									<td align="left">n: 225 GI<sup>||</sup>: 112 GC<sup>§</sup>: 113</td>
									<td align="left">HPB<sup>¶</sup> determinada por el puntaje *AUASI &gt; 8, sin antecedentes de cirugía de próstata; 62,9 (±8,7) años (GI<sup>||</sup>); 63,0 (±7,4) años (GC<sup>§</sup>).</td>
									<td align="left">Cápsula 160 mg de <italic>S. palmetto</italic> (distribuido por Rexall-Sundown, Inc), 2x/día (320 mg diarios).</td>
									<td align="left">Cápsula de placebo (polietilenoglicol, 400, líquido amargo con aspecto oleoso ácidos grasos libres y tinte marrón), 2x/día.</td>
									<td align="left">12</td>
									<td align="left">*AUASI</td>
									<td align="left">Qmax<sup>||||||</sup>, volumen prostático y VRP</td>
									<td align="left">Reducción (mejora) discreta en el puntaje AUASI*, 0,72 (±0,35) puntos en el GC§ y 0,68 (±0,35) puntos en el GI<sup>||</sup>, pero sin diferencia significativa entre los grupos (IC**95%: -0,93 a 1,01). No se observaron cambios en el Qmax<sup>||||</sup>, volumen prostático y VRP.</td>
								</tr>
								<tr>
									<td align="left">Barry, et al. (2011)<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>; EE. UU.</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Determinar el efecto del extracto de <italic>S. palmetto</italic>, hasta tres veces la dosis estándar, en STUI<sup>‡‡‡</sup> atribuidos a la HPB<sup>¶</sup>.</td>
									<td align="left">n: 357 GI<sup>||</sup>: 176 GC<sup>§</sup>: 181</td>
									<td align="left">Puntaje AUASI entre 8 y 24, sin antecedentes de cirugía de próstata; 61,3 ± 8,7 años (GI<sup>||</sup>); 60,7 ± 8,1 años (GC<sup>§</sup>).</td>
									<td align="left">Cápsula 320 mg de <italic>S. palmetto</italic> (distribuido por Rottapharm) Aumento progresivo de la dosis: -1 cápsula/día de la semana 1 a la 23 (320 mg diarios); -2 cápsulas/día de la semana 24 y a la 48 (640 mg diarios); -3 cápsulas/día de la semana 48 y a la 72 (960 mg diarios).</td>
									<td align="left">Cápsulas de placebo (375 mg de polietilenoglicol, 25 mg de glicerol y 75 mg de gelatina) siguiendo un aumento progresivo del número de cápsulas como en el GI.</td>
									<td align="left">18</td>
									<td align="left"> AUASI*</td>
									<td align="left">Qmax<sup>||||</sup> y VRP<sup>||||||</sup></td>
									<td align="left">Puntaje medio AUASI* disminuyó (mejoró) 2,99 puntos (IC**95%: -3,81 a -2,17) en el GC y 2,20 puntos (IC95%: -3,04 a -0,36) en el GI<sup>||</sup>, hubo una diferencia de 0,79 puntos entre los dos grupos a favor del GC<sup>§</sup>. La comparación de dosis-respuesta no mostró mejoría en el GI<sup>||</sup> con ninguna de las dosis en comparación con el GC§. No se observaron cambios en Qmax yVRP<sup>||||||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Ye, et al. (2019)<xref ref-type="bibr" rid="B26"><sup>26</sup></xref>; China</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Evaluar la efectividad y seguridad del <italic>S. palmetto</italic> en pacientes con STUI<sup>‡‡‡</sup>/ HPB<sup>¶</sup>.</td>
									<td align="left">n: 325 GI<sup>||</sup>: 159 GC<sup>§</sup>: 166</td>
									<td align="left">HPB<sup>¶</sup> con puntaje I-PSS &lt; 19; 61,5 (± 5,2) años (GI<sup>||</sup>); 60,3 (± 6,0) años (GC<sup>§</sup>).</td>
									<td align="left">Cápsula 160 mg de <italic>S. palmetto</italic> (distribuido por Tad Pharma GmbH)<italic>,</italic> 2x/día (320mg diarios).</td>
									<td align="left">Cápsula de placebo (composición no descrita), 2x/día.</td>
									<td align="left">6</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>‡‡</sup>, volumen prostático y frecuencia de micción</td>
									<td align="left">El puntaje I-PSS<sup>††</sup> se redujo (mejoró) en ambos grupos, pero la reducción fue significativamente mayor después de 24 semanas en el GI<sup>||</sup> (<italic>p</italic> &lt; 0,001). El GI<sup>||</sup> demostró un aumento significativo (mejoría) en el Qmax<sup>‡‡</sup> a partir de la 4ª semana (<italic>p</italic> = 0,011) hasta la semana 24 (<italic>p</italic> &lt; 0,001). No se observaron cambios en el volumen prostático ni en la frecuencia urinaria.</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al. (2008)<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>; Japón</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Evaluar la seguridad y eficacia del extracto de <italic>Ganoderma lucidum (G. lucidum),</italic> en hombres con síntomas del tracto urinario inferior de un estudio con dosis escalonadas.</td>
									<td align="left">n: 50 GI<sup>||</sup>/0,6: 12 GI<sup>||</sup>/6: 12 GI<sup>||</sup>/60: 14 GC<sup>§</sup>: 12</td>
									<td align="left">Puntaje I-PSS<sup>††</sup> &gt; 5, sin antecedentes de cirugía de próstata; 59,1 (51-70) años (GI<sup>||</sup>/0,6); 59,2 (50-72) años (GI<sup>||</sup>/6); 59,4 (50-70) años (GI<sup>||</sup>/60); 59,7 (50-67) años (GC<sup>§</sup>). </td>
									<td align="left">GI<sup>||</sup>/0,6: Comprimido 0,6 mg <italic>G. lucidum</italic>, 1x/día; GI<sup>||</sup>/6: Comprimido 6 mg <italic>G. lucidum</italic>, 1x/día; GI<sup>||</sup>/60: Comprimido 60 mg <italic>G. lucidum</italic>, 1x/día. (Todos comprimidos fueron distribuidos por Chlorella Industry).</td>
									<td align="left">Comprimido de placebo (83,75% maltitol, 10% almidón de maíz, 3% vitamina C, 0,2% de gardenia amarilla y 3% éster de ácido graso de sacarosa), 1x/día.</td>
									<td align="left">2</td>
									<td align="left">I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, volumen prostático y VRP<sup>||||||</sup></td>
									<td align="left">En la semana 4, el cambio medio en el puntaje I-PSS<sup>††</sup> fue significativamente mayor en el GI<sup>||</sup>/60, en comparación con el GC<sup>§</sup> (<italic>p</italic> = 0,012) y GI<sup>||</sup>/0,6 (<italic>p</italic> &lt; 0,001). En la 8ª semana, el cambio medio en el GI<sup>||</sup>/0,6 fue significantemente menor que en el GI<sup>||</sup>/6 (<italic>p</italic> = 0,016) y GI<sup>||</sup>/60 (p = 0,005). Ligera mejoría en el Qmax<sup>||||</sup>, pero sin diferencias significativas entre grupos. No se observaron cambios en el volumen prostático y VRP<sup>||||||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al. (2008)<xref ref-type="bibr" rid="B24"><sup>24</sup></xref>; Japón</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Evaluar la seguridad y la eficacia en hombres con síntomas leves a moderados del tracto urinario inferior de <italic>G. lucidum,</italic> que demostró la mayor actividad inhibidora de la 5α-reductasa en los extractos de 19 hongos comestibles y medicinales.</td>
									<td align="left">n: 88 GI<sup>||</sup>
 <sub>:</sub> 44 GC<sup>§</sup>: 44</td>
									<td align="left">Puntaje I-PSS<sup>††</sup> entre 5 y 19, sin antecedentes de cirugía de próstata; 64,0 (± 6,9) años (GI<sup>||</sup>); 64,0 (± 8,0) años (GC<sup>§</sup>).</td>
									<td align="left">2 comprimidos 3 mg de <italic>G. lucidum</italic> (distribuidos por Chlorella Industry), 1x/día (6mg diarios).</td>
									<td align="left">2 comprimidos placebos (83,75% maltitol, 10% almidón de maíz, 3% vitamina C, 0,2% de gardenia amarilla y 3% éster de ácido graso de sacarosa), 1x/día.</td>
									<td align="left">3</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, volumen prostático y VRP<sup>||||||</sup></td>
									<td align="left">El puntaje I-PSS<sup>††</sup> se redujo (mejoró) de forma más pronunciada en el GI<sup>||</sup> hasta la semana 12, lo que demuestra una diferencia significativa (<italic>p</italic> &lt; 0,001) en el cambio medio del puntaje entre los dos grupos. El Qmax<sup>||||</sup> (<italic>p</italic> = 0,400) y Qave<sup>‡‡</sup> (<italic>p</italic> = 0,080) mostraron un aumento (mejoría) en el GI<sup>||</sup> en la semana 4 y 8, pero no diferencia significativa entre los grupos en la semana 12. No se observaron cambios en el volumen prostático y VPR<sup>||||||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al. (2010)<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>; República Checa</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Evaluar la eficacia y tolerancia del polvo de <italic>cranberry</italic> en hombres con síntomas del tracto urinario inferior, PSA<sup>§§</sup> elevado, HPB<sup>¶</sup> y prostatitis no bacteriana crónica.</td>
									<td align="left">n: 42 GI<sup>||</sup>: 21 GC<sup>§</sup>: 21</td>
									<td align="left">Hallazgos histológicos de prostatitis no bacteriana, aguda o crónica; 62,0 (± 5,4) años (GI<sup>||</sup>); 64,0 (± 5,4) años (GC<sup>§</sup>);</td>
									<td align="left">Cápsula 500mg de <italic>cranberry</italic> en polvo (distribuidas por Decas Botanical Synergies). 3x/día, (1500mg diarios).</td>
									<td align="left">Cápsula de placebo (composición no descrita), 3x/día.</td>
									<td align="left">6</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax, Qave, y VRP<sup>||||||</sup></td>
									<td align="left">Puntaje I-PSS<sup>††</sup> significativamente menor (mejor) en el GI|| que en el GC<sup>§</sup> (<italic>p</italic> &lt; 0,050). Mejora significativa (p &lt; 0,050) del Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, y VRP<sup>||||||</sup> en al menos el 70% de los participantes del GI<sup>||</sup>, y empeoramiento significativo (<italic>p</italic> &lt; 0,050) del VRP<sup>||||||</sup> en el GC<sup>§</sup>.</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al. (2015)<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>; República Checa</td>
									<td align="left">FT<sup>‡</sup></td>
									<td align="left">Evaluar el efecto del <italic>cranberry</italic> en hombres con síntomas del tracto urinario inferior de moderados a graves.</td>
									<td align="left">n: 122 GI<sup>||</sup>/500: 38 GI<sup>||</sup>/250: 43 GC<sup>§</sup>: 41</td>
									<td align="left">Puntaje I-PSS<sup>††</sup> &gt; 8, sin antecedentes de cirugía de próstata; 52,5 (± 5,4) años (GI<sup>||</sup>/500); 53,3 (± 5,2) años (GI<sup>||</sup>/250); 54,0 (±5,1) años (GC§).</td>
									<td align="left">GI<sup>||</sup>/500: 2 cápsulas 250 mg de <italic>cranberry</italic> 1x/día (500 mg diarios); GI<sup>||</sup>/250: 1 cápsula 250mg de <italic>cranberry</italic> y 1 cápsula de placebo, 1x/día (250 mg diarios); (todas las cápsulas fueron distribuidas por Decas Botanical Synergies).</td>
									<td align="left">2 cápsulas de placebo (maltodextrina de baja densidad, aceite de canola, silicato de aluminio y sodio, rojo 40 lago y azul 1 lago), 1x/día.</td>
									<td align="left">6</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, Qave<sup>‡‡</sup>, VRP<sup>||||||</sup> y volumen de vaciado de la vejiga</td>
									<td align="left">Reducción (mejora) significativa en el puntaje I-PSS<sup>††</sup> del GI<sup>||</sup>/500 y GI<sup>||/</sup>250, de -4,1 (± 1,9) (<italic>p</italic> &lt; 0,001) y -3,1 (± 3,0) (<italic>p</italic> = 0,050) puntos respectivamente. Qmax<sup>||||</sup> (<italic>p</italic> = 0,018), Qave<sup>‡‡</sup> (<italic>p</italic> = 0,040), VRP<sup>||||||</sup> (<italic>p</italic> = 0,027) y volumen de vaciado de la vejiga (<italic>p</italic> = 0,014) mejoraron significativamente en el GI<sup>||</sup>/500. </td>
								</tr>
								<tr>
									<td align="left">Johnstone, et al. (2003)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>; EE. UU.</td>
									<td align="left">EA<sup>†</sup></td>
									<td align="left">Evaluar la respuesta de los síntomas del tracto urinario inferior y el nivel de PSA<sup>§§</sup> a la EA<sup>†</sup> en una población de pacientes con biopsia negativa para cáncer de próstata.</td>
									<td align="left">n: 30 (No especifica muestra en cada grupo de estudio)</td>
									<td align="left">Puntaje I-PSS<sup>††</sup> &gt; 8; 60,7 (± 8,2) años (GI<sup>||</sup>); 64,7 (± 5,2) años (GC<sup>§</sup>/EA<sup>†</sup> placebo); 63,5 (± 3,4) años (GC<sup>§</sup>/observación).</td>
									<td align="left">PtA***: R10, B40, B32 y B10. Eletroestimulación de 4-5 Hz en R10 y B40. Sesiones 3x/semana en la 1ª y 2ª semana, y posteriormente 1x/semana en la 3ª, 4ª y 8ª semana, 20 min/sesión.</td>
									<td align="left">GC<sup>§</sup>/EA<sup>†</sup> placebo: inserción de 5 agujas en la región posterior de los hombros, zonas no relacionadas con los PtA*** y sin electroestimulación. GC<sup>§</sup>/observación: sin intervención durante el estudio.</td>
									<td align="left">3 (9 sesiones)</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">No fue evaluado</td>
									<td align="left">No se observaron cambios en el puntaje I-PSS<sup>††</sup> (<italic>p</italic> = 0,063).</td>
								</tr>
								<tr>
									<td align="left">Ricci, et al. (2004)<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>; Italia</td>
									<td align="left">EA<sup>†</sup></td>
									<td align="left">Evaluar si la EA<sup>†</sup> en reflexoterapia/acupuntura es capaz de tratar los componentes sensoriales irritativos de los síntomas del tracto urinario inferior que persisten después de la RTU<sup>†††</sup></td>
									<td align="left">n: 42 GI<sup>||</sup>:13 GC<sup>§</sup>/placebo: 14 GC<sup>§</sup>/con v: 15</td>
									<td align="left">Persistencia de síntomas sensoriales irritativos del tracto urinario inferior después de RTU<sup>†††</sup>; 64,76 años (52-78 años).</td>
									<td align="left">PtA somáticos: Vaso concepción: 1, 2, 4, 5; Vejiga 21, 23 y 32; PtA*** auriculares: próstata y genitales externos. Eletroestimulación de 5-10 Hz, con mayor intensidad tolerada por el paciente. Sesiones 3x/semana, más sesiones de mantenimiento cada 15 días, a partir de la semana 4, 20 min/sesión.</td>
									<td align="left">CG<sup>§</sup>/placebo: comprimido de placebo (no define composición, número de comprimidos, ni repeticiones por día); GC<sup>§</sup>/conv: Comprimido de oxibutinina 5 mg, 2x/día (10 mg diarios).</td>
									<td align="left">3 (12 sesiones)</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup>, volumen prostático, frecuencia de micción y nicturia</td>
									<td align="left">Puntaje I-PSS<sup>††</sup> se redujo (mejoró) en el GC<sup>§</sup> y en el GI<sup>||</sup> durante los primeros 3 meses, pero la diferencia fue significativa sólo en el GI<sup>||</sup> (<italic>p</italic>&lt;0,001). No se observaron cambios en el Qmax<sup>||||</sup> y volumen prostático. Reducción de la frecuencia de micción diurna del 20% y del 8% en el GI<sup>||</sup> y en el GC<sup>§</sup>, respectivamente. Los informes de nocturia también se redujeron en un 60% y un 20% en el GI<sup>||</sup> y el GC<sup>§</sup>, respectivamente.</td>
								</tr>
								<tr>
									<td align="left">Yu, et al. (2011)<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>; Taiwán</td>
									<td align="left">EA<sup>†</sup></td>
									<td align="left">Evaluar el efecto de la EA<sup>†</sup> sobre los síntomas del tracto urinario inferior en hombres con HPB<sup>¶</sup>.</td>
									<td align="left">n: 37 GI<sup>||</sup>: 18 GC<sup>§</sup>: 19</td>
									<td align="left">HPB<sup>¶</sup> confirmada por US<sup>§§§</sup> transrectal con puntaje I-PSS<sup>††</sup> &gt; 8, sin antecedentes de cirugía de próstata; 63,2 (± 10,0) años (GI<sup>||</sup>); 59,8 (± 9,0) años (GC<sup>§</sup>).</td>
									<td align="left">PtA***: Vaso concepción 3 y 4; Estómago 36 y Bazo-Páncreas 6. Agujas insertadas y manipuladas por 3-5 minutos hasta alcanzar <italic>Qi</italic>. Estimulación eléctrica de 2 Hz con una intensidad de 2-2,5 mA. Sesiones 2x/semana, 20 min/sesión.</td>
									<td align="left">Agujas insertadas superficialmente (tejido subcutáneo), 1 cm lateral a los PtA*** del GI||, sin manipulación manual ni estimulación eléctrica. Misma frecuencia de sesiones que en el GI<sup>||</sup>.</td>
									<td align="left">1,5 (12 sesiones)</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax||||, Qave‡‡ y volumen de vaciado de la vejiga</td>
									<td align="left">No se observaron cambios en el puntaje I-PSS†† entre los grupos. Aumento (mejora) del Qmax|||| (<italic>p</italic> = 0,030), Qave<sup>‡‡</sup> (<italic>p</italic> = 0,026) volumen de vaciado (<italic>p</italic> = 0,038) significativo en el GI<sup>||</sup>.</td>
								</tr>
								<tr>
									<td align="left">Wang, et al. (2013)<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>; China</td>
									<td align="left">EA †</td>
									<td align="left">Evaluar los efectos de la EA<sup>†</sup> sobre el puntaje I-PSS<sup>††</sup>, sobre el VRP<sup>||||||</sup>, y sobre el Qmax<sup>||||</sup>, explorar las diferencias entre la EA<sup>†</sup> en los PtA*** y puntos no relacionados con estos, en pacientes con HPB<sup>¶</sup> moderada o grave.</td>
									<td align="left">n: 100 GI<sup>||</sup>: 50 GC<sup>§</sup>: 50</td>
									<td align="left">HPB<sup>¶</sup> determinada por el puntaje I-PSS<sup>††</sup> &gt; 8; 64,8 (±7,1) años (GI<sup>||</sup>); 65,9 (±6,7) años (GC<sup>§</sup>);</td>
									<td align="left">PtA***: Vejiga 33, con manipulación hasta que el paciente sienta sensación de pesadez y entumecimiento. Electroestimulación de 20 Hz, con la máxima intensidad tolerada por el paciente. Sesiones 1x/día en total 5 sesiones/semana durante la 1ª y 2ª semana, y posteriormente 3 sesiones/semana en la 3ª y 4ª semana</td>
									<td align="left">Agujas insertadas en dos puntos aproximadamente 6,7 cm lateral a los PtA***, sin manipulación, con electroestimulación igual al grupo de intervención. Misma frecuencia de sesiones que en el GI<sup>||</sup>.</td>
									<td align="left">1 (16 sesiones)</td>
									<td align="left"> I-PSS<sup>††</sup></td>
									<td align="left">Qmax<sup>||||</sup> y VRP<sup>||||||</sup></td>
									<td align="left">Puntaje I-PSS<sup>††</sup> tuvo una reducción (mejoría) de 3,2 puntos más en el GI<sup>||</sup> que en el GC<sup>§</sup> en la semana 18 (<italic>p</italic> = 0,001). No se observaron cambios en el Qmax<sup>||||</sup> o VRP<sup>||||||</sup>.</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN5">
								<p>* AUASI = <italic>American Urological Association Symptom Index</italic>; <sup>†</sup>EA = Electroacupuntura; <sup>‡</sup>FT = Fitoterapia; <sup>§</sup>GC = Grupo de control; <sup>||</sup>GI = Grupo de intervención; <sup>¶</sup>HPB = Hiperplasia prostática benigna; **IC = Intervalo de confianza; <sup>††</sup>I-PSS = <italic>International Prostate Symptom Score</italic>; <sup>‡‡</sup>Qave = Tasa de flujo urinario promedio; <sup>§§</sup>PSA = Antígeno prostático específico; <sup>||||</sup>Qmax = Tasa máxima de flujo urinario; <sup>¶¶</sup>TC = Terapias complementarias; ***PtA = Puntos de acupuntura; <sup>†††</sup>RTUP = Resección transuretral de la próstata; <sup>‡‡‡</sup>STUI = Síntomas del tracto urinario inferior; <sup>§§§</sup>US = Ultrasonido; <sup>||||||</sup>VRP = Volumen residual postmiccional</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>Un total de 1503 hombres fueron evaluados en los estudios incluidos en esta revisión, de los cuales 1294 formaron parte de los ensayos clínicos de fitoterapia y 209 de los ensayos clínicos de electroacupuntura. Considerando los estudios individualmente, este número varió de 30<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> a 357 participantes<xref ref-type="bibr" rid="B31"><sup>31</sup></xref>. La edad media de los participantes fue de 60,7 años (±5,6). El tiempo de seguimiento de los ensayos clínicos de fitoterapia (±5,1) varió de 2 a 18 meses y el de los ensayos de electroacupuntura (±4,7) de uno a tres meses.</p>
				<p>Para evaluar la efectividad de las TC, los estudios utilizaron parámetros subjetivos y objetivos. Se consideraron los cuestionarios <italic>American Urological Association Symptom Index</italic> (AUASI)<xref ref-type="bibr" rid="B31"><sup>31</sup></xref> e <italic>International Prostate Symptom Score</italic> (I-PSS)<xref ref-type="bibr" rid="B32"><sup>32</sup></xref> que clasifican subjetivamente la gravedad de los STUI (cuadros leves 0-7 puntos, moderados 8-19 puntos o graves 20-35 puntos)<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. Como parámetros objetivos se utilizaron los siguientes resultados urodinámicos: frecuencia miccional, nicturia, flujo urinario máximo (Qmax), flujo urinario promedio (Qave), volumen residual postmiccional (VRP), volumen prostático y de vaciado de la vejiga.</p>
				<p>De los estudios incluidos en esta revisión, dos utilizaron el cuestionario AUASI<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref> y diez el I-PSS para evaluar STUI<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Solo un estudio<xref ref-type="bibr" rid="B20"><sup>20</sup></xref> no incluyó ningún parámetro urodinámico como uno de los resultados de la evaluación STUI. La mayoría (n=7) consideró al menos el Qmax y el VRP<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
				<p>Cuatro estudios de fitoterapia evaluaron la eficacia del <italic>Saw palmetto</italic> (<italic>S. palmetto</italic>) para el control de los STUI. El fitoterápico se comparó con el placebo en dosis diarias de 320 mg<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, 640 mg<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> y 960 mg<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>. La dosis de 320 mg diarios, divididos en dos veces al día, mejoró significativamente (<italic>p</italic> &lt; 0,001) el puntaje I-PSS después de 24 semanas de tratamiento<xref ref-type="bibr" rid="B26"><sup>26</sup></xref> y demostró una reducción media de 4,4 (± 5,9) puntos en el grupo de intervención, y una diferencia significativa (<italic>p</italic> = 0,038) con el placebo después de seis meses<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>. Esta misma dosis también redujo 0,68 (± 0,35) puntos el puntaje AUASI medio del grupo de intervención, pero no se registró una diferencia estadísticamente significativa con el grupo placebo (IC 95%: -0,93 a 1,01)<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>. Las dosis diarias más altas de 640 mg y 960 mg redujeron 2,20 puntos (IC del 95 %: -3,04 a -0,36 puntos) el puntaje medio de AUASI, pero también se observó una mejoría en el grupo placebo<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>. Ninguna de las dosis evaluadas de <italic>S. palmetto</italic> mejoró los parámetros de urodinámicos, Qmax, VRP y volumen prostático<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
				<p>Otros dos ensayos clínicos evaluaron la efectividad del fitoterápico <italic>Ganoderma lucidum</italic> (<italic>G. lucidum</italic>)<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>. El fitoterápico fue evaluado en dosis diarias de 0,6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>, 6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> y 60 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>. En comparación con el placebo, las dosis diarias de 6 mg<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> y 60 mg<xref ref-type="bibr" rid="B24"><sup>24</sup></xref> redujeron significativamente (<italic>p</italic> &lt; 0,001; <italic>p</italic> = 0,012; respectivamente) el puntaje I-PSS y mejoraron ligeramente el Qmax y el Qave<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, pero no se produjeron diferencias significativas entre los grupos.</p>
				<p>Además, dos estudios de fitoterapia evaluaron la efectividad del uso de <italic>cranberry</italic> en el control de los STUI<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. El fitoterápico se comparó con el placebo en dosis diarias de 250 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, 500 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> y 1500 mg<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. En la dosis más alta de 1500 mg, dividida en tres tomas al día, se observó una reducción significativa (p &lt; 0,050) del puntaje I-PSS en el grupo de intervención, y una mejora en los parámetros urodinámicos, Qmax, Qave y PRV, en el 70% de los pacientes que participó en este grupo<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. En el estudio que evaluó las dosis de 500 y 250 mg, hubo reducción de 4,1 (± 1,9) y 3,1 (± 3,0) puntos en los puntajes I-PSS, respectivamente<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. Los parámetros urodinámicos, Qmax (<italic>p</italic> = 0,018), Qave (<italic>p</italic> = 0,040), VPR (<italic>p</italic> = 0,027) y volumen de vaciado de la vejiga (<italic>p</italic> = 0,014) también indicaron una mejoría significativa en el grupo que recibió 500 mg de <italic>cranberry</italic><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
				<p>En cuanto a los estudios que evaluaron la efectividad de la electroacupuntura, tres incluyeron puntos de acupuntura (PtA) que pertenecían al meridiano de la vejiga<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. El punto B32, que pertenece a este meridiano, fue el PtA más utilizado<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Cabe destacar que en comparación con el fármaco convencional (Oxibutinina 5 mg) y el comprimido de placebo, la electroestimulación de 5 a 10 Hz a la intensidad más alta tolerada del PtA B32 promovió el control de los STUI con una mejora significativa del puntaje I-PSS (<italic>p</italic> &lt; 0,001) y una reducción de la frecuencia de micción y nocturia del 20 y 60%, respectivamente<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. </p>
				<p>Otros PtA del meridiano de la vejiga fueron B10 y B40<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>, B21 y B23<xref ref-type="bibr" rid="B29"><sup>29</sup></xref> y B33<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. El PtA B33 fue el único que mostró una reducción de 3,2 puntos en el puntaje I-PSS del grupo de intervención, lo que demuestra una mejora significativa (<italic>p</italic> = 0,001) en comparación con la electroacupuntura placebo cuando se estimula a 20 Hz a la mayor intensidad tolerada<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>.</p>
				<p>Otro estudio de electroacupuntura evaluó la efectividad de los PtA que pertenecían a los distintos meridianos bazo-páncreas (BP6), estómago (E36) y vaso concepción (VC3 y VC4)<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Los puntos de estos meridianos, al ser estimulados con 3 Hz e intensidad de 2 a 2,5 mA, mostraron una mejora significativa en los parámetros urodinámicos Qmax (p = 0,030), Qave (p = 0,026) y volumen de vaciado de la vejiga (p = 0,038) en comparación con la electroacupuntura placebo<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Sin embargo, no hubo reducción del puntaje I-PSS<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>Los estudios incluidos en esta revisión se sometieron a un análisis de calidad metodológica, basado en la <italic>Joanna Briggs Institute</italic> (JBI) <italic>Critical Appraisal Tool</italic> - <italic>checklist</italic> para ensayos clínicos aleatorizados<xref ref-type="bibr" rid="B18"><sup>18</sup></xref>. En esta evaluación, seis estudios fueron clasificados como de bajo riesgo de sesgo, cinco eran de fitoterapia<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> y uno de electroacupuntura<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>.</p>
				<p>Tres estudios fueron clasificados como de riesgo moderado de sesgo, uno sobre fitoterapia<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> y dos sobre electroacupuntura<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Los estudios fueron clasificados como de moderado riesgo de sesgo porque no describieron las pérdidas que hubo durante el seguimiento ni el cegamiento del equipo de investigación responsable por el análisis de los resultados<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. En el estudio de fitoterapia<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> no se informó el método de cegamiento de los investigadores que aplicaron la intervención. En los estudios de electroacupuntura, se observaron fallas en la descripción del proceso de asignación de los participantes<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>, además de la ausencia de doble ciego<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>Se identificó alto riesgo de sesgo en tres estudios, dos sobre fitoterapia<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref> y uno sobre electroacupuntura<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Los ítems de las falencias metodológicas incluyen: descripción incompleta del método de aleatorización, diferencias entre los grupos al inicio del estudio, falta de descripción del cegamiento y de las pérdidas de muestra durante el seguimiento<xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Los resultados de la evaluación del riesgo de los estudios incluidos se presentan en el <xref ref-type="table" rid="t9">Figura 4</xref>.</p>
				<p>
					<table-wrap id="t9">
						<label>Figura 4</label>
						<caption>
							<title>Calificación del riesgo de sesgo de los estudios incluidos (N=12)</title>
						</caption>
						<table>
							<colgroup>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Autor, año</th>
									<th align="left">P1<sup>||</sup></th>
									<th align="left">P2<sup>||</sup></th>
									<th align="left">P3<sup>||</sup></th>
									<th align="left">P4<sup>||</sup></th>
									<th align="left">P5<sup>||</sup></th>
									<th align="left">P6<sup>||</sup></th>
									<th align="left">P7<sup>||</sup></th>
									<th align="left">P8<sup>||</sup></th>
									<th align="left">P9<sup>||</sup></th>
									<th align="left">P10<sup>||</sup></th>
									<th align="left">P11<sup>||</sup></th>
									<th align="left">P12<sup>||</sup></th>
									<th align="left">P13<sup>||</sup></th>
									<th align="left">Total</th>
									<th align="left">Riesgo de sesgo</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="left">Gerber, et al., 2001<xref ref-type="bibr" rid="B19"><sup>19</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">I</td>
									<td align="left">S</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">76,92%</td>
									<td align="left">Bajo</td>
								</tr>
								<tr>
									<td align="left">Bent, et al., 2006<xref ref-type="bibr" rid="B21"><sup>21</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">100%</td>
									<td align="left">Bajo</td>
								</tr>
								<tr>
									<td align="left">Barry, et al., 2011<xref ref-type="bibr" rid="B22"><sup>22</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">100%</td>
									<td align="left">Bajo</td>
								</tr>
								<tr>
									<td align="left">Ye, et al., 2019(26)</td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">46,15%</td>
									<td align="left">Alto</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al., 2008<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">92,31%</td>
									<td align="left">Bajo</td>
								</tr>
								<tr>
									<td align="left">Noguchi, et al., 2008<xref ref-type="bibr" rid="B24"><sup>24</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">92,31%</td>
									<td align="left">Bajo</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al., 2010<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>
									</td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">38,46%</td>
									<td align="left">Alto</td>
								</tr>
								<tr>
									<td align="left">Vidlar, et al., 2015<xref ref-type="bibr" rid="B28"><sup>28</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">69,23%</td>
									<td align="left">Moderado</td>
								</tr>
								<tr>
									<td align="left">Johnstone, et al., 2003<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">S*</td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">53,85%</td>
									<td align="left">Moderado</td>
								</tr>
								<tr>
									<td align="left">Ricci, et al., 2004<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>
									</td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">38,46%</td>
									<td align="left">Alto</td>
								</tr>
								<tr>
									<td align="left">Yu, et al., 2011<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">I<sup>‡</sup></td>
									<td align="left">S*</td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">N<sup>†</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">69,23%</td>
									<td align="left">Moderado</td>
								</tr>
								<tr>
									<td align="left">Wang, et al., 2013<xref ref-type="bibr" rid="B25"><sup>25</sup></xref>
									</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">NA<sup>§</sup></td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">S*</td>
									<td align="left">92,31%</td>
									<td align="left">Bajo</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN6">
								<p>*S = Sí; <sup>†</sup>N = No; <sup>‡</sup>I = Incierto; <sup>§</sup>NA = No se aplica; <sup>||</sup>P = Pregunta.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
			</sec>
			<sec sec-type="discussion">
				<title>Discusión</title>
				<p>La presente revisión sistemática buscó identificar y evaluar la efectividad de las TC utilizadas para controlar los STUI en la población masculina. De los 12 ensayos clínicos incluidos, ocho abordaron el uso de fitoterapia<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> y cuatro abordaron la electroacupuntura<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>Para el análisis de la efectividad de las TC, uno de los métodos adoptados consideró la evaluación subjetiva de los STUI. Por ende, se utilizaron cuestionarios autoadministrados y validados internacionalmente<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref> que clasifican y estandarizan el registro de los STUI, y es una herramienta importante para determinar la gravedad de esta condición<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B34"><sup>34</sup></xref>.</p>
				<p>Entre los cuestionarios para evaluar los STUI, se destacan los cuestionarios AUASI del comité de la <italic>American Urological Association</italic><xref ref-type="bibr" rid="B31"><sup>31</sup></xref> y el cuestionario I-PSS<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>, que hace referencia a una adaptación del AUASI con la inclusión de un ítem que evalúa la calidad de vida que clasifica el impacto de las molestias causadas por STUI en una escala de cero a seis<xref ref-type="bibr" rid="B33"><sup>33</sup></xref>. Ambos instrumentos evalúan la gravedad de los STUI a partir de siete preguntas relacionadas con: sensación de vaciado incompleto de la vejiga, micción frecuente, flujo intermitente, flujo débil, dolor o dificultad para orinar, nocturia y urgencia<xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. La frecuencia de cada síntoma recibe un puntaje de cero a cinco, cuya suma determina la gravedad (cuadros leves 0-7 puntos, moderados 8-19 puntos o graves 20-35 puntos)<xref ref-type="bibr" rid="B31"><sup>31</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B32"><sup>32</sup></xref>.</p>
				<p>Otro de los métodos para evaluar los STUI que presentan los estudios se basó en el estudio urodinámico. Es una prueba objetiva para evaluar la función del tracto urinario inferior, considerada el estándar de oro en el contexto de la práctica clínica<xref ref-type="bibr" rid="B35"><sup>35</sup></xref>. Entre los parámetros del estudio urodinámico que consideraron los estudios predominaron el flujo urinario máximo (Qmax), el volumen prostático y el volumen residual postmiccional (VRP). Hay que destacar que solo un estudio no consideró la efectividad de la intervención aplicada a partir de la evaluación urodinámica<xref ref-type="bibr" rid="B20"><sup>20</sup></xref>.</p>
				<p>En cuanto a la efectividad de las TC, nueve estudios las consideraron una alternativa eficaz para controlar los STUI en la población masculina<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. La fitoterapia se destaca como una de las TC más utilizadas por la población general<xref ref-type="bibr" rid="B16"><sup>16</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B36"><sup>36</sup></xref>. La fitoterapia se basa en el uso de plantas medicinales para tratar ciertos síntomas, y es una práctica ampliamente reconocida y difundida por la Organización Mundial de la Salud<xref ref-type="bibr" rid="B37"><sup>37</sup></xref>. En esta revisión se analizaron los fitoterápicos <italic>S. palmetto</italic><xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, <italic>G. lucidum</italic><xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> y <italic>cranberry</italic><xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
				<p>De los cuatro estudios que evaluaron la efectividad del <italic>S. palmetto</italic><xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, la mitad<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref> concluyó que este fitoterápico en una dosis diaria de 320 mg fue efectivo para controlar los STUI en los hombres. Ambos estudios mostraron una reducción estadísticamente significativa de los puntajes I-PSS en el grupo de intervención en comparación con el grupo placebo<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Uno de ellos<xref ref-type="bibr" rid="B26"><sup>26</sup></xref> demostró que el <italic>S. palmetto</italic> también fue capaz de mejorar el Qmax, al igual que otros estudios que también indican que hubo una mejora del Qmax, además de una reducción de la nocturia<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B38"><sup>38</sup></xref>.</p>
				<p>El <italic>S. palmetto</italic>, cuyo nombre científico es <italic>Serenoa repens</italic>, es un fitoterápico de la familia de las palmeras que, debido a sus propiedades antiinflamatorias y antiandrogénicas, se ha utilizado comúnmente para controlar los STUI, especialmente los asociados con la HPB<xref ref-type="bibr" rid="B39"><sup>39</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B40"><sup>40</sup></xref>. A pesar de que hay evidencia favorable de que puede ser utilizado, su aplicabilidad y efectividad en la práctica clínica aún son cuestionables<xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. En parte, la gran variabilidad en la concentración y biodisponibilidad de los componentes, dependiendo del laboratorio responsable de producir el extracto, puede explicar la dificultad para definir su efectividad<xref ref-type="bibr" rid="B41"><sup>41</sup></xref>. Además, la falta de estandarización de las concentraciones dificulta establecer comparaciones entre ensayos clínicos<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>.</p>
				<p>Respecto a dos estudios que no constataron la efectividad del fitoterápico <italic>S. palmetto</italic>, variables como el tipo de extracto<xref ref-type="bibr" rid="B21"><sup>21</sup></xref> y la dosis administrada<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> pueden justificar los resultados obtenidos. Existe más de un tipo de extracto de <italic>S. palmetto</italic>, y las formas de extracto etanólico y hexano presentan mayor efectividad clínica del compuesto<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. En ese caso, se destaca que en uno de los estudios<xref ref-type="bibr" rid="B21"><sup>21</sup></xref> se adoptó el extracto de dióxido de carbono, cuya efectividad es menor<xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. Ninguno de los otros estudios especificó el tipo de extracto de <italic>S. palmetto</italic> evaluado<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>.</p>
				<p>En cuanto a la dosificación del fitoterápico <italic>S. palmetto</italic>, uno de los estudios incluidos<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> concluyó que el <italic>S. palmetto</italic> no fue superior al placebo. Este ensayo clínico<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> evaluó la efectividad del <italic>S. palmetto</italic> en dosis escalonadas de 320 mg, 640 mg y 960 mg diarios, es decir, consideró el doble y el triple de la dosis utilizada en otros estudios<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Por lo tanto, debido a la discrepancia que hay entre las dosis establecidas, se sugiere cautela en la interpretación de los resultados y la relevancia de futuros estudios.</p>
				<p>El <italic>G. lucidum</italic>, fitoterápico elegido en otros dos estudios de esta revisión<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>, consiste en un tipo de hongo muy conocido en los países asiáticos, cuyos principales componentes bioactivos son los triterpenos y los polisacáridos<xref ref-type="bibr" rid="B43"><sup>43</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B44"><sup>44</sup></xref>. Aunque los mecanismos que justifican sus efectos antitumorales, antioxidantes y antibacterianos no están del todo dilucidados<xref ref-type="bibr" rid="B44"><sup>44</sup></xref>, hay que destacar que los estudios incluidos<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> presentaron resultados satisfactorios en los que hubo una mejora significativa en los puntajes I-PSS en el grupo de intervención. Por lo tanto, la evidencia<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref> sugiere que el <italic>G. lucidum</italic> es efectivo en dosis de 6 mg diarios para el control de los STUI en los hombres.</p>
				<p>Esta revisión también incluye dos estudios<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref> que analizaron el <italic>cranberry,</italic> cuyo nombre científico es <italic>Vaccinium spp</italic>., una fruta ampliamente consumida en los países de América del Norte para el control de infecciones del tracto urinario inferior<xref ref-type="bibr" rid="B45"><sup>45</sup></xref>. El polvo de <italic>cranberry</italic> analizado en ambos estudios fue proporcionado por el mismo laboratorio, lo que favorece la comparación de resultados. En dosis de 250 mg<xref ref-type="bibr" rid="B28"><sup>28</sup></xref> y 1500 mg diarios<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>, este fitoterápico redujo significativamente el puntaje I-PSS en el grupo de intervención<xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. Sin embargo, considerando la evaluación urodinámica, los resultados más efectivos fueron mejores a dosis más altas, por ejemplo, 1500 mg diarios<xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. Se sugiere que el ácido siálico que se encuentra en el extracto de <italic>cranberry</italic> tiene un efecto antiinflamatorio y analgésico, especialmente debido a la capacidad de disminuir la adhesión de microorganismos a la pared de la vejiga<xref ref-type="bibr" rid="B45"><sup>45</sup></xref>.</p>
				<p>La electroacupuntura fue otra TC evaluada en cuatro ensayos clínicos de esta revisión<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Los efectos terapéuticos de la acupuntura se obtienen a partir de la activación del flujo de energía o <italic>Qi</italic>, mediante la inserción de agujas en determinados PtA con el fin de restablecer el equilibrio homeostático<xref ref-type="bibr" rid="B46"><sup>46</sup></xref>. En ese caso, la electroacupuntura representa una variación de la acupuntura en la que se aplica una corriente eléctrica a las agujas buscando acentuar y potenciar los efectos terapéuticos<xref ref-type="bibr" rid="B47"><sup>47</sup></xref>. El flujo de corriente eléctrica a través de un medio conductor biológico desencadena efectos fisiológicos, que involucran fenómenos electroquímicos, electrofísicos y electrotérmicos. Entre los parámetros físicos más relevantes estudiados en la electroacupuntura se destaca la frecuencia estimulatoria, especialmente su relación con la liberación de opioides endógenos en procesos analgésicos y antiinflamatorios<xref ref-type="bibr" rid="B48"><sup>48</sup></xref>.</p>
				<p>En cuanto al cegamiento, los métodos de electroacupuntura placebo utilizados en los estudios incluidos fueron: uso de puntos no asociados a PtA<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>, profundidad más superficial<xref ref-type="bibr" rid="B30"><sup>30</sup></xref> y ausencia de electroestimulación<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Debido a la dificultad que representa cegar los estudios clínicos en esta área<xref ref-type="bibr" rid="B47"><sup>47</sup></xref>, se cree que este hecho puede justificar el diseño simple ciego de los cuatro estudios que evaluaron el efecto de esta terapia<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>.</p>
				<p>En cuanto a los PtA utilizados en electroacupuntura, la mayoría incluía al menos un punto referente al meridiano de la vejiga<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>, especialmente el PtA B32 (<italic>Ciliao</italic>)<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Estudios recientes han identificado resultados significativos para el tratamiento de los síntomas de HPB en hombres<xref ref-type="bibr" rid="B49"><sup>49</sup></xref> y los síntomas de vejiga hiperactiva (VH) en ratas mediante la estimulación del PtA B32<xref ref-type="bibr" rid="B50"><sup>50</sup></xref>. Se sabe que la PtA B32 es uno de los cuatro puntos ubicados en los cuatro agujeros sacros, y es considerado el más importante porque tiene amplias indicaciones (disfunciones miccionales, dismenorrea, lumbalgia y ciática e infertilidad) y es uno de los puntos que produce el mayor efecto tonificante de Riñón y Esencia<xref ref-type="bibr" rid="B51"><sup>51</sup></xref>.</p>
				<p>Solo un estudio incluido de esta revisión optó por utilizar PtA de otros meridianos que no corresponden a la vejiga<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>, a saber: bazo, páncreas (BP6 - <italic>Sanyinjiao</italic>), estómago (E36 - <italic>Zusanli</italic>) y vaso concepción (VC3 - <italic>Zhongji</italic>; VC4 - <italic>Guanyuan</italic>). Un estudio realizado en ratas con vejiga hiperactiva mostró que el punto B33 (<italic>Zhongliao</italic>) tuvo un efecto mayor que los puntos BP6 (<italic>Sanyinjiao</italic>) y B40 (<italic>Weizhong</italic>) para aumentar el intervalo entre contracciones<xref ref-type="bibr" rid="B52"><sup>52</sup></xref>. Por lo tanto, se sugiere que este hecho puede justificar que predominen los protocolos que adoptan PtA asociados al meridiano de la vejiga.</p>
				<p>En cuanto a la heterogeneidad de los criterios de inclusión establecidos por los estudios, en los ensayos clínicos de fitoterapia, tres consideraron puntajes I-PSS o AUASI mayores a ocho para la inclusión de los participantes<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>, dos definieron un puntaje máximo de 19 para el puntaje I-PSS<xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>, uno definió un límite máximo de 24 puntos en el puntaje AUASI<xref ref-type="bibr" rid="B22"><sup>22</sup></xref> y otro estudio consideró un puntaje mínimo de cinco en el puntaje I-PSS<xref ref-type="bibr" rid="B23"><sup>23</sup></xref>. Solo un estudio<xref ref-type="bibr" rid="B27"><sup>27</sup></xref> no consideró los puntajes de los cuestionarios de evaluación del STUI para definir la muestra.</p>
				<p>Además, dos ensayos clínicos de fitoterapia utilizaron los puntajes AUASI e I-PSS para definir el diagnóstico de HPB en sus participantes<xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref> y la mayoría consideró la participación solo de hombres sin antecedentes de cirugía de próstata<xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. Esta heterogeneidad para definir la causa subyacente y la gravedad de los STUI puede influir en la evaluación de la efectividad de las intervenciones, ya que la influencia de la gravedad de los STUI en la respuesta a los TC no está definida en la literatura.</p>
				<p>Asimismo, los participantes de los ensayos clínicos de electroacupuntura presentaron distintas características de selección. Tres estudios consideraron hombres con puntajes I-PSS superiores a ocho puntos<xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref> y un estudio no consideró ningún puntaje para definir la muestra<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. En cuanto a la causa subyacente de los STUI, dos estudios incluyeron hombres con HBP en la muestra, un estudio definió el diagnóstico en función del puntaje I-PSS<xref ref-type="bibr" rid="B25"><sup>25</sup></xref> y el otro hizo el diagnóstico basándose en un ultrasonido transrectal<xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Además, uno de los estudios de electroacupuntura incluyó hombres que ya habían sido sometidos a resección transuretral de próstata<xref ref-type="bibr" rid="B29"><sup>29</sup></xref>, mientras que la muestra de otro estudio<xref ref-type="bibr" rid="B30"><sup>30</sup></xref> solo incluyó hombres sin antecedentes de cirugía de próstata. </p>
				<p>Otro dato relevante es la diferencia existente en el tiempo de seguimiento de los estudios, que varió entre dos y 18 meses para la fitoterapia y entre uno y tres meses para la electroacupuntura. Uno de los principales retos a la hora de realizar estudios clínicos que evalúen la eficacia de las TC se basa en la dificultad para establecer protocolos fijos de tratamiento. Se sabe que este es un método que contradice los preceptos básicos de la gran mayoría de las TC. Sin embargo, se debe considerar que la estandarización del tiempo ideal de seguimiento en base a estudios clínicos puede favorecer la replicabilidad de los protocolos y el alcance de los mismos resultados en futuras investigaciones.</p>
				<p>En lo que respecta a las perspectivas de inclusión de estas terapias en el cuidado de enfermería, se sabe que la Clasificación de Intervenciones de Enfermería (NIC) incluye las intervenciones “fitoterapia” (2420) y “estimulación cutánea” (1340)<xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. Los enfermeros son profesionales que se destacan en la implementación y el uso de diversas TC, dado que los principios de su formación son similares a los paradigmas de las racionalidades médicas que involucran la medicina integrativa. Sin embargo, el contingente de estos profesionales que trabajan con estas terapias o que tienen el conocimiento para prescribir y derivar a los usuarios a este tipo de atención es aún pequeño. Aunque es incipiente, hay un movimiento de enfermeros que realizan cursos de especialización en esta área, lo que contribuye a la difusión de estas terapias en la comunidad y, por consiguiente, a mejorar la atención de enfermería<xref ref-type="bibr" rid="B54"><sup>54</sup></xref>.</p>
				<p>Una de las limitaciones de la presente revisión es la selección de estudios del tipo ensayo clínico. Por lo tanto, se sugiere una futura expansión considerando diferentes diseños metodológicos. Otra limitación se basó en la evidencia identificada y que no se pudo incluir debido a que el efecto de la TC está asociado a otros tratamientos convencionales como fármacos o cirugía. Como resultado, la evidencia presentada debe ser considerada preliminar, generadora de hipótesis y un recurso para guiar futuras investigaciones basadas en los vacíos de conocimiento que se identificaron.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>Conclusión</title>
				<p>La presente revisión sistemática identificó y evaluó doce ensayos clínicos que analizaron la efectividad de las TC para el control de los STUI en los hombres. La mayoría de estos estudios evaluaron la fitoterapia, que se identificó como una alternativa eficaz en seis de los ocho ensayos clínicos, dado que redujo la frecuencia de los STUI mediante la reducción de los puntajes I-PSS y los parámetros urodinámicos. También destacamos que, en los estudios de fitoterapia, predominaron los clasificados como de bajo riesgo de sesgo. Por ende, considerando que la mitad de los estudios indica que tienen efectividad y que poseen buena calidad metodológica, se considera adecuado indicar el uso de fitoterapia para el control de los STUI en los hombres.</p>
				<p>Con respecto a la electroacupuntura, a pesar de los resultados prometedores, se sugiere el desarrollo de investigaciones más sólidas y metodologías con mayor nivel de evidencia, dado que solo uno de los ensayos clínicos fue clasificado como de bajo riesgo de sesgo. Se sabe que este hecho puede tener impacto en la veracidad de la efectividad de la terapia implementada.</p>
				<p>En el contexto de los STUI, siguen siendo alternativas predominantes el no tratamiento de los casos leves o el tratamiento convencional basado en medicación y cirugías para los casos refractarios. Sin embargo, si se considera los efectos que pueden tener las TC, especialmente en lo que respecta al control de los STUI, es fundamental realizar futuras investigaciones que puedan generar recomendaciones más consistentes. En general, se sabe que las TC son mínimamente invasivas, lo que implica menor riesgo de secuelas en comparación con los procedimientos quirúrgicos, además de tener pocos reportes de eventos adversos, a diferencia de los medicamentos.</p>
			</sec>
		</body>
		<back>
			<fn-group>
				<fn fn-type="financial-disclosure" id="fn12">
					<label>Apoyo financiero</label>
					<p>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), proceso nº 429958/2018-8 y de la Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), proceso APQ 01034-21, Brasil.</p>
				</fn>
			</fn-group>
		</back>
	</sub-article>
</article>